Componenta’s Auditor’s Report for the financial period 1 January - 31 December 2018

Componenta Corporation Stock Exchange Release on 12 April 2019 at 8.00 EET The Auditor of Componenta Corporation has today issued the following Auditor’s Report for the financial period 1 January - 31 December 2018. In addition to the standard format text the report includes an additional paragraph related to uncertainties related to going concern. “Auditor’s Report (Translation of the Finnish Original) To the Annual General Meeting of Componenta Oyj Report on the Audit of the Financial Statements Opinion In our opinion · the consolidated financial statements give a true and fair view of the group’s financial position and financial performance and cash flows in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU · the financial statements give a true and fair view of the parent company’s financial performance and financial position in accordance with the laws and regulations governing the preparation of the financial statements in Finland and comply with statutory requirements. Our opinion is consistent with the additional report to the Board of Directors. What we have audited We have audited the financial statements of Componenta Oyj (business identity code 1635451-6) for the year ended 31 December 2018. The financial statements comprise: · the consolidated statement of financial position, income statement, statement of comprehensive income, statement of changes in shareholders’ equity, cash flow statement and notes, including a summary of significant accounting policies · the parent company’s balance sheet, income statement, cash flow statement and notes. Basis for Opinion We conducted our audit in accordance with good auditing practice in Finland. Our responsibilities under good auditing practice are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the parent company and of the group companies in accordance with the ethical requirements that are applicable in Finland and are relevant to our audit, and we have fulfilled our other ethical responsibilities in accordance with these requirements. To the best of our knowledge and belief, the non-audit services that we have provided to the parent company and to the group companies are in accordance with the applicable law and regulations in Finland and we have not provided non-audit services that are prohibited under Article 5(1) of Regulation (EU) No 537/2014. The non-audit services that we have provided are disclosed in note 6 to the Financial Statements. Material uncertainties related to going concern We draw attention to the accounting principles of the consolidated financial statements and of the financial statements of the parent company, which describe the status and progress of the corporate restructuring proceedings of the group companies and their ability to continue as a going concern. The Board of Directors and Management of Componenta Group have assessed the company’s ability to continue as going concern taking into consideration the company’s liquidity situation and the impact of the restructuring proceedings to the financial position and cash flows of the group and group companies. The Board of Directors and Management assessed that the liquidity situation, the financial performance of the group companies as well as the success of the restructuring programmes and the financing transactions are affected by significant uncertainty factors. The Board of Directors and Management conclude that the cash flow forecasts and financing of group companies under restructuring programs include significant estimates and assumptions as well as uncertainties. Significant estimates and assumptions and uncertainties related to the ability to continue as a going concern are described in the accounting principles of the consolidated financial statements. The Board of Directors and Management consider that the company can, within the foreseeable future, realize its assets and pay back its liabilities as part of normal business operations within the framework of the restructuring programmes. As such, the Board of Directors and Management believe that going concern basis of presentation in the consolidated and parent company financial statements is appropriate. In our opinion, the success of the restructuring programmes as well as the outcome of the cash flow forecasts are such uncertainties that may cast significant doubt on the Componenta Group’s and its subsidiaries’ ability to continue as a going concern. Our opinion is not qualified in respect of this matter. Our Audit Approach Overview Materiality Overall group materiality: € 1 200 000 Group scoping Audit scope: The group audit scope has included the parent company and its subsidiaries in Finland and Sweden. Key audit matters Key Audit Matters in the audit of the financial statements in the current period · Timing of revenue recognition · Valuation of assets taking into consideration the corporate restructuring proceedings and reorganisation of the business operations · The effect of the corporate restructuring proceedings and reorganising of the business operations to the parent company’s financial statements. As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements. In particular, we considered where management made subjective judgements; for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. Materiality The scope of our audit was influenced by our application of materiality. An audit is designed to obtain reasonable assurance whether the financial statements are free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements. Based on our professional judgement, we determined certain quantitative thresholds for materiality, including the overall group materiality for the consolidated financial statements as set out in the table below. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements on the financial statements as a whole. Overall group materiality                                 1 200 000 euros (previous year 1 200 000 euros) How we determined it                                     Overall group materiality is determined as a percentage of the group’s FY2018 net sales of continued operations. Rationale for the materiality benchmark applied We chose net sales as the benchmark because, in our view, it is the appropriate benchmark, which the users of the financial statements regularly use to evaluate the performance of the group. How we tailored our group audit scope We tailored the scope of our audit, taking into account the structure of the group, the accounting processes and controls, and the industry in which the group operates. The scope included the parent company and its subsidiaries in Finland and Sweden. We have predefined the audit focus areas of financial information to each group component. When a task was to be performed by a component auditor we have guided the component auditor with audit instructions that have included among other things our risk assessment, materiality, audit approach and centralized audit procedures. Key Audit Matters Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. As in all of our audits, we also addressed the risk of management override of internal controls, including among other matters consideration of whether there was evidence of bias that represented a risk of material misstatement due to fraud. In addition to matter described in paragraph above “Material uncertainties related to going concern” we have concluded that the matters listed below are key audit matters. Key audit matter in the audit of the group         Timing of revenue recognition Refer to Note 1 of the consolidated financial statements Componenta's revenue consist of sale of goods and services. The main sales products are non-machined, machined and painted iron cast components. Products sold to customers are recognized when disposed, that is the moment when the customer assumes control of the goods. The timing of revenue recognition has been considered a key audit matter in the auditing of the consolidated financial statements due to the significance of revenue to the financial statements. How our audit addressed the key audit matter Our audit procedures included for example the following procedures: · Evaluation of internal control activities over revenue recognition and testing of key controls. · Analysis of significant sales contracts to test correct accounting treatment. · Testing timeliness of revenue recognition by comparing individual sales transactions to delivery documents and by checking significant credit notes issued after year-end. · Analysis of revenue transactions using data analysis techniques. · Testing of accounts receivables by requesting confirmations from the company’s customers and by reconciling cash payments received after the year end against the accounts receivable balances at the year end. Key audit matter in the audit of the group         Valuation of assets taking into consideration the corporate restructuring proceedings and reorganisation of the business operations Refer to accounting principles and Note 13 of the consolidated financial statements The Componenta Group’s parent company Componenta Corporation and its Swedish subsidiary Componenta Främmestad AB and Finnish subsidiary Componenta Finland Oy are under corporate restructuring programmes. The uncertainties described in section “Material uncertainties related to going concern” cast significant doubt on the group’s ability to continue as a going concern. The Board of Directors and Management have used significant judgment in assessing the effect of above mentioned matters in valuation of assets. For this reason the valuation of assets taking into consideration the corporate restructuring proceedings and reorganising of the business operations are considered a key audit matter in the group audit.                                                             How our audit addressed the key audit matter Our audit procedures included for example the following procedures: · We updated our perception of the contents of the corporate restructuring proceedings and progress. · We discussed with the management and examined the matters discussed by the board of directors related to reorganization of the business operations. · We assessed cash flow analysis prepared by management and reviewed by the board of directors used as a basis of valuation of assets. · We assessed the management´s estimates related to valuation of properties. Key audit matter in the audit of the parent company The effect of the corporate restructuring proceedings and reorganising of the business operations to the parent company’s financial statements Refer to the accounting principles of the consolidated financial statements and the parent company’s financial statements The Componenta Corporation’s Swedish subsidiary Componenta Främmestad AB and the Finnish subsidiary Componenta Finland Oy are under corporate restructuring programmes. The assets on Componenta Corporation’s balance sheet consist to a large extent of subsidiary shares and loan receivables from subsidiaries. Management have used significant judgment in assessing the valuation of subsidiary shares and loan receivables. When making the assessment the Management have considered among other things the effect of the parent company’s and subsidiaries’ restructuring proceedings and their ability to continue as a going concern. The Management have used significant judgment and estimations of future development in assessing the effect of above mentioned matters in Componenta Corporations financial statements. For this reason this matter is considered a key audit matters in the audit of the parent company.                                                             How our audit addressed the key audit matter Our audit procedures included for example the following procedures: · We have updated our perception of the contents of the corporate restructuring proceedings and progress.            · We read the analyses of alternative outcomes of restructuring programs and reorganisations of business prepared by management and approved by the board of directors. · We assessed cash flow analysis prepared by management used as a basis of valuation of certain assets. · We assessed the management´s estimates related to valuation of properties. We have not identified significant risks of material misstatement referred to in Article 10(2c) of Regulation (EU) No 537/2014 with respect to the consolidated financial statements or the parent company financial statements. Responsibilities of the Board of Directors and the Managing Director for the Financial Statements The Board of Directors and the Managing Director are responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU, and of financial statements that give a true and fair view in accordance with the laws and regulations governing the preparation of financial statements in Finland and comply with statutory requirements. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Board of Directors and the Managing Director are responsible for assessing the parent company’s and the group’s ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting. The financial statements are prepared using the going concern basis of accounting unless there is an intention to liquidate the parent company or the group or to cease operations, or there is no realistic alternative but to do so. Auditor’s Responsibilities for the Audit of the Financial Statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with good auditing practice will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with good auditing practice, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: · Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. · Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the parent company’s or the group’s internal control. · Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management. · Conclude on the appropriateness of the Board of Directors’ and the Managing Director’s use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the parent company’s or the group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the parent company or the group to cease to continue as a going concern. · Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events so that the financial statements give a true and fair view. · Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication. Other Reporting Requirements Appointment We were first appointed as auditors by the annual general meeting on 28 February 2011. Other Information The Board of Directors and the Managing Director are responsible for the other information. The other information comprises the report of the Board of Directors and the information included in the Annual Review, but does not include the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. With respect to the report of the Board of Directors, our responsibility also includes considering whether the report of the Board of Directors has been prepared in accordance with the applicable laws and regulations. In our opinion · the information in the report of the Board of Directors is consistent with the information in the financial statements · the report of the Board of Directors has been prepared in accordance with the applicable laws and regulations. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact. We have nothing to report in this regard. Helsinki 12 April 2019 PricewaterhouseCoopers Oy Authorised Public Accountants Samuli Perälä Authorised Public Accountant (KHT)” COMPONENTA CORPORATIONHarri SuutariPresident and CEO For further information, please contact:Harri SuutariPresident and CEOtel. +358 10 403 2200Marko KarppinenCFOtel. +358 10 403 2101 Componenta is an international technology company. Componenta specializes in supplying cast and machined components to its global customers, who are manufacturers of vehicles, machines and equipment. The company’s share is listed on Nasdaq Helsinki.

Publishing of YIT Corporation's Interim Report for January-March 2019 on April 26, 2019

YIT Corporation's Interim Report for January-March 2019 will be published on Friday, April 26, 2019 at approximately 12:00 noon Finnish time (EET, approx. 10:00 a.m. GMT). The stock exchange release and the presentation materials in Finnish and in English will be published at that time on the company's website at www.yitgroup.com/investors. News conference for investors and media YIT will arrange a news conference on Friday, April 26, 2019 at 1:00 p.m. Finnish time (EET, at 11:00 a.m. GMT) at YIT's head office, Panuntie 11, 00620 Helsinki, Finland. The event is in English and targeted for analysts, portfolio managers and the media. Welcome! Webcast The news conference and presentation by the President and CEO of YIT Corporation Kari Kauniskangas can also be followed through a live webcast at www.yitgroup.com/webcast. The live webcast starts at 1:00 p.m. (EET) and a recording of the webcast will be available at the same address later that day. Conference call The news conference can be participated also through a conference call. Conference call participants are requested to dial in at least five minutes prior to the start of the conference, at 12:55 p.m. (EET). Conference call numbers are: Participants from Finland +358 (0)9 7479 0361 Participants from UK and outside of Nordic countries +44 (0)330 336 9105 Participants from Sweden +46 (0)8 5033 6574 Participants from Norway +47 2100 2610 The participants will be asked to provide the following confirmation code: 1446499. During the webcast and conference call, all questions should be presented in English. At the end of the event, the media has the opportunity to ask questions also in Finnish. For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi   YIT CORPORATION Hanna Jaakkola Vice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT is the largest Finnish and significant North European construction company. We develop and build apartments and living services, business premises and entire areas. We are also specialised in demanding infrastructure construction and paving. Together with our customers, our nearly 10,000 professionals are creating more functional, more attractive and more sustainable cities and environments. We work in 11 countries: Finland, Russia, Scandinavia, the Baltic States, the Czech Republic, Slovakia and Poland. The new YIT was born when over 100-year-old YIT Corporation and Lemminkäinen Corporation merged on February 1, 2018. Our pro forma revenue for 2018 was approximately EUR 3.8 billion. YIT Corporation's share is listed on Nasdaq Helsinki Oy. www.yitgroup.com

Notice to the Annual General Meeting of Componenta Corporation

Componenta Corporation Stock Exchange Release on 12 April 2019 at 8.00 EET Notice is given to the shareholders of Componenta Corporation to the Annual General Meeting to be held at Messukeskus Helsinki meeting room 201 (Siipi entrance), at address Messuaukio 1, 00520 Helsinki on Thursday 16 May 2019, at 13.00 EET. The reception of persons who have registered for the meeting will commence at 12.30 EET. Refreshments will be served after the meeting.A. MATTERS ON THE AGENDA OF THE GENERAL MEETING At the General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Presentation of the financial statements, the consolidated financial statements, the report of the Board of Directors and the auditor’s report for the year 2018. - Review by the CEO 7. Adoption of the financial statements, which includes the adoption of the consolidated financial statements 8. Resolution on the use of profit shown on the balance sheet The Board of Directors proposes that no dividend will be paid for the financial period 1 January – 31 December 2018. 9. Resolution on the discharge of the members of the Board of Directors and the CEO from liability  10. Resolution on the remuneration of the members of the Board of Directors The Nomination Board proposes that the members of the Board of Directors, who will be elected to the term continuing to the annual general meeting 2020, will be paid annual remuneration as follows: EUR 50,000 to the Chairman and EUR 25,000 to the members of the Board of Directors. If the Board of Directors decides to establish Board committees, an annual fee of EUR 5,000 will be paid to the members of Board committees. Travel expenses of the members of the Board of Directors will be compensated in accordance with the company’s travel policy. 11. Resolution on the number of members of the Board of Directors The Nomination Board proposes that four members are elected to the Board of Directors. 12. Election of members of the Board of Directors The Nomination Board proposes that the current members of the Board of Directors Petteri Walldén, Anne Leskelä and Asko Nevala are re-elected as Board members and Harri Pynnä is elected as new Board member. The presentation of the persons nominated for the Board of Directors is available at Componenta Corporation’s website at www.componenta.com. All nominated persons are independent of the company and significant shareholders and have given their consent to the election. 13. Election of auditor The Board of Directors proposes that the audit firm PricewaterhouseCoopers Oy is elected as the auditor of the company for the following term of office. PricewaterhouseCoopers Oy has informed that Samuli Perälä, Authorised Public Accountant, will act as the responsible auditor should it be elected as the auditor of the company. 14. Amendment of the Articles of Association The Board of Directors proposes that the General Meeting resolve that the Articles of Association of the company be amended so that general meetings may be held, in addition to the domicile of the company, alternatively in Vantaa, Espoo or Karkkila. Section 8 of the Articles of Association is therefore proposed to be amended to read as follows: “8. Notice of General Meeting The notice of the General Meeting shall be delivered by releasing the notice of meeting on the company’s webpage and as stock exchange release no more than three (3) months and no less than three (3) weeks prior to the General Meeting, however, always at least nine (9) days prior to the record date of the General Meeting. The Board of Directors may in addition decide to announce the notice of meeting in other ways. A shareholder wishing to participate in the General Meeting shall register his/her participation as required in the notice of meeting and at the latest on the date stated in the notice, which date may be no earlier than ten (10) days before the meeting. The general meeting of shareholders may be held either at the company's domicile or in Vantaa, Espoo or Karkkila.” 15. Closing of the Meeting B. DOCUMENTS OF THE GENERAL MEETING The proposals for the decisions on the aforementioned matters on the above agenda of the General Meeting as well as this notice are available on Componenta Corporation’s website at www.componenta.com. The financial statements, the consolidated financial statements, the report of the Board of Directors and the auditor’s report of Componenta Corporation are available on the above-mentioned website on Friday 12 April 2019. The proposals for decisions and the other above-mentioned documents are also available at the meeting. Copies of these documents and of this notice will be sent to shareholders upon request. The minutes of the meeting will be available on the above-mentioned website as from 30 May 2019. C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE GENERAL MEETING 1. Shareholders registered in the shareholders’ register Each shareholder, who is registered on 6 May 2019 (the record date of the General Meeting) in the shareholders’ register of the company held by Euroclear Finland Ltd., has the right to participate in the General Meeting. A shareholder, whose shares are registered on his/her personal Finnish book-entry account, is registered in the shareholders’ register of the company. Changes in shareholdings occurring after the record date of the General Meeting shall not affect the right to attend the General Meeting or the number of votes of the shareholder. A shareholder, who is registered in the shareholders’ register of the company and who wants to participate in the General Meeting, shall register for the meeting no later than 13 May 2019 at 16.00 EET by giving a prior notice of participation, which shall be received by the company no later than on above-mentioned time and date. Such notice can be given: a) by e-mail ir.componenta@componenta.com;b) by telephone +358 10 403 2202 on weekdays between 9 and 16 (EET); orc) by regular mail to Componenta Corporation / Pia Juntunen, Teknobulevardi 7, FI-01530 Vantaa. In connection with the registration a shareholder shall notify his/her name, personal identification number (social security number) and telephone number and also the name of possible assistant or proxy representative as well as the personal identification number (social security number) of the proxy representative. The personal data given to Componenta Corporation by the shareholders is used only in connection with the General Meeting and with the processing of related registrations. The shareholder, his/her authorized representative or proxy representative shall, if needed, be able to prove his/her identity and/or right of representation. 2. Holders of nominee registered shares A holder of nominee registered shares has the right to participate in the General Meeting by virtue of such shares based on which he/she on 6 May 2019 (the record date of the General Meeting) would be entitled to be registered in the shareholders’ register of the company held by Euroclear Finland Ltd. The right to participate in the General Meeting requires, in addition, that the shareholder on the basis of such shares has been registered into the temporary shareholders’ register held by Euroclear Finland Ltd. at the latest by 13 May 2019 at 10.00 EET. As regards nominee registered shares this constitutes due registration for the General Meeting. A holder of nominee registered shares is advised to request without delay necessary instructions regarding the registration in the temporary shareholders’ register of the company, the issuing of proxy documents and registration for the General Meeting from his/her custodian bank. The account management organization of the custodian bank has to register a holder of nominee registered shares, who wants to participate in the General Meeting, into the temporary shareholders’ register of the company at the latest by the time stated above. 3. Proxy representatives and powers of attorney A shareholder may participate in the General Meeting and exercise his/her rights at the meeting by way of proxy representation. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder. When a shareholder participates in the General Meeting by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the General Meeting. Possible proxy documents should be delivered in originals to Componenta Corporation at address Teknobulevardi 7, FI-01530 Vantaa, before the last date for registration. 4. Other instructions and information Pursuant to Chapter 5, Section 25 of the Limited Liability Companies Act, a shareholder who is present at the General Meeting has the right to request information with respect to the matters to be considered at the meeting. On the date of this notice to the General Meeting, 12 April 2019, the total number of shares and votes in Componenta Corporation is 177,269,224. COMPONENTA CORPORATIONBoard of Directors For further information, please contact: Harri SuutariPresident and CEOtel. +358 10 403 2200 Marko KarppinenCFOtel. +358 10 403 2101 Componenta is an international technology company. Componenta specializes in supplying cast and machined components to its global customers, who are manufacturers of vehicles, machines and equipment. The company’s share is listed on Nasdaq Helsinki. 

Interim-report January-March 2019

· Rental income increased to SEK 718m (546). In an identical portfolio, income rose by approximately 19 per cent. · Net operating income increased to SEK 509m (439). In an identical portfolio, net operating income rose by approximately 19 per cent. · The surplus ratio was 71 per cent (72). · Profit from property management increased with 33 per cent to SEK 366m (274). · Realised and unrealised changes in value amounted to SEK 1,324m (2,783) · Net lettings during the period totalled SEK -107m (9) after the Swedish Tax Agency terminated its agreement for the property Nöten 4. · After-tax profit for the period amounted to SEK 1,148m (2,539), corresponding to SEK 3.47 per share (7.86).  - “The year began with rising rental income, improved profit from property management and continued value growth, primarily via projects and higher rent levels. I see no signs of a slowdown at this time. The rental market in Stockholm is still characterized by low vacancies and increasing rents. The negative net lettings during the period were the result of the decision by the Swedish Tax Agency to move to new premises, commented Christian Hermelin, CEO  Market outlook - ” Fabege has every opportunity to continue its successful value-creating development. Stockholm is strong and growing, which provides excellent prospects for Fabege’s continued growth. Fabege is well-positioned and can offer office space in attractive, modern and sustainable districts in Greater Stockholm - both north and south.  Our value-generating projects continue to contribute to Fabege’s total performance. We are intensively working on completing more scheduled development rights to offer to office customers on the Stockholm market,” says Christian Hermelin, CEO. Fabege AB (publ) Presentation of the reportToday at 09:00 CET Christian Hermelin, CEO and Åsa Bergström, CFO present the report on Operaterrassen Stockholm. The Swedish presentation can be followed via webcast .  An English conference call will also be held at 10:30 CET. Follow it via webcast  or phono: UK: +44 333 300 92 65, US: +1 833 526 8 380, Swe +46 8 505 583 66   More information is available from: Christian Hermelin, CEO, +46 8 555 148 25 or +733 87 18 25Åsa Bergström, CFO, +46 8 555 148 29 or +46 706 66 13 80 This information is information that Fabege AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on 12 April 2019. This information is also such information that Fabege AB is obliged to publish in accordance with the Swedish Securities Market Act. The information was submitted for publication on 12 April 2019, at 07:30 CET. Fabege is a property company focusing on city district development and commercial properties. We develop attractive and sustainable districts with modern offices, housing and a broad range of services - together with strategic partners. Both our perspective and approach to ownership are long term and our passion is creating the right conditions for all those living, working and visiting our areas. We have a presence in a limited number of high-growth submarkets in the Stockholm region. Fabege’s shares are listed on Nasdaq Stockholm, in the Large Cap segment. For more information, www.fabege.com 

The Board of Artificial Solutions International AB Resolves on an Issue in Kind

The board of directors of Artificial Solutions International AB has resolved, in accordance with the authorization from the annual general meeting on 28 February 2019, to issue maximum 48,610 new shares against contribution in kind, to the remaining shareholders of Artificial Solutions Holding ASH AB. Artificial Solutions International AB (Nasdaq First North: ASAI) (”Artificial Solutions International” or the ”Company”) resolved at the annual general meeting on 28 February 2019, in accordance with the board of directors’ proposal, to acquire all the shares and warrants in Artificial Solutions Holding ASH AB (”Artificial Solutions Holding”) by an issue of not more than 645,392,020 shares in Artificial Solutions International against contribution in kind (the ”Issue in Kind”). Of these, 643,933,819 shares were subscribed for, corresponding to 99.8 percent of the Issue in Kind. Scope Growth II L.P. and Scope Growth III L.P. (together referred to as “Scope”) has, under a shareholders’ agreement between the previous owners of Artificial Solutions Holding, including drag-along rights, called that the remaining shareholders of Artificial Solutions Holding who did not participate in the Issue in Kind, shall transfer their shares in Artificial Solutions Holding to Artificial Solutions International, under the same terms and conditions as in the Issue in Kind. By reason of this, the board of directors of Artificial Solutions International has resolved, in accordance with the authorization from the annual general meeting on 28 February 2019, to increase the share capital by an issue of new shares in the Company against contribution in kind with the remaining shares in Artificial Solutions Holding that the Company does not own. Based on the closing price of the Company’s share on 11 April 2019 of SEK 27 per share, the Artificial Solutions International shares to be issued are valued at approximately SEK 1,312,470 in total if fully subscribed. As a result, the Company’s share capital is increased by not more than SEK 87,498.01 to not more than SEK 39,614,861.47 and the number of shares increases by not more than 48,610 new shares, if fully subscribed. With regards to the drag-along right under the shareholders’ agreement the Company plans for the issue in kind to be fully subscribed and to hold all shares in Artificial Solutions Holding in short.

Intrum ups efficiency with new contact-centre technology

“Advania will handle application operations across Europe, where just over 6,000 employees in the contact centres will seamlessly communicate with individuals and companies about their late payments. In addition, we are entering into a strategic partnership with Intrum and developing customer services so that they function optimally across all the different channels. It’s a new and fun business-oriented step for us,” explains Pär Lindström, Communications Centre Customer Manager at Advania. Intrum has already implemented the system Pure Connect in Denmark. It will be up and running in Sweden, Finland, the UK and the Baltics by February next year. Once every country is using the same system, there will be around 24 countries in Europe and 6,000 agents that will be able to communicate seamlessly in everything from ordinary phone calls to chat, WhatsApp and Messenger. “The aim is to minimise the number of solutions for our contact centres, while at the same time outsourcing the development and optimisation of the system. This will enable us to save money and focus on what we’re good at – helping companies and organisations get paid and individuals to become debt-free,” says Juuso Rantasalo, Business Development Manager at Intrum. By choosing Pure Connect, Intrum has gone from having different local solutions in each country to a common online and digital-based contact-centre platform. The platform provides functions for chatbots and instant messaging for Facebook and Twitter. All the functionality is built into the platform so that there is no need for third-party providers. Advania is responsible for supplying and operating the platform, plus applications and function development. The agreement was signed on 1 February 2019 and will run for three years with an option for extension.

Castellum’s Interim report January-March 2019 to be published on April 24, 2019 – invitation to teleconference

The Interim report January-March 2019 will be presented during the teleconference which will be hosted by Castellum’s CEO Henrik Saxborn and CFO Ulrika Danielsson. The presentation will also include a Q&A session and will be held in English. Date:                 April 24, 2019Time:                Report published 08:00 am (CET)                             Teleconference 09:00 am (CET) To participate in the teleconference, please dial in on any of the telephone numbers below at least ten minutes before the teleconference: SE:                      +46856642706UK:                    +443333009264US:                     +18338230590NL:                    +31207219496 You can access the presentation and the conference via the streaming link below:https://financialhearings.com/event/11808The Interim Report January-March 2019 and presentation will be available on Castellum.com:https://www.castellum.se/en/investor-relations/download-center/ Castellum AB (publ) For further information, contact:Ulrika Danielsson, CFO, Castellum AB, phone +46-(0)706 47 12 61Isabelle Ljunggren, Investor Relations, Castellum AB, phone +46-(0)708 30 08 90www.castellum.com Castellum is one of the largest listed real estate companies in Sweden. Property values amount to SEK 89.2 billion and holdings comprise office, warehousing/logistics and public sector properties, covering a total leasable area of 4.3 million square metres.      The real estate portfolio is owned and managed under the Castellum brand through a decentralized organization with strong and clear local presence in 20 cities in Sweden and also in Copenhagen and Helsinki.   In 2018, Castellum received two awards for sustainability efforts; designated Number One in the world by GRESB for the offices-and-logistics sector, as well as the Level Gold award for sustainability reporting from the EPRA (European Public Real Estate Association). In addition, Castellum is the only Nordic real-estate and construction company elected to the Dow Jones Sustainability Index (DJSI), joining a select group of companies in the world who perform best on sustainability issues.   The Castellum share is listed on Nasdaq Stockholm Large Cap. Castellum AB (publ), Box 2269, SE-403 14 Gothenburg | Corp Id no SE 556475-5550 | Phone +46 (0)31-60 74 00 | www.castellum.com

Invitation to the presentation of Resurs’s first quarter report 2018

The presentation will be held in Swedish and can be followed on the web or over the phone. The presentation will also be translated into English and can be followed on the web or over the phone. To participate in the conference call, call one of the following numbers: Sweden +46851999383UK +443333009269 You can follow and listen to the presentation and the conference on the following pages: Swedish: https://tv.streamfabriken.com/sv-resurs-holding-q1-2019 English: https://tv.streamfabriken.com/en-resurs-holding-q1-2019 The presentation material will be available before the conference begins on Resurs web www.resursholding.com It will also be possible to access the recorded version of the webcast after it is finished on this page. For additional information:Sofie Tarring Lindell, IR-Officer, sofie.tarringlindell@resurs.se +46 736 44 33 95   About Resurs:Resurs Holding (Resurs), which operates through the subsidiaries Resurs Bank and Solid Försäkring, is the leader in retail finance in the Nordic region, offering payment solutions, consumer loans and niche insurance products. Since its start in 1977, Resurs Bank has established itself as a leading partner for sales-driven payment and loyalty solutions in retail and e-commerce, and Resurs has thus built a customer base of approximately 5.9 million private customers in the Nordics. Resurs Bank has had a banking licence since 2001 and is under the supervision of the Swedish Financial Supervisory Authority. The Resurs Group operates in Sweden, Denmark, Norway and Finland. At the end of 2018, the Group had 765 employees and a loan portfolio of SEK 28 billion. Resurs is listed on Nasdaq Stockholm. 

Notice to attend the annual general meeting of Recipharm AB (publ)

The shareholders in Recipharm AB (publ), reg. no. 556498-8425, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Monday 13 May 2019 at 3.00 pm at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden. Notification to attend etc. Shareholders who wish to attend the AGM must · be recorded in the share register kept by Euroclear Sweden AB no later than on Tuesday 7 May 2019; and · notify the Company of their intention to attend the AGM at the latest by Wednesday 8 May 2019. Notification to participate in the AGM must be in writing via the booking form available on the Company’s website www.recipharm.com  or by e-mail to AGM2019@recipharm.com. Notification can also be made by telephone at +46-8-602 45 44. The notification shall state name, personal identification number/ company registration number, address, telephone number and number of shares held. Proxies Shareholders represented by proxy must issue a written, signed and dated proxy. If the proxy is issued by a legal entity, a certified copy of the valid registration certificate (Sw. registreringsbevis) of the legal entity (or similar document for non-Swedish legal entity) must be attached to the proxy. The proxy may not be older than one year unless it states that it is valid for a longer period of time (the validity of the proxy may not exceed five years). In order to facilitate the registration, proxies in its original as well as registration certificates and other authorization documents should be sent to the Company at the address Recipharm AB (publ), Att: Anna Krantz, Box 603, SE-101 32 Stockholm, well in advance before the meeting. Proxy forms for shareholders who wish to attend the meeting by proxy will be available on the Company website, www.recipharm.com. Shareholding in the name of a nominee In order to be entitled to participate in the meeting, shareholders who hold their shares through nominees (Sw. förvaltare) must request a temporary registration of the shares in their own name, with Euroclear Sweden AB. Shareholders who wishes to obtain such registration must contact the nominee regarding this well in advance of 7 May 2019. Proposal for agenda 1. Opening of the meeting 2. Election of Chairman of the meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of one or two persons to approve the minutes 6. Determination as to whether the meeting has been duly convened 7. Presentation of the annual report and the auditor’s report as well as the consolidated annual report and the auditor’s report on the consolidated annual report 8. Statement by the CEO 9. Adoption of the profit and loss statement and the balance sheet as well as the consolidated profit and loss statement and the consolidated balance sheet10. Resolution in respect of appropriation of the Company’s profit or loss as set forth in the adopted balance sheet11. Resolution in respect of discharge of the board members and the CEO from liability12. Determination of number of board members and auditors13. Determination of fees for board members and auditors14. Election of board members and Chairman of the Board of Directors15. Election of auditor16. Determination of the rules of procedure for the appointment of the Nomination Committee and the instruction for the Nomination Committee17. Resolution in respect of guidelines for remuneration for senior executives18. Resolution to implement a share savings program for 2019, including:(a) approval of the program;(b) authorization for the Board of Directors to resolve on direct issues of shares of series D;(c) authorization for the Board of Directors to resolve to repurchase of shares of series D19. Resolution in respect of authorization for the board to issue shares and/or convertible bonds20. Closing of the meeting Proposals by the nomination committee The Nomination Committee has consisted of Axel Calissendorff, Chairman of the Nomination Committee, representing Flerie Participation AB, Lars Backsell, Chairman of the Board of Directors of Recipharm AB, Johan Lannebo, representing Lannebo Fonder, and Ossian Ekdahl, representing Första AP-fonden. Election of chairman of the meeting (item 2) The Nomination Committee proposes that Lars Backsell is elected as Chairman of the meeting. Determination of number of board members and auditors (item 12) The Nomination Committee proposes that the board shall consist of eight (seven) board members elected by the general meeting. The Nomination Committee also proposes that the Company shall have one registered auditing company as auditor. Determination of fees for board members and auditors (item 13) The Nomination Committee proposes that the total remuneration for the Board of Directors shall amount to SEK 2,270,000 (previous SEK 1,765,000 but then for seven board members), of which SEK 500,000 (previous SEK 400,000) shall be paid to the Chairman of the Board of Directors and SEK 250,000 (previous SEK 220,000) shall be paid to each of the other board members elected by the general meeting and who are not employees of the group. The Nomination Committee proposes that a fee of SEK 100,000 (previous SEK 70,000) shall be paid to the Chairman of the Audit Committee and that a fee of SEK 50,000 (previous SEK 45,000) shall be paid to each of the other two members. The Nomination Committee proposes that a fee of SEK 40,000 (previous SEK 35,000) shall be paid to the Chairman of the Remuneration Committee and that a fee of SEK 30,000 (previous SEK 25,000) shall be paid to the other member. The Nomination Committee proposes that the audit fees shall be paid in accordance with approved invoices. Election of board members and chairman of the board of directors (item 14) As members of the Board of Directors until the end of the next annual general meeting, the Nomination Committee proposes re-election of Marianne Dicander Alexandersson, Lars Backsell, Carlos von Bonhorst, Anders G. Carlberg, Thomas Eldered and Helena Levander and new election of Eva Sjökvist Saers and Ashwini Kakkar. Wenche Rolfsen has declined to be re-elected. The Nomination Committee also proposes re-election of Lars Backsell as the Chairman of the Board of Directors. Election of auditor (item 15) The Nomination Committee proposes that the registered auditing company Ernst & Young AB shall be re-elected as auditor for the period until the next AGM 2020. Ernst & Young AB has informed that, if Ernst & Young AB is re-elected as auditor, Jennifer Rock-Baley will continue as the responsible auditor. The Nomination Committee’s proposal is recommended by the Company’s Audit Committee.      Determination of the rules of procedure for the appointment of the Nomination Committee and the instruction for the Nomination Committee (item 16) The Nomination Committee shall consist of four members – one representative from each of the three largest shareholders in terms of voting rights who wish to appoint a member of the Nomination Committee and the Chairman of the Board. In these instructions, ‘three largest shareholders in terms of voting rights’ refers to the three largest shareholders in terms of voting rights registered and grouped as owners by Euroclear Sweden AB. The Chairman of the Board shall, as soon as possible after the information about the largest shareholders in terms of voting rights becoming known, contact the three largest shareholders in terms of voting rights in order to ascertain if they wish to appoint members of the Nomination Committee. If one or more of the three largest shareholders in terms of voting rights refrains from appointing a member of the Nomination Committee, the Chairman of the Board shall offer other major shareholders the opportunity to appoint a member of the Nomination Committee. Should such offer be made, it shall be made in turn to the largest shareholders in terms of voting rights (i.e. first to the fourth largest shareholder in terms of voting rights, thereafter to the fifth largest shareholder in terms of voting rights, and so on). This procedure is continued until the Nomination Committee consists of four members including the Chairman of the Board. Information concerning ownership/owner groups held in Euroclear Sweden AB’s registers as of the last banking day in September shall constitute the basis for determining which shareholders are entitled to appoint a member of the Nomination Committee. At its first meeting, the Nomination Committee shall elect a Chairman. The Chairman of the Board of Directors or other board member shall not be the Chairman of the Nomination Committee. The Nomination Committee’s term of office shall run until a new Nomination Committee has been appointed. Should any change in ownership occur among the largest shareholders in terms of voting rights and a shareholder who has previously not been entitled to appoint a member of the Nomination Committee thereby becomes a larger shareholder than any of those who have appointed a member of the Nomination Committee (“new major shareholder”), the Nomination Committee shall, if the new major shareholder expresses a desire to appoint a member of the Nomination Committee, decide that the member of the Nomination Committee who represents the smallest shareholder in terms of voting rights shall be dismissed and replaced by the member appointed by the new major shareholder. Should a new major shareholder wish to appoint a member of the Nomination Committee, this shareholder shall notify this to the Nomination Committee’s chairperson. Such notification shall include the name of the person whom the new major shareholder appoints as member of the Nomination Committee. A shareholder who has appointed a member of the Nomination Committee has the right to dismiss the member and appoint a new member. The Nomination Committee shall submit proposals for: (a) Chairman of the AGM, (b) number of board members to be elected by the AGM, (c) Chairman and other members elected as the Board of Directors by the AGM; (d) fees and other remuneration to each of the board members elected by the AGM and to members of the committees of the Board of Directors, (e) auditors, (f) fees to auditors; (g) the election of the Nomination Committee, or a resolution on rules of procedures for the appointment of the Nomination Committee, and a resolution on the instructions for the Nomination Committee, and (h) remuneration for the members of the Nomination Committee. Should the Nomination Committee’s proposal entail a deviation from the Swedish Corporate Governance Code, the Nomination Committee shall, at the same time as it submits its proposal, provide the company with an explanation for the deviation. No fee shall be paid to the members of the Nomination Committee. The members of the Nomination Committee are entitled to payment from the company for proven reasonable expenses for the execution of their duties, such as, for example, the cost of recruitment services. These rules of procedure for appointment of the Nomination Committee and instructions for the Nomination Committee at Recipharm AB (publ) shall apply until further notice. Proposals by the board Dividend (item 10) The board proposes that the AGM decides on a dividend of SEK 1.25 per share and that the record date for the dividend shall be Wednesday 15 May 2019. If the AGM decides in accordance with the proposal, the dividend will be paid to shareholders on Monday 20 May 2019. Resolution in respect of guidelines for remuneration of senior executives (item 17) The Board of Directors proposes that the AGM shall resolve on guidelines for remuneration and other terms of employment for senior executives according to the following. These guidelines for remuneration of senior executives include salary and other terms for the CEO and other senior executives in Recipharm. Other senior executives are those who, besides the CEO, constitute the group management. The opinion of Recipharm is that remuneration shall be paid according to competitive terms, which enables senior executives to be recruited and retained. Remuneration of senior executives may consist of basic salary, annual bonus, pension, other benefits and share-based incentive programs. The remuneration of the CEO and other senior executives shall be based on factors such as duties, expertise, experience, position and performance. Furthermore, the relationship between basic salary and annual bonus shall be proportionate to employees’ responsibilities and duties. The annual bonus shall be linked to pre-determined criteria designed to promote the Company’s creation of value in the long-term. The remuneration shall not discriminate on grounds of gender, ethnic background, national origin, age, disability, religion or other irrelevant factors. In addition to salary, the CEO and other senior executives are generally entitled to an annual bonus of up to 40 percent of the base salary, annual pension equivalent to up to 35 percent of annual salary or according to collective agreements, sick pay equivalent to 75-90 percent of the monthly salary during the first 3-6 months of a period of sickness. The CEO and other senior executives generally have the right to health insurance and company car as well as other benefits in accordance with local practice. When possible, the pension arrangements shall be in accordance with current collective agreements. In addition to the bonus, approved share or share-price related incentive programs may be added. Regarding senior executives, provided that collective agreements do not state otherwise, the employee and the employer have a mutual notice period of up to six months. In addition to salary during the notice period, severance pay of up to six months of salary may occur. Senior executives residing outside Sweden may receive other remuneration or benefits that are competitive in the country of their residence, preferably equivalent to those of other senior executives residing in Sweden. The board members are paid fees determined by the general meeting. Board members elected by the shareholders’ meeting shall, in specific cases, receive a fee for services within their respective areas of expertise, which do not constitute work of the board. These services shall be remunerated according to market terms, which shall be approved by the board. The board shall be entitled to deviate from the guidelines in individual cases if there are special reasons for doing so. Resolution to implement a share savings program for 2019 (item 18) The AGMs of 2014 – 2018 decided to implement share savings programs for all employees of the Recipharm group (“Previous Programs”). The board’s intention is to make the structure of Previous Programs long-lasting, which is why the board intends to make similar proposals to be decided upon by the AGMs in the years to come. The board therefore proposes that the AGM approves a share savings program for 2019 (the “Program”), which is to include all employees in the group according to the following. Objective and motivation The main purpose of the Program is to increase the possibilities to recruit and retain employees in the group. Ownership commitment among the participants of the Program is also expected to increase the interest for the operations and the results, as well as raise the motivation and the affinity with Recipharm. The Program will constitute a competitive and motivating incitement for senior executives and other key members of the Recipharm group. The board therefore proposes that the AGM resolves to approve a share savings program for 2019 mainly based on the Previous Programs and based on the following conditions and principles. Preconditions for participation The Program will cover all employees in the Recipharm group operating in Sweden and other countries. Participation in the Program requires that participants, with their own funds, during the period from July 2019 to July/August 2020, acquires shares of series B in Recipharm (“Saving Shares”) at market price on Nasdaq Stockholm and for an amount not exceeding 5 percent of each participant’s annual fixed gross salary. Participation for senior executives, members of the subsidiaries executive groups and selected key employees, who are also eligible for the Performance Shares as described below, requires that participants acquire Saving Shares for an amount not exceeding 10 percent of the annual fixed gross salary. Scope and dilution of shares The maximum number of shares covered by the Program amounts to 1,119,026 shares of series B, corresponding to approximately 1.62 percent of the number of issued shares after dilution and approximately 0.54 percent of the votes after dilution. Considering the number of shares estimated to be issued according to the group’s other outstanding share saving programs, the total dilution effect for the 2019 Program and other outstanding programs is expected to amount to a total of approximately 1.80 percent of issued shares after dilution and approximately 0.60 percent of the votes after dilution. The expected dilution has been calculated on actual allocated shares in the 2016 and 2017 program and actual allocated shares and shares expected to be allocated in relationship with actual number of participants in the 2018 program. For the 2019 program the expected dilution has been calculate with the parameters disclosed in section “Estimated costs and value of the Program, and effects on key ratios”. Safety measures To ensure the delivery of Matching Shares and Performance Shares (see definitions below) the board proposes an authorization for the board to decide upon a directed issue of convertible and redemption shares of series D, which are to be repurchased and converted to shares of series B within the Program, according to item 18(b) and 18(c) below. Estimated costs and value of the Program, and effects on key ratios The Program will be accounted for in accordance with IFRS 2 which stipulates that the rights should be recorded as a personnel expense in the income statement during the vesting period. Based on the assumptions of a share price of SEK 136.5 (closing share price on 9 April 2019), a participation of 50 percent, no annual employee turnover among the participants of the Program and full satisfaction of performance conditions, the cost for the Program, excluding social security costs, is estimated to approximately SEK 76.4 million. The cost will be allocated over the years 2019-2022. The estimated social security costs will be recorded as a personnel expense in the income statement by current reservations. The social security costs are estimated to around SEK 30.5 million with the assumptions above, an average social security tax rate of 30 percent and an annual share price increase for Recipharm’s shares of series B of 10 percent during the vesting period. However, the board assess that the positive effects on the financial results of Recipharm, which are expected to arise from the Program, will outweigh the costs related to the Program. Preparation of the matter The Program has been initiated by the Board of Directors of Recipharm and has been worked out in detail in cooperation with external advisors. The Program has been prepared in the Remuneration Committee and processed at the board meetings held in the beginning of 2019. Resolution on the adoption of share savings program for 2019 (item 18(a)) With reference to the description above, the board proposes that the AGM decides to adopt a share savings program substantially based on the terms and principles below. 1. The Program will encompass all employees of the Recipharm group who are active in Sweden as well as other countries. Participation in the Program requires that participants, with their own funds, during the period from July 2019 to July/August 2020, acquires Saving Shares in Recipharm at market price on Nasdaq Stockholm and for an amount not exceeding 5 percent of each participant’s annual fixed gross salary. Participation for senior executives, members of the subsidiaries’ managerial groups and selected key employees, who are also eligible for the Performance Shares as described below, requires that participants acquire Saving Shares for an amount not exceeding 10 percent of the annual fixed gross salary. 2. The duration of the Program is suggested to be set at just above 3 years from the effective date of the Program (“Saving Period”). 3. A participant who keeps the Saving Shares during the entire Saving Period, and additionally remain employed in the group during the entire Saving Period, will, after the expiration of the Saving Period, receive one new Saving Share of series B for every old Saving Share (“Matching Share”), free of charge. 4. The senior executives within the company group, members of local managerial groups and selected key employees will, in addition to Matching Shares, also be eligible for free additional shares of series B in Recipharm (”Performance Shares”), provided that the participant remains employed within the group for the entire Saving Period, and also fulfils certain requirements of performance. These requirements of performance involve that the yield on the Recipharm share remains positive during the entire Saving Period and that the outcome of the Program is made dependent on the total yield in relation to certain predetermined reference companies. The CEO of the company is entitled to a maximum of six Performance Shares per Saving Share, and certain other senior executives (including affiliates’ CEOs) are entitled to a maximum of four Performance Shares respectively. Members of local managerial groups (excluding affiliates’ CEOs) and selected key employees are entitled to one Performance Share per Saving Share. As a board member (who is, moreover, one of the main owners of the company), the current CEO of the company, Thomas Eldered will refrain from participating in the Program. 5. The number of Matching Shares and Performance Shares can be subject of recalculation in the event of an intervening bonus issue, preferential issue, split, and/or other similar measures. 6. The board, or the remuneration committee of the company, shall be responsible for the further construction of the detailed conditions for the Program, within the scope of the conditions and guidelines stated above. The board shall have the right to make necessary adjustments in order to observe legislation, market conditions or restrictions of certain jurisdictions. The board shall also, in the event that participation and/or delivery of shares to participants outside Sweden cannot be fulfilled at reasonable costs and with a reasonable amount of administrative efforts, have the right to make adjustments, encompassing inter alia a right to decide upon a cash deduction-offer to an employee. Furthermore, it is proposed that the board shall have the right to make other amendments, if the board finds it suitable, if changes occur within the Recipharm group or its surroundings, which imply that the Program does no longer fulfils its overarching purpose. 7. The maximum number of shares covered by the Program amounts to 1,119,026 shares of series B, corresponding to approximately 1.62 percent of the number of issued shares after dilution and approximately 0.54 percent of the votes after dilution. Considering the number of shares estimated to be issued under the group’s other outstanding share saving programs, the expected total dilution effect amounts to approximately 1.80 percent of the issued shares after dilution and approximately 0.60 percent of the number of votes after dilution. Resolution on authorization for the Board of Directors to decide on a direct issue of shares of series D (item 18(b)) The board proposes that the AGM resolves to authorize the board to, at one or several occasions during the period until the next AGM, issue of up to 1,119,026 shares of series D, each with a quota value of SEK 0.50. The new shares may, with deviation from the shareholders’ preferential rights, be subscribed for by a bank or a securities company. The amount to be paid for each new share (the subscription price) shall correspond to the share’s quota value at the time of the subscription. The purpose of the authorization and the reason for deviation from the shareholders’ preferential rights is to assure delivery of shares to the participants in accordance with all Recipharm’s share saving programs. Resolution on authorization for the board to decide on a repurchase of shares of series D (item 18(c)) The board proposes that the AGM resolves to authorize the board to, for the period until the next AGM, decide on a repurchase of shares of series D. Repurchase may only take place by way of an acquisition offer directed to all holders of shares of series D and shall encompass all outstanding shares of series D. Purchases shall be made at a price per share corresponding to the quota value per share applicable at the time of subscription. Payment of repurchased shares shall be made in cash. The purpose of the authorization is to hedge to undertakings of the delivery of shares in accordance with all Recipharm’s share saving programs. The board’s opinion, pursuant to Chapter 19, section 22 of the Swedish Companies Act, on the proposal to authorize the board to decide on a repurchase of shares of series D is available in accordance to the section “Documents” below. Resolution in respect of authorization for the board to resolve to issue of shares and/or convertible bonds (item 19) Recipharm has a clear acquisition strategy aimed at enabling the Company to participate in the consolidation of CDMO industry. Through acquisitions, Recipharm is offered the opportunity to have access to both new technologies and extended capacity, and new customers and markets. Through acquisitions, Recipharm also strengthen its presence in emerging markets. The Board of Directors proposes that the AGM authorizes the Board of Directors to, on one or several occasions during the period until the next AGM, with or without deviation from the shareholders’ preferential rights, resolve on share issues and/or issues of convertible bonds that involve the issue of or conversion to a maximum of 6,800,000 shares of series B, corresponding to a dilution of approximately 10.0 percent of the share capital and approximately 3.3 percent of the voting rights, based on the current number of shares in the Company. The purpose of the authorization and the reason for the deviation from the shareholders’ preferential rights, if any, is to enable the Company to carry out issues of shares and/or convertible bonds in a time-efficient way to finance acquisitions or investments in new or existing businesses. The issuance of shares or convertible bonds under the authorisation shall, in case of deviation from the shareholders’ preferential rights, be made at a subscription price according to the prevailing market conditions at the time of the issuance of the shares and/or convertible bonds. Payment for subscribed shares and/or convertible bonds shall be made in cash, in kind or by way of set-off. OTHER INFORMATION Number of shares and votes As per 12 April 2019 the total number of shares in the Company amounts to 67,775,793 representing a total of 204,781,515 votes, whereof 15,222,858 shares of series A, 52,182,935 shares of series B and 370,000 shares of series D. The Company holds 10,121 shares of series B and 370,000 shares of series D. Majority requirement of the proposed resolutions in items 18-19 A resolution pursuant to item 18(a) is only valid if approved by shareholders representing at least nine-tenths of the votes cast as well as the shares represented at the AGM. The items 18(a), 18(b) and 18(c) are conditional upon each other. Resolutions pursuant to item 18(b), 18(c) and 19 are only valid if approved by shareholders representing at least two-thirds of the votes cast as well as the shares represented at the shareholders’ meeting. Documents The Board of Directors’ complete proposal pursuant to items 16 and 18, the Board of Directors’ reports and the auditor’s statements pursuant to the Swedish Companies Act (SFS 2005:551), the Nomination Committee’s statement regarding the proposals relating to the Board of Directors and information about the proposed board members will, no later than on 12 April 2019, be held available at the Company’s website, www.recipharm.com, at the Company’s office at Drottninggatan 29 in Stockholm and will be sent free of charge to shareholders who so request and provide their postal address or email address. The annual report and the audit report will be available at the Company’s website and at the Company’s office at the address set out above as from 17 April 2019.   The shareholders’ right to submit questions The Board of Directors and the CEO shall, if any shareholder so requests and the board believes that it may be done without significantly harming the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda, circumstances that can affect the assessment of the Company’s or its subsidiaries’ financial position and the Company’s relationship to other companies within the group as well as the consolidated financial statements. Anyone wishing to submit questions in advance can do so by sending them to the Company at the address mentioned above. ____________________ Stockholm, April 2019 RECIPHARM AB (PUBL) The Board of Directors

Notice of Annual General Meeting in Balco Group AB

The shareholders in Balco Group AB, reg. no. 556821-2319, are hereby invited to the Annual General Meeting, to be held on Tuesday 21 May 2019, at 3.00 pm at Kök 11, Honnörsgatan 15 in Växjö. Registration starts at 2.30 pm. RIGHT TO ATTEND AND NOTIFICATION TO THE COMPANYShareholders who wish to attend the Annual General Meeting shall: -be registered in the shareholders’ register maintained by Euroclear Sweden AB on Wednesday 15 May 2019, and -notify the Company of their intention to attend the meeting no later than Wednesday 15 May 2019 by mail to Balco Group AB, Annual General Meeting 2019, Box 191, 101 23 Stockholm or by telephone on +46 8 402 91 98. The notification shall set forth the name/business name, personal identity/reg. number, address, telephone number (daytime), the number of shares held and, when applicable, the number of assistants (not more than two). A shareholder’s rights at the Annual General Meeting may be exercised by an authorized proxy with a dated power of attorney, which shall be in writing and signed by the shareholder. If the power of attorney is issued by a legal entity, a certified copy of a certificate of registration for that entity or equivalent certificate of authority must be enclosed to it. The power of attorney, certificate of registration and other certificates of authority should be submitted to the Company to the above address in due time prior to the meeting. A form of power of attorney is available on the Company’s website www.balcogroup.se and can also be obtained at the Company’s office or ordered by telephone according to the above. Shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names to be entitled to participate in the meeting. Such registration, which can be temporarily, shall be executed by Euroclear Sweden AB no later than 15 May 2019, which means that the shareholder must inform the nominee of such request well before 15 May 2019. PROPOSED AGENDA1. Opening of the Annual General Meeting2. Election of chairman for the Annual General Meeting3. Preparation and approval of the voting list4. Approval of the agenda5. Election of one or two persons to verify the minutes6. Determination of whether the Annual General Meeting has been duly convened7. Presentation of the annual report and the auditor’s report as well as the consolidated accounts and the auditor’s report on the consolidated accounts8. Statement by the CEO and the auditor9. Resolutions regarding:a) adoption of the profit and loss statement and the balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet;b) disposition of the Company’s profits according to the adopted balance sheet and determination of the record day for dividends; andc) discharge from liability for the members of the Board of Directors and the CEO for the financial year 201810. The Nomination Committee’s statement regarding its proposals for the Annual General Meeting and the Nomination Committee’s justified statement regarding their proposal of election of Board members11. Determination of the number of Board members12. Determination of the number of auditors13. Determination of remuneration to the Board members14. Determination of remuneration to the auditor15. Election of Board members and chairman16. Election of auditor17. Resolution on guidelines for remuneration to senior executives18. Resolution on issue authorisation for the Board of Directors19. Resolution regarding:a) authorization for the Board of Directors to resolve on acquisition of own shares; andb) authorization for the Board of Directors to resolve on transfer of own shares20. Closing of the Annual General Meeting THE NOMINATION COMMITTEEThe Nomination Committee ahead of the Annual General Meeting has consisted of the following members: Gabriel Urwitz, appointed by Segulah IV L.P. (chairman of the Nomination Committee), Lennart Björkman, appointed by Skandrenting AB, Carl-Mikael Lindholm, appointed by Carl-Olof och Jenz Hamrin’s Foundation, Marianne Flink, appointed by Swedbank Robur, and Lennart Kalén, Balco’s chairman. THE BOARD OF DIRECTORS’ AND THE NOMINATION COMMITTEE’S PROPOSALSProposal under item 2: Election of chairman of the Annual General MeetingThe Nomination Committee proposes Lennart Kalén, Balco’s chairman, as chairman of the Annual General Meeting. Proposal under item 9b: Disposition of the Company’s profits according to the adopted balance sheetThe Board of Directors proposes a dividend of SEK 2.00 per share, equivalent to a total of SEK 42,857,546. The proposed record date for the dividend is 23 May 2019. If the Annual General Meeting approves the proposal, the dividend is expected to be paid through Euroclear Sweden AB on Tuesday 28 May 2019. Proposal under item 11: Determination of the number of Board membersThe Nomination Committee proposes that the Board of Directors, for the period until the end of the next Annual General Meeting, shall consist of six members, without deputies. Proposal under item 12: Determination of the number of auditorsThe Nomination Committee proposes that the number of auditors, for the period until the end of the next Annual General Meeting, remains unchanged and that there shall be one auditor, without deputies. Proposal under item 13: Determination of remuneration to the Board membersThe Nomination Committee proposes, for the period until next Annual General Meeting, remuneration on a yearly basis as follows:(i) SEK 500,000 to the chairman of the Board of Directors;(ii) SEK 190,000 to each of the other members of the Board of Directors;(iii) SEK 70,000 to the chairman of the Audit Committee;(iv) SEK 40,000 to each of the other members of the Audit Committee;(v) SEK 40,000 the chairman of the Remuneration Committee; and(vi) SEK 25,000 to each of the other members of the Remuneration Committee. Proposal under item 14: Determination of remuneration to the auditorThe Nomination Committee proposes that remuneration to the auditor shall be paid in accordance with the approved bill. Proposal under item 15: Election of Board members and chairmanThe Nomination Committee proposes, for the period until the end of the next Annual General Meeting, re-election of Ingalill Berglund, Tomas Johansson, Carl-Mikael Lindholm, Johannes Nyberg and Åsa Söderström Winberg as Board members and election of Mikael Andersson. Mikael has had a long career within Asea/ABB AB, Saint Gobain, Trelleborg AB (currently part of Nordic Waterproofing) as well as PMC Group AB. Mikael Andersson was born in 1955 and holds a degree in engineering from the Faculty of Engineering, Lund University. Mikael Andersson currently has no other Board assignments. The chairman of the Board of Directors Lennart Kalén and member of the Board member Percy Calissendorff have declined re-election. Tomas Johansson is proposed to be elected as chairman of the Board of Directors. The Nomination Committee makes the assessment that Mikael Andersson, with his broad industrial background from senior positions in several international companies as well as hislong career as a CEO, will bring valuable expertise to the work of the Board of Directors. A full presentation of the Nomination Committee’s proposed Board members is available on the Company’s website www.balcogroup.se. Proposal under item 16: Election of auditorThe Nomination Committee proposes, in accordance with the Audit Committee’s recommendation, for the period until the end of the next Annual General Meeting, re-election of the authorized accounting firm Öhrlings PricewaterhouseCoopers (”PwC”) as the Company’s auditor. PwC has notified that, if the Annual General Meeting approves the Nomination Committee’s proposal, the authorized auditor Martin Odqvist will be auditor in charge. Proposal under item 17: Resolution on guidelines for remuneration to senior executivesThe Board of Directors proposes guidelines for remuneration to senior executives, which in all essential parts are equivalent to last year’s guidelines, as follows: Guidelines for remuneration to the senior executivesThe senior management, which consists of nine people and the CEO, are regarded as senior executives. The guidelines’ purpose is to ensure that Balco can attract, motivate and retain senior executives. The aim of the remuneration is to be competitive in comparison with prevailing market standards and at the same time in accordance with the shareholders’ interests. The remuneration to senior executives shall consist of fixed and variable remuneration, the opportunity to participate in a long-term incentive program as well as pension contributions. These components shall together create a well-balanced remuneration, which reflects individual competence, responsibility and performance, both short-term and long-term, as well as the Company’s total performance. Fixed and variable remunerationThe fixed remuneration shall be competitive in comparison with prevailing market standards and shall be based on the individual senior executive’s competence, responsibility and performance. Senior executives shall be able, in addition to fixed remuneration, to receive variable remuneration. Such variable remuneration may not exceed 50 per cent of the fixed remuneration. The variable remuneration shall be based on pre-defined and documented financial and individual targets. Other benefits and pensionThe Group offers other benefits to the senior executives in accordance with local practice. Such other benefits can for example consist of a company car and health services. When applicable, accommodation is offered during a limited time. The senior executives shall be offered pension contributions in line with market terms in the country where they are employed. Pension obligations are secured through payments of premiums to insurance companies. Deviations from the guidelinesIn special circumstances, the Board of Directors may deviate from the above guidelines, for example in relation to additional variable remuneration after exceptional achievements. In such a case, the Board of Directors is obligated to give account for the reason for the deviation at the following Annual General Meeting. Notice periods and severance compensationFor the CEO a notice period of twelve months applies in case of termination by the Company and six months in the case of termination by the CEO. The CEO is bound by a non-competition clause, which is valid for two years after the termination. For the other senior executives, the mutual notice period is between three and twelve months. Proposal under item 18: Resolution on issue authorisation for the Board of DirectorsThe Board of Directors proposes that the Annual General Meeting shall decide to authorize the Board of Directors to, at one or several occasions until the next Annual General Meeting, resolve to issue, with or without preferential rights for the shareholders, against payment in cash, payment in kind or payment through set-off, shares or share warrants or convertibles referring to such shares, signifying an increase or potential increase of the Company’s share capital with a maximum of ten (10) per cent or 2,142,877 shares. The purpose of the authorization and the reasons for a possible deviation from the shareholders’ preferential rights is that new issues of shares shall be able to occur to finance company acquisitions or to finance further growth in the Company in other ways. Proposal under item 19 (a) Resolution regarding authorization for the Board of Directors to resolve on acquisition of own sharesThe Board of Directors proposes that the Annual General Meeting shall decide to authorize the Board of Directors to, on the following terms, acquire own shares in the share class that, at the time of the authorization, is admitted to trading on Nasdaq Stockholm. Any shares purchased shall be purchased on Nasdaq Stockholm. The authorization may be utilized on one or several occasions during the period until the next Annual General Meeting. The number of shares that may be acquired shall not exceed a number implying that the Company’s total shareholding of own shares after acquisition corresponds to more than 10 per cent of all shares in the Company at any time. The shares in the Company on Nasdaq Stockholm shall be acquired only within the price range, i.e. the spread between the highest purchase price and the lowest selling price. The purpose of the authorization to acquire own shares is to enable an improvement of the Company’s capital structure and to give the Board of Directors an increased scope of action in relation to future company acquisitions by facilitating a fast and cost-effective financing through the disposition of own shares. Proposal under item 19 (b) Resolution regarding authorization for the Board of Directors to resolve on transfer own sharesThe Board of Directors proposes that the Annual General Meeting shall decide to authorize the Board of Directors to, on the following terms, resolve on transfers of own shares in the share class that, at the time of the utilization of the authorization, is admitted to trading on Nasdaq Stockholm. Transfers of own shares may be carried out on Nasdaq Stockholm or by other means. The authorization may be utilized on one or several occasions during the period until the next Annual General Meeting. Transfers of own shares may be made without preferential rights for the shareholders. The maximum number of shares that may be transferred is the total number of own shares held by the company at the time of the Board of Directors’ resolution to transfer the shares. Transfers made on Nasdaq Stockholm shall be carried out at a price within the price range, i.e. the spread between the highest purchase price and the lowest selling price. Transfer of own shares in another manner shall be made at a minimum price that shall be determined in close connection with the shares’ quoted price at the time of the Board’s resolution to transfer the shares. Payment for own shares that are transferred can be made in cash, in kind or through set-off. The Board of Directors is entitled to determine the other terms and conditions of the transfer which, however, shall be in accordance with the market practice. The purpose of the authorization to acquire own shares and transfer own shares and the reason for the deviation from the shareholders’ preferential rights is to enable an improvement of the Company’s capital structure and to give the Board of Directors an increased scope of action in relation to future company acquisitions by facilitating a fast and cost-effective financing through the disposition of own shares. NUMBER OF SHARES AND VOTESThe total number of shares and votes in the Company, at the time of issue of the notice, is 21,428,773. The Company does not possesses shares that cannot be represented at the Annual General Meeting. SHAREHOLDERS’ RIGHT TO REQUEST INFORMATIONThe Board of Directors and the CEO shall, if requested by a shareholder and if the Board of Directors considers that it can be done without significant harm to the Company, at the Annual General Meeting, provide information about circumstances that may affect the assessment of an item on the agenda and about circumstances that may affect the assessment of the Company’s or the subsidiary Company’s financial situation, the consolidated accounts as well as the Company’s relation to another group company. PROCESSING OF PERSONAL DATAFor information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. AVAILABLE DOCUMENTSAccounts, the auditor’s report, complete proposals and required statements of the Board of Directors as well as other documents that shall be provided prior to the Annual General Meeting according to the Companies Act and the Swedish Code of Corporate Governance, will be available at the Company’s office and on the Company’s website, www.balcogroup.se, at the latest on Tuesday 30 April 2019 and will also be sent free of charge to the shareholders who make a request to that effect and provide their postal address. * * *Växjö in April 2019Balco Group AB (publ)The Board of Directors For more information, please contact: Cecilia Lannebo, Head of IR, 072-220 82 77, cecilia.lannebo@balco.seThis pressrelease was submitted for publication at 08:00 CET on April 12, 2019. 

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in BONESUPPORT HOLDING AB, Reg. No. 556802-2171, are hereby invited to attend the annual shareholders’ meeting (Sw. årsstämma) to be held at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden on Tuesday 14 May 2019 at 10.00 a.m. Right to participate and notice of participation Shareholders wishing to attend the annual shareholders’ meeting must: · partly be registered in the company’s share register kept by Euroclear Sweden AB (the Swedish Securities Register Center) as of Wednesday 8 May 2019; and · partly notify the company of their intention to participate in the annual shareholders’ meeting no later than on Wednesday 8 May 2019, by mail to address BONESUPPORT HOLDING AB, att: Bolagsstämma, Scheelevägen 19, SE-223 70 Lund, by e-mail to legal@bonesupport.com or by phone to +46 (0)46 286 53 70. The notice shall specify the shareholder’s complete name, personal or company registration number, registered shareholding, address, telephone number during work hours and, when applicable, information on the number of advisors (two at the most). Trustee registered shares Shareholders who have their holdings trustee-registered must temporarily register the shares in their own name with Euroclear Sweden AB in order to be entitled to participate in the annual shareholders’ meeting. Such temporary re-registration of ownership must be implemented no later than as of Wednesday 8 May 2019, meaning that the shareholders must well in advance before this date request their trustees thereof. Proxies etc. A proxy representing a shareholder must bring a written, dated and by the shareholder signed power of attorney to the annual shareholders’ meeting. The power of attorney must not be older than one year, unless a longer validity term (maximum five years) has been stipulated. Should the power of attorney be issued by a legal entity, an up-to-date copy of a registration certificate (Sw. registreringsbevis) or equivalent document shall be presented by the proxy at the meeting. In order to facilitate the preparations before the annual shareholders’ meeting, a copy of the power of attorney and other proof of authority should be attached to the notice of participation. A template power of attorney can be found at the company website (www.bonesupport.com), and will be sent to the shareholders who request it and state their address. Proposed agenda 0.   Opening of the meeting.1.   Election of chairman of the meeting.2.   Preparation and approval of voting list.3.   Approval of the agenda.4.   Election of one or two persons to approve the minutes.5.   The question as to whether the meeting has been duly convened.6.   Address by the CEO.7.   Presentation of the annual report and the auditor’s report and the annual report for the group and the auditor’s report      for the group.8.   Resolutions in respect of      a) adoption of the profit and loss statement and balance sheet and the group profit and loss statement and the group balance           sheet;       b) allocation of the company’s loss in accordance with the adopted balance sheet; and      c) the discharge from liability of the members of the board of directors and the CEO.9.   Determination of the number of members of the board and the number of auditors.10. Determination of fees to the board of directors and the auditors. 11. Election of members of the board, chairman of the board as well as election of auditors and deputy auditors.12. Resolution on instruction and charter for the Nomination Committee.13. Determination of Remuneration Policy for senior executives. 14. Resolution on implementation of a long-term incentive program for employees by way of (A) implementation of a       performance-based share saving program; (B) authorization on a directed issue of series C shares; (C) authorization       for repurchase of series C shares; and (D) resolution on transfer of own ordinary shares. 15. Closing of the meeting. Resolution proposals Item 1: Election of chairman of the meeting The Nomination Committee, consisting of Jacob Gunterberg (chairman), appointed by HealthCap V L.P., Johan Kördel, appointed by Lundbeckfonden Invest A/S, Jonas Jendi, appointed by Stiftelsen Industrifonden, and the chairman of the board, Håkan Björklund, proposes that attorney Ola Grahn is elected as chairman of the annual shareholders’ meeting. Item 8 b: Resolution in respect of allocation of the company’s loss in accordance with the adopted balance sheet The board of directors proposes that no dividends are paid and that available total funds of SEK 874,619,723 are carried forward to a new account. Item 9: Determination of the number of members of the board and the number of auditors  The Nomination Committee proposes to the annual shareholders’ meeting that the number of the members of the board shall be six. Furthermore, it is proposed that one registered accounting firm is appointed as auditor until the end of the next annual shareholders’ meeting. Item 10: Determination of fees to the board of directors and the auditors The Nomination Committee proposes to the annual shareholders’ meeting that board remuneration shall be paid with SEK 325,000 to the chairman of the board (unchanged since previous year) and with SEK 150,000 to each of the other board members who are not employed by the company (unchanged since previous year). It is further proposed that remuneration for committee work shall be paid with SEK 125,000 to the chairman of the audit committee (unchanged since previous year), with SEK 70,000 to each of the other members of the audit committee (unchanged since previous year), with SEK 50,000 to the chairman of the remuneration committee (unchanged since previous year) and with SEK 25,000 to each of the other members of the remuneration committee (unchanged since previous year). Remuneration to the auditor is proposed to be paid in accordance with invoiced amounts in accordance with customary charging standards. Item 11: Election of members of the board, chairman of the board as well as election of auditors and deputy auditors The Nomination Committee proposes to the annual shareholders’ meeting that Håkan Björklund, Björn Odlander, Lars Lidgren, Tone Kvåle, Lennart Johansson and Simon Cartmell are re-elected as ordinary board members. The Nomination Committee further proposes to the annual shareholders’ meeting that Lennart Johansson is elected as new chairman of the board. The present board member Nina Rawal has declined re-election and the present chairman of the board Håkan Björklund has declined re-election as chairman of the board. Information on the board members proposed for re-election can be found at the company website and in the annual report (www.bonesupport.com). Furthermore, the Nomination Committee proposes to the annual shareholders’ meeting, in accordance with the recommendation from the audit committee, that Ernst & Young AB is re-elected as accounting firm. Ernst & Young AB has announced that the authorized public accountant Ola Larsmon will be the auditor in charge. Item 12: Resolution on instruction and charter for the Nomination Committee The Nomination Committee proposes that that an instruction and charter for the Nomination Committee is adopted in accordance with the following main content. The Nomination Committee shall consist of four members, appointed by the three largest shareholders as per the end of September, together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known shareholders as per the end of September. The chairman of the board of directors shall as soon as possible when the information regarding the three shareholders as per the end of September is known, contact the three largest shareholders to find out whether they wish to appoint a representative to the Nomination Committee. In case one of the three largest shareholders refrain from appointing a representative, or such representative resign prior to completion of the assignment and without the shareholder who has appointed the representative appointing a new member, the chairman of the board of directors shall encourage the next owner in size (i.e. in the first place the fourth largest shareholder) to appoint a representative. The procedure shall go on until the Nomination Committee is composed of four members including the chairman of the board of directors. The Nomination Committee shall appoint the chairman of the Nomination Committee among its members. The chairman of the board of directors or another member of the board of directors should not be appointed as chairman of the Nomination Committee. The members of the Nomination Committee shall be announced no later than six months before the annual shareholders’ meeting. When significant changes in the ownership occur after the date the Nomination Committee was appointed, the Nomination Committee may, if it considers it necessary, decide to offer a new owner a position in the Nomination Committee in accordance with the principles above. Changes in the Nomination Committee shall be made public immediately. The Nomination Committee’s term shall run until such time as a new Nomination Committee has been elected. No fees shall be paid to the members of the Nomination Committee. The Nomination Committee shall prepare and propose the following to the coming annual shareholders’ meeting: (a) election of chairman at the shareholders’ meeting; (b) election of chairman of the board of directors and other members of the board of directors; (c) fees to the board of directors, divided between the chairman and other members, and any fees for committee work; (d) election of auditor and fees to the auditor; and (e) principles for appointment of the Nomination Committee. Item 13: Determination of Remuneration Policy for senior executives The board of directors proposes to the annual shareholders’ meeting that the following guidelines for remuneration to senior executives are adopted. The company shall offer remuneration levels and employment terms at market terms, aimed at facilitating the recruitment and retention of senior executives with high competence and capacity, in order to achieve established targets. It is noted that the company is highly international with employees in several countries. When determining the remuneration level and other employment terms, the starting point should be that the terms should be competitive considering the situation in the country in which the employee is employed. The guidelines shall apply to employment agreements entered into after the adoption of these guidelines by the shareholders’ meeting or amendments to existing agreements made after the adoption of the guidelines. The remuneration to the CEO and other senior executives can be comprised of fixed salary, variable remuneration, pension benefits, share-based incentive programs resolved by the shareholders’ meeting and other benefits. Senior executives refer to the CEO and the other persons forming part of the company’s management team. Remuneration and other employment terms for the CEO and other senior executives are prepared by the Remuneration Committee and resolved by the board of directors. The fixed salary shall take into consideration the individual’s competence, area of responsibility and performance. A review should generally be made annually. The variable remuneration is to be based on the outcome of predetermined well defined objectives. The variable consideration is to be limited and may not exceed 75 per cent of the fixed annual salary for the CEO and 40 per cent of the fixed annual salary for other senior executives, whereby the individual highest level should be based on factors such as the position held by the specific individual. The company’s commitments in reference to variable remuneration for the CEO and other senior executives who can be entitled to variable remuneration targets are for 2019 calculated to amount to, if all targets are met in full and based on the current exchange rates, approximately SEK 5 million (excluding social charges) at the highest. The calculation is based on the persons currently being senior executives and who can be entitled to variable remuneration. In addition to what follows from law or collective bargain agreements or other agreements, the CEO and other senior executives may be entitled to arrange individual pension schemes. Refrained salaries and variable remuneration can be used for increased pension contributions, provided that the total cost for the company is unchanged over time. Share-based incentive programs shall, where applicable, be resolved by the shareholders’ meeting. The senior executives may be awarded other customary benefits, such as a company car, occupational health services, etc. In case of termination of the CEO’s employment by the company, the notice period should not exceed 6 months. In case the company terminates the CEO without cause the CEO shall, in addition to salary during the notice period, be entitled to severance payment corresponding to 12 months’ base salary. The notice period for other senior executives shall, in case of termination by the company, not exceed 12 months. In case of termination by the company, in addition to salary during the notice period, severance payment corresponding to an amount equal to up to 12 months base salary may be paid. At the time of the annual shareholders’ meeting on 14 May 2019, the company has no outstanding remuneration commitments towards senior executives except for running commitments. To the extent that a member of the board of directors performs consultancy work on behalf of the company, in addition to the assignment as member of the board of directors, consultancy fees and other remuneration for such consultancy work should be payable. Such remuneration shall be paid on market terms and the remuneration as well as other terms shall be resolved upon by the board of directors. The board of directors shall be entitled to deviate from the guidelines in individual cases if there are special reasons for doing so. Item 14: Resolution on implementation of a long-term incentive program for employees by way of (A) implementation of a performance-based share saving program; (B) authorization on directed issues of series C shares; (C) authorization on repurchase of series C shares; and (D) resolution on transfer of own ordinary shares The board of directors proposes that the annual shareholder’s meeting resolves to implement a long-term incentive program in the form of a performance-based share saving program (the “LTI 2019”) for employees in accordance with A below. The resolution shall be conditional upon that the annual shareholders’ meeting also resolves on hedging measures in accordance with B – D below. A. Implementation of a performance-based share saving program Background At the annual shareholders’ meeting 2018, it was resolved to implement a corresponding incentive program for persons who were employed by the end of 2018 at the latest (LTI 2018) as well as a warrants program (warrants program 2018/2021) directed to senior executives. During 2018, the company has undergone a revision of the company's strategy and made significant changes in order to accelerate the market penetration. In connection with this, the organization has been restructured and a number of key individuals have been added, or is expected to be added, during 2019. Under LTI 2018 and the warrants program 2018/2021, which were approved by annual shareholders’ meeting 2018, a maximum of 500,000 and 1,175,000 shares, respectively, could be issued, i.e. a total maximum of 1,675,000 shares. However, the programs were not fully subscribed as a result of restructurings and a declining share price development during the implementation of the warrants program. As a result hereof, the programs resolved upon at the annual shareholders’ meeting 2018 will, altogether, result in a maximum of 746,096 shares being issued, i.e. 928 904 shares fewer than what was approved at the annual shareholders’ meeting 2018. The now proposed LTI 2019 will, at full outcome, result in a maximum of 795,000 shares being issued, and will thus not result in any further dilution than what was approved by the annual shareholders’ meeting 2018. In light of this, the board of directors considers that it is justified to propose to the annual shareholders’ meeting to resolve upon LTI 2019, wherein the "difference" between what was approved at the annual shareholders’ meeting 2018 and what actually came to be allocated is "reused" in the form of a new program. The overall purpose of LTI 2019 is to align the interests of the employees with those of the shareholders and thus ensure a maximum long-term value adding commitment. LTI 2019 is also considered to create a long-term focus on increase in earnings and growth among the participants. LTI 2019 is further considered to facilitate for the company to recruit and retain employees. Terms and conditions for LTI 2019 LTI 2019 shall comprise (i) the CEO; (ii) up to four other senior executives and up to six key employees who are deemed to be essential for the company to be able to develop in accordance with the company's revised strategy; and (iii) up to 19 other employees. For the category “other employees”, LTI 2019 shall as a starting point preferably comprise newly recruited employees. However, in exceptional cases, the board of directors may decide to offer LTI 2019 also to employees in the category "other employees" who are already participating in existing incentive programs. In total, LTI 2019 is considered to comprise up to 30 employees. In order to be entitled to participate in LTI 2019, it is required that the participant has been employed by the company or another company within the Group at the latest on the date of expiration of the Investment Period in accordance with the below. LTI 2019 means that the participants will invest in ordinary shares in the company (”Saving Shares”). In order to be entitled to participate in LTI 2019, each participant must at least acquire the number of Savings Shares which has been specified for each category below (which amount also corresponds to the maximum number of Saving Shares that each participant in each category may acquire within the framework of LTI 2019). The investment in Saving Shares shall be made through acquisition of ordinary shares on the stock market on 31 December 2019 at the latest (the "Investment Period"). If the Saving Shares are retained as from the expiration of the Investment Period to and including 31 December 2022 (the “Saving Period”) and the participant has continued to be employed by the company throughout the Saving Period, the participant is entitled to allotment of additional ordinary shares in the company free of charge (the “Performance Shares”), provided that the performance targets (the “Performance Targets”) mentioned below are achieved or exceeded. Participants shall acquire the following number of Saving Shares and shall have the opportunity to be allotted with up to the following number of Performance Shares per Saving Share: +--------------------+---------------+----------------------+|Position |Number of |Maximum number of || |Saving Shares |Performance Shares per|| | |Saving Share |+--------------------+---------------+----------------------+|CEO |80,000 |4 |+--------------------+---------------+----------------------+|Other senior |10,000 – 15,000|3 ||executives (up to 4 |per participant| ||persons) | | |+--------------------+---------------+----------------------+|Key employees (up to|5,000 – 10,000 |3 ||6 persons) |per participant| |+--------------------+---------------+----------------------+|Other employees (up |5,000 per |2 ||to 19 persons) |participant | |+--------------------+---------------+----------------------+ For the categories "Other senior executives" and "Key employees", the board of directors shall, within the above-mentioned intervals, resolve upon the number of Saving Shares that the participant shall acquire. The total number of Performance Shares shall not exceed 795,000. The Performance Targets that have to be achieved or exceeded relate to (i) the share price development of the company’s shares (the “Share Price Target”), (ii) the net sales for each respective financial year of 2019-2022 (the “Sales Target”), and (iii) the EBITDA for each respective financial year of 2019-2022 (the “EBITDA Target”), whereby each Performance Target is weighted by 1/3 and with regard to the Sales Target and EBITDA Target, each respective financial year is weighted by 1/4 for these two performance targets. The Share Price Target relates to the development of the company’s share price over the period from the date of the annual shareholders’ meeting 2019 to and including 31 December 2022. The share price development will be measured based on the volume weighted average share price 30 trading days immediately following the annual shareholders’ meeting 2019 and 30 trading days immediately preceding 31 December 2022. An increase in the share price with less than 25 per cent does not entitle to any vesting of any of the Performance Shares pertaining to the Share Price Target and an increase in the share price with 100 per cent or more does entitle a vesting of all of the Performance Shares pertaining to the Share Price Target. In the event of an increase in the share price of between 25 and 100 per cent, vesting of the Performance Shares pertaining to the Share Price Target will occur linearly. The Sales Target and the EBITDA Target shall be determined by the board of directors annually and with regard to the financial year 2019, before LTI 2019 is offered to the participants. For each respective target, a minimum level and a target level (maximum) shall be determined for each respective financial year. If the minimum level is not achieved, no Performance Shares are vested in relation to the actual Performance Target for the financial year and if the target level is achieved, full vesting shall take place of the Performance Shares pertaining to the actual Performance Target for the financial year. If the minimum level is exceeded but the target level is not achieved, vesting of the Performance Shares pertaining to the actual Performance Target for the financial year will occur linearly. The board of directors intends to present the determined targets regarding the Sales Target and the EBITDA Target as well as the achievement of these in connection with the expiration of LTI 2019 at the latest. The final number of Performance Shares vested by each participant shall be rounded downwards to the nearest whole number. Before the number of Performance Shares to be allocated is finally determined, the board of directors shall evaluate if allocation pursuant to the principles set out above is reasonable, with regard to the company’s results and financial standing, conditions on the stock market and other circumstances in general. If the board of directors finds that it is not reasonable, then the board of directors may decrease the number of Performance Shares to be allocated to the lower number of shares that the board of directors finds reasonable. The number of Performance Shares that may be allotted by virtue of Saving Shares shall be subject to recalculation in consequence of a bonus issue, split, rights issue, and/or other similar company actions. Allotment of Performance Shares shall take place within 30 days from the publication of the year-end report for the financial year 2022. Participation in LTI 2019 presupposes that the participation is legally possible and that the participation in the company’s sole opinion can be made with reasonable administrative costs for the company. The board of directors shall be responsible for the details and management of LTI 2019 within the framework of the main conditions as set out above, and the board of directors shall be authorized to make minor adjustments to these conditions as required by law or for administrative reasons. The board of directors shall also be authorized to adjust or deviate from the terms and conditions as required by local laws and regulations as well as existing market practices. Furthermore, in the event of a public take-over offer, a sale of the company’s business, liquidation, merger or any other such transaction affecting the company, the board of directors shall, at its sole discretion, be entitled to resolve that the Performance Shares (partially or in full) shall vest and be allotted on completion of such transaction. The board of directors will make this resolution based on the level of achievement of the Performance Targets, the remainder of the Saving Period and any other factors deemed relevant by the board of directors. B. Authorization on directed issues of series C shares The board of directors proposes that the annual shareholders’ meeting resolves to authorize the board of directors, for the period up until the next annual shareholders’ meeting, on one or several occasions, to issue a maximum of 795,000 series C shares. The new shares may, with deviation from the shareholders' preferential rights, only be subscribed for by a bank or a securities company at a subscription price which corresponds to the quota value of the shares. The purpose of the authorization and the reason for the deviation from the shareholders' preferential rights in connection with an issue of shares is to secure delivery of Performance Shares under LTI 2019, which shall be effected through the company repurchasing the series C shares issued pursuant to the authorization in section C below and thereafter, when the series C shares have been converted to ordinary shares, by transferring ordinary shares to the participants in LTI 2019 in accordance with section D below. C. Authorization on repurchase of series C shares The board of directors proposes that the annual shareholders’ meeting resolves to authorize the board of directors, for the period up until the next annual shareholders’ meeting, on one or several occasions, to repurchase its own series C shares. Repurchase may only be effected through a public offer directed to all holders of series C shares and shall comprise all outstanding series C shares. Repurchase may also be made of so-called interim shares, by Euroclear Sweden AB designated as a Paid Subscribed Share (Sw. Betald Tecknad Aktie (BTA)), regarding a series C share. Repurchase shall be made at a purchase price per share which corresponds to the quota value of the share. The purpose of the proposed repurchase authorization is to secure delivery of Performance Shares under LTI 2019. D. Resolution on transfer of own ordinary shares In order to fulfil the company’s obligations towards participants in LTI 2019, the board of directors proposes that the annual shareholders’ meeting resolves that the company shall be entitled to transfer the company’s own ordinary shares as follows: 1. The company shall have the right to transfer the number of ordinary shares that the company has a maximum obligation to allocate as Performance Shares to participants in LTI 2019, at most 795,000 shares. 2. The number of shares that may be transferred pursuant to LTI 2019 shall be subject to recalculation in consequence of a bonus issue, split, rights issue, and/or other similar corporate action which affects the number of shares in the company. 3. The right to acquire ordinary shares shall, with deviation from the shareholders’ preferential rights, vest in participants in LTI 2019 who are entitled to be allotted Performance Shares in accordance with the terms and conditions of the program. 4. Transfer of shares to participants in LTI 2019 shall be made free of charge and be executed at the relevant time specified in the terms and conditions for LTI 2019. The reason for the deviation from the shareholders' preferential rights in connection with the transfers of own ordinary shares is to enable the company’s delivery of Performance Shares to participants in LTI 2019. Costs, impact on key ratios, existing incentive programs and dilution The board of directors has made a preliminary cost calculation for LTI 2019. The costs for LTI 2019, which will reported under the profit and loss statement, are calculated in accordance with the accounting standard IFRS 2 and are accrued over the vesting period which runs until December 2022. The calculation has been made based on the quoted closing price for shares in the company as per 10 April 2019, i.e. SEK 20.80 per share, and with the following assumptions: (i) an annual dividend yield of 0 per cent; (ii) an estimated annual employee turnover of 0 per cent; (iii) an achievement of the Performance Targets with 100 per cent; and (iv) that a total maximum of 795,000 Performance Shares may be allocated. In addition to the above, the costs for LTI 2019 have been based on LTI 2019 comprising a maximum of 30 participants. In total, the costs for LTI 2019 are, according to IFRS 2, estimated to amount to approximately SEK 12.9 million, excluding social security contributions. The costs for social security contributions are estimated to amount to approximately SEK 7.3 million, based on the above assumptions, and under the assumption of a share price increase of 100 per cent during the duration of LTI 2019 and an average tax rate of 22 percent for social security contributions. The anticipated annual costs of SEK 5.8 million, including social security contributions, correspond to approximately 4.4 per cent of the company's total employee costs for the financial year 2018. Based on the calculation of costs as described above, the key figure earnings per share for the full year 2018 had been changed from SEK −3.46 to SEK −3.57. As per the date of the notice, the number of shares in the company amounts to 52,300,917 shares, of which 51,795,917 are ordinary shares and 505,000 are series C shares which were issued in connection with the share saving programs resolved at the annual shareholders’ meeting 2018 and which will be converted into ordinary shares prior to delivery to the participants. In addition thereto, warrants have been issued in connection with a previous financing agreement which could result in a maximum of 599,114 additional ordinary shares being issued. The maximum number of Performance Shares amounts to 795,000, which corresponds to a dilution of approximately 1.51 per cent of the company’s ordinary shares after full dilution, calculated on the number of ordinary shares that will be added upon full issuance of Performance Shares in connection with LTI 2019. The dilution calculation as described above does not consider the ordinary shares that may be issued in connection with an exercise of the warrants which have been issued in connection with the previous financing agreement. In case these warrants are to be considered as well, the maximum total dilution from LTI 2019 amounts to approximately 1.49 per cent. Since previously, there are incentive programs in the form of three employee option programs, two warrant programs and two performance-based share saving programs outstanding in the company. In case all outstanding incentive programs as well as the proposed LTI 2019 are exercised in full, a total of 3,147,134 new ordinary shares will be issued, which corresponds to a dilution of approximately 5.73 per cent of the company’s ordinary shares after full dilution, calculated on the number of ordinary shares that will be added upon full exercise of all outstanding incentive programs and the proposed LTI 2019. The dilution calculation as described above does not consider the ordinary shares that may be issued in connection with an exercise of the warrants which have been issued in connection with the previous financing agreement. In case these warrants are to be considered as well, the maximum total dilution of all outstanding incentive programs and the proposed LTI 2019 amounts to approximately 5.67 per cent. The above calculations regarding dilution and impact on key ratios are subject to re-calculation of the warrants in accordance with the customary recalculation terms included in the complete applicable warrant terms. Preparation of the proposal The proposal for LTI 2019 has been prepared by the Remuneration Committee together with external consultants. The final proposal has been resolved upon by the board of directors. Particular majority requirements For a valid resolution on the proposal pursuant to item 14, the proposal has to be supported by shareholders representing at least nine-tenths of the votes cast as well as of all shares represented at the annual shareholders’ meeting. Duty of disclosure at the annual shareholders' meeting The board and the CEO shall at the annual shareholders’ meeting, if any shareholder so requests and the board believes that it can be done without significant harm to the company, provide information regarding circumstances that may affect the assessment of items on the agenda, circumstances that can affect the assessment of the company’s or its subsidiaries financial position and the company’s relation to other companies within the group. Accounting documents and complete proposals Accounting documents, the audit report, the statement by the auditor on the compliance of the applicable guidelines for remuneration to senior executives as well as complete proposals for resolutions and the board of directors’ statement pursuant to Chapter 19, Section 22 of the Swedish Companies Act will be made available for the shareholders at the company’s office at Scheelevägen 19, SE-223 70 Lund, Sweden and at the company website (www.bonesupport.com) as from no later than three weeks prior to the annual shareholders’ meeting. Copies of the documents will be sent to the shareholders upon their request to the company, provided that such shareholders state their address, and will also be made available at the annual shareholders’ meeting. Processing of personal data For information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Number of shares and votes in the company As per the date of this notice, the total number of shares in the company amounts to 52,300,917 shares, of which 51,795,917 are ordinary shares with one vote per share and 505,000 are series C shares with one-tenth of a vote per share. As per the date of this notice, the number of votes in the company amounts to 51,846,417 votes. The company holds 505,000 own series C shares, corresponding to 50,500 votes, which cannot be represented at the annual shareholders’ meeting. ____________________ Lund in April 2019 BONESUPPORT HOLDING AB (publ) The Board of Directors About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information. BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB. For more information contact: BONESUPPORT HOLDING ABEmil Billbäck, CEO+46 (0) 46 286 53 70 Håkan Johansson, CFO+46(0) 46 286 53 70ir@bonesupport.com Cord CommunicationsCharlotte Stjerngren+46 (0)708 76 87 87charlotte.stjerngren@cordcom.sewww.cordcom.se This information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 12 April 2019.

CLAVISTER HOLDING AB CONVENES ANNUAL GENERAL MEETING

Örnsköldsvik, April 12, 2019 08:00 CET The Clavister Holding AB board of directors has resolved to convene an annual general meeting of shareholders to be held on Tuesday, 14 May, 2019. Details on the proposals for the annual general meeting are found in the notice convening the meeting which is found below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar) and on the company’s website within the next few days. For further information, please contact Håkan Mattisson, CFO, Clavister Holding AB.  Notice of the annual general meeting of Clavister Holding AB Clavister Holding AB will hold its annual general meeting on Tuesday 14 May 2019 at 1:00 PM at the company’s offices at Sjögatan 6J in Örnsköldsvik. Right to participate and notice of intention to attend Shareholders wishing to participate in the shareholders’ meeting must: •    be registered as a shareholder in the shareholder register maintained by Euroclear Sweden AB on Wednesday, 8 May 2019; and •    give notice to the company of their intention to participate not later than Thursday 9 May 2019. Notice of intention to participate must be given in writing by email to finance@clavister.com or by post to Clavister Holding AB, Sjögatan 6J, 891 60 Örnsköldsvik. Please state in the notice the name or company name, personal ID number or company registration number, address and a daytime telephone number. The notice procedure set forth above also applies to notice of any assistants who will assist the shareholder at the meeting (a maximum of two). See below for information on the processing of personal data. Nominee registered shares In order to participate at the meeting, any shareholder who has their shares registered with a nominee must, through the auspices of the nominee, cause the shares to be registered in their own name so that the shareholder is registered in the shareholder register maintained by Euroclear Sweden AB on Wednesday, 8 May 2019. Such registration may be temporary. Proxies and proxy forms Shareholders who are represented through a proxy must issue a written and dated proxy form. Proxy forms are available on the company’s website, www.clavister.com. Proxy forms can also be obtained from the company or ordered through the address or email set forth above. In the event the proxy has been issued by a legal entity, a certificate of registration or corresponding authorization document, evidencing that the persons who have signed the proxy form are authorized signatories for the legal entity, must be appended to the proxy form. The proxy form may not be older than one year unless the validity period is stated in the proxy form, however not more than five years from the date of issuance. A copy of the proxy form and any certificate of registration should be sent to the company at the address set forth above in ample time prior to the meeting. Proposed agenda 1. Opening of the meeting and election of a chairperson for the meeting 2. Preparation and approval of the voting register 3. Election of one or two persons to attest the minutes 4. Determination of whether the meeting was duly convened 5. Approval of the agenda 6. Presentation of the annual report and the auditor’s report and the consolidated financial statements and the auditor’s report for the group 7. Resolutions regarding: ads. adoption of the income statement and balance sheet and the income statement for the group and balance sheet for the group adt. allocations regarding the company’s profit or loss according to the adopted balance sheet; and adu. discharge from liability for the directors and CEO 8. Resolution regarding the number of directors 9. Determination of the fees for the directors and auditors10. Election of the Board of Directors and auditors11. Resolution regarding guidelines for salary and other remuneration to senior management12. Resolution on adoption of instruction for the Nomination Committee13. Resolution on issue authorisation14. Closing of the meeting INFORMATION ON THE NOMINATION COMMITTEE The Nomination Committee for the annual general meeting of Clavister Holding AB (publ) in 2019 has comprised the following members Olof Nord, representing Fondita Nordic Micro Cap SR, Fondita 2000+ and RGG ADMGruppen AB; Jan Ramkvist, representing Peter Laurén, John Vestberg, Peter Dahlander, Jan Ramkvist, Håkan Mattisson, Håkan Wallberg, Nils-Erik Sandberg with. family and Ängby Sportklubb; Hannu Heinonen, representing Hannu Heinonen; and Joakim Kindahl, representing Infinitum AB, Niclas Marken, Peter Roosling, Peter Johansson, Episteme AS, Rasmus Nygård and Omid Gholamifar. Olof Nord has been appointed chair of the Nomination Committee. The composition of the Nomination Committee was published October 23, 2018 on the company's website. ITEM 1: OPENING OF THE MEETING AND ELECTION OF THE CHAIRPERSON FOR THE MEETING The Nomination Committee proposes that Advokat Dennis Westermark be elected chair of the meeting. ITEM 8: RESOLUTION REGARDING NUMBER OF DIRECTORS The Nomination Committee proposes that, for the period until the close of the next annual general meeting, the Board of Directors consist of five directors elected by the shareholders’ meeting. ITEM 9: DETERMINATION OF THE FEES FOR THE DIRECTORS AND AUDITORS The Nomination Committee proposes that, for the period until the next annual general meeting, the directors’ fees remain unchanged in the amount of SEK 350,000 for the chairperson of the Board of Directors and SEK 160,000 for each of the other directors who are not employees of the group. In addition, the Nomination Committee proposes that, for the period until the next annual general meeting, remuneration remain unchanged in the amount of SEK 75,000 to the chairperson of the audit committee and SEK 50,000 to the other members; in the amount of SEK 75,000 to the chairperson of the remuneration committee and SEK 50,000 to the other members. The Nomination Committee further proposes that fees be payable to the auditor according to approved invoice. ITEM 10: ELECTION OF THE BOARD OF DIRECTORS AND AUDITORS The Nomination Committee proposes reelection of Staffan Dahlström, Jan Frykhammar, Bo Askvik and Viktor Kovacs and proposes Kimberly Matenchuk as new director of board. Viktor Kovacs is proposed as chair of the Board of Directors. Information regarding the proposed directors is available on the company’s website at www.clavister.com. The Nomination Committee further proposes that, for the period until the next annual general meeting, the annual general meeting resolve to reelect as auditor the registered accounting firm Ernst & Young AB. Ernst & Young has notified the company that in the event Ernst & Young is reelected, Rikard Grundin will be the auditor in charge. The Nomination Committee’s proposal for auditor corresponds to the recommendation by the audit committee. ITEM 11: RESOLUTION REGARDING GUIDELINES FOR SALARIES AND OTHER REMUNERATION TO SENIOR MANAGEMENT The Board of Directors proposes that the shareholders’ meeting adopt guidelines for salaries and other remuneration to senior management mainly as set out below: Generally The Clavister group, of which Clavister Holding AB is the parent company (the “Group”) shall apply remuneration levels and employment terms and conditions for senior management as required in order to ensure the Group’s access to senior management with the necessary expertise and capacity to achieve established targets at costs adapted to the Group. The purpose is to create incentives for senior management to implement strategic plans and provide sound operating results, and to align the interests of senior management with those of the shareholders. Remuneration to senior management may consist of fixed salary, variable remuneration, and long-term equities or share price-related incentive programs, in addition to pensions and other customary benefits. As used in these guidelines, senior management means the CEO and other corporate management of Clavister Holding AB and the CEO and other corporate management of Clavister AB. The guidelines do not include remuneration in the form of fees and other remuneration for board work. Fixed salary The basic premise for remuneration to senior management is that remuneration is payable in the form of a market-based fixed salary and must be individually established based upon the aforementioned principles and each manager’s specific expertise. Variable remuneration including equities-related and share price related incentive programs Variable compensation for senior management must be linked to predetermined and measurable targets and performance criteria and intended to promote the Group’s long-term creation of value. Variable remuneration which is paid in cash may not exceed 50 per cent of the total remuneration, and is neither a pensionable income nor a basis for holiday pay. Equities-based incentive programs must be approved by the shareholders’ meeting of Clavister Holding AB and designed with the purpose of achieving greater community of interest between senior management and the shareholders of Clavister Holding AB. Building up one’s own shareholdings in Clavister Holding AB must be promoted. The qualifying period or the period for final acquisition of shares, share options, or other share-related instruments may not be less than three (3) years. Remuneration to board directors Board directors elected by the general meeting may in certain situations receive remuneration or other compensation for work performed for the company in addition to the director’s responsibilities as a director. Any such services may be compensated with market-based remuneration that must be approved by the Board of Directors. Pension benefits Clavister Holding and Clavister AB have a pension policy “Premium” adopted by the Board of Directors. The pension terms and conditions of senior management must be on market terms in relation to what generally applies to corresponding positions on the market and individually adapted taking into consideration each manager’s specific expertise and adapted to the Group’s costs. Pension allocations must be to defined contribution plans. Other benefits Other benefits for senior management may consist of health insurance and other customary benefits. Other benefits may not constitute a significant part of the total remuneration. Salary during the notice of termination period and severance compensation Severance compensation, including fixed salary during the notice of termination period, may not exceed twelve (12) months fixed remuneration. Information regarding previously adopted remuneration programs which have not yet become payable The company has six ongoing incentive programs for the company’s employees. Program 2016/2019, covers 530,800 warrants with an exercise price of SEK 72, expiring on June 30, 2019, Program 2017/2020:1, covers 75,000 warrants with an exercise price of SEK 79, expiring on February 28, 2020, Program 2017/2020:2, covers 70,000 warrants with an exercise price of SEK 72, expiring on February 28, 2020, Program 2017/2020:3, covers 300,000 warrants with an exercise price of SEK 30, expiring on June 30, 2020. Program 2018/2021:1, covers 50,000 warrants with an exercise price of SEK 36.3, expiring on June 13, 2021. Program 2018/2021:2, covers 700,000 warrants with an exercise price of SEK 36.3, expiring on June 13, 2021. Disapplying the guidelines The Board of Directors shall be entitled to disapply the guidelines where there is special cause to do so in an individual case. The Board of Directors shall report the cause for disapplying the guidelines at the next annual general meeting. ITEM 12: RESOLUTION ON ADOPTION OF INSTRUCTION FOR THE NOMINATION COMMITTEE The Nomination Committee proposes that the general meeting resolve to adopt instructions for the Nomination Committee mainly as set out below. The company shall have a Nomination Committee consisting of four (4) representatives. The Chair of the Board shall during the month of September contact the four (4) largest shareholders of the company in terms of voting rights, and ask them to appoint one (1) representative each to form the Nomination Committee. The voting rights shall be based on the shareholders‘ register maintained by Euroclear Sweden AB as per the last workday of August and other relevant information the company has received as per the same date. While establishing the four largest shareholders in terms of voting rights, a group of shareholders shall be considered as one if they: 1. have been registered as a group in the Euroclear Sweden system alternatively, 2. to the company announced in writing that they have a written agreement stating that they on a long-term basis shall be considered as one owner. In the event that any of the four largest shareholders refrain from being part of the Nomination Committee, the following shareholder in terms of voting rights shall be offered to appoint a representative to the Nomination Committee. If deemed appropriate, the Nomination Committee can decide to let a group apply one representative as a co-opted member. In the event that a member leaves the Nomination Committee prior to the work of the committee having been completed, a representative from the same shareholder may replace the leaving member. In the event that a shareholder refrains from such a possibility, the option to appoint a representative to the Nomination Committee shall go the following shareholder in terms of voting rights, that is not already represented (or has refrained from being represented). This is under the condition that the event occurs earlier than three (3) months before the date of the annual general meeting. In the event that any shareholder, who initially has not been among the four largest shareholders in terms of voting rights, should become one of the four largest shareholders, this shareholder should be given the opportunity to appoint a representative and to replace the representative that up until then has been representing the least number of shares on the nomination committee. This is under the condition that the event occurs earlier than three (3) months before the date of the annual general meeting. Changes in the composition of the Nomination Committee shall be made public immediately. The chair of the Board of Directors will convene the first meeting of the Nomination Committee. The representative of the largest shareholder in terms of voting rights shall be appointed as chair of the Nomination Committee, unless the representatives agree otherwise. The term of office for the Nomination Committee ends when the composition of the following Nomination Committee has been announced. The composition of the Nomination Committee is to be announced no later than six months before the annual general meeting. The Nomination Committee shall propose the following: · chair at the general meeting · Board of Directors · chair of the Board of Directors · auditor · remuneration to the Board of Directors divided between the chair and the other directors as well as remuneration for committee work · remuneration to the company’s auditor and · if deemed necessary, changes to this instruction for the Nomination Committee. The Nomination Committee shall fulfil its responsibilities according to the Swedish Code of Corporate Governance, including the obligation to pass on certain information to the company, so that the company can fulfil its information duty in line with the Code. The company shall, if requested by the Nomination Committee, provide the committee with secretarial support, in order to simplify the work of the committee. If needed, the company can cover reasonable costs for external consultants that the Nomination Committee consider to be necessary in order to fulfil its mandate. This instruction shall apply until further notice. ITEM 13: RESOLUTION ON ISSUE AUTHORISATION The Board of Directors proposes that the General Meeting passes a resolution on issue authorisation mainly as set out below: The Board of Directors is to be authorised to, on one or more occasions until the next Annual General Meeting, issue new shares, warrants and/or convertible bonds as follows. An issue of new shares, warrants and/or convertible bonds can be decided with or without regard of shareholders’ pre-emption rights. Following this authorisation, a total maximum number of shares equivalent to 10 per cent of the total number of outstanding shares in the company on the date when the authorisation is utilised for the first time may be issued in new share issues, by utilising the warrants and/or through the conversions of convertible bonds (this does not prevent warrants or convertible bonds from being combined with conversion terms which, if applied, may result in a different number of shares). This authorisation is to include the right to issue shares, warrants and/or convertible bonds with cash payment, payment by contribution in kind or payment by way of set-off, and otherwise subject to conditions as set out in Chapter 2, section 5, second paragraph 1–3 and 5 of the Swedish Companies Act. The Board of Directors, or a party designated by the Board, has the right to decide on minor changes to the General Meeting’s resolution that may be necessary in connection with registration of the resolution with the Swedish Companies Registration Office or due to other formal requirements. A resolution according to this item is valid only if supported by shareholders holding at least two-thirds of both the votes cast and the shares represented at the General Meeting. Information at the meeting The shareholders are reminded of their right to request information from the Board of Directors and the CEO in accordance with Chapter 7, section 32 of the Swedish Companies Act. Documents The complete proposals, along with financial statements and the auditor’s report for 2018 will be available at the company and on the company’s website www.clavister.com no later than three weeks before the meeting, and will be sent immediately without charge to any shareholders who so request and state their postal address. The documents will also be available at the meeting. Processing of personal data For information on how your personal data is processed, please see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf __________ Örnsköldsvik in April 2019 Clavister Holding AB (publ) The Board of Directors For more information, please contact: Håkan Mattisson, CFO, Clavister Holding AB Phone: +46 (0)660-29 92 00 About Clavister Clavister is a leading European cybersecurity vendor with over 20 years of experience. Seated in Sweden, the company has customers in more than 150 countries; Communication Service Providers, Governments, Enterprises and Managed security service providers (MSSPs). The stock, Clavister Holding AB, is listed at NASDAQ First North. FNCA Sweden AB is the Company’s Certified Advisor (+46 8-528 00 399, e-mail: info@fnca.se).

Immunovia advances strategic collaboration with primary care physicians in the US to build awareness of the importance of early detection of pancreatic cancer

LUND, SWEDEN - Immunovia AB (publ.) (“Immunovia”) today announced its continued commitment to its strategic initiative of collaborating with primary care physicians (PCPs) in the US that are united in their goal of detecting pancreatic cancer early. This initiative began in 2018 with Immunovia’s educational program for PCPs at Fenway Park on World Pancreatic Cancer Day . The program highlighted the important role that primary care physicians can play in detecting pancreatic adenocarcinoma early in patients. In early March of this year, Immunovia held a primary care advisory board meeting with four distinguished PCPs practicing in the Boston area. The goal of this meeting was to discuss and identify the best methods for educating PCPs about the risk factors for pancreatic cancer and about the IMMray™ PanCan-d test. The feedback from the PCP advisors’ was very valuable and is now being incorporated into Immunovia’s educational strategies going forward, and will also be presented at Immunovia’s exhibit booth at the American College of Physicians’ Internal Medicine Meeting, April 11-13, 2019 in Philadelphia. The advisory board meeting also confirmed that PCPs remain largely unaware of the connection between new onset diabetes after age 50 and pancreatic cancer. It was agreed that this is an important educational element for identifying patients at higher risk for developing pancreatic cancer. Dr. Jeffrey Gorodetsky from Winchester Physician Associates stated, “As a Family Physician for over 28 years, I was both honored and excited to be part of Immunovia’s pancreatic cancer PCP advisory board, especially after having lost my mother to pancreatic cancer 10 years ago. With screening tests for pancreatic cancer on the horizon, which will improve the outcomes for patients with this terrible condition, it is especially important to raise awareness of pancreatic cancer and the importance of early detection among primary care physicians.” Mats Grahn, CEO Immunovia added: “Educating PCPs on the importance of considering pancreatic cancer with the onset of early symptoms will have a huge impact on treating the disease. Immunovia looks forward to further collaborations with primary care experts, aligning our strategies to best meet PCP’s educational and clinical needs. We strongly believe this give the best opportunity for Immunovia’s IMMray™ PanCan-d test to improve patient outcomes”. For more information, please contact:Julie SilberDirector of Investor RelationsEmail: julie.silber@immunovia.comTel: +46 7 93 486 277 About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. About Pancreatic Cancer   Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 5-8 %. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early diagnosis can significantly improve pancreatic cancer patients’ 5-year survival rates from 5-8 % to up to 49%. ### 

Kesko’s sales in March

The sales of Kesko Group’s continuing operations in March 2019 totalled €889.3 million, representing a decrease of 1.1% in comparable terms. Reported sales from continuing operations decreased by 1.2%. “The fact that Easter this year falls on April had a significant impact on sales in March, especially in the grocery trade. In the building and technical trade, sales grew in comparable terms especially in the Baltics and Finland. In the car trade, sales decreased due to the implementation of the WLTP emissions testing and the resulting delays in car deliveries and due to weakened market demand among consumers," says Mikko Helander, Kesko’s President and CEO. Sales in the grocery trade totalled €463.2 million in March, a decrease of 3.7% in comparable terms. Reported sales decreased by 4.7% in March. Sales were significantly affected by the fact that Easter this year falls on April, while in 2018 Easter was in March-April. Sales in the building and technical trade totalled €353.8 million in March, an increase of 6.8% in comparable terms in local currencies. Comparable sales in the building and technical trade excluding the speciality goods trade grew by 9.6%. Sales in Finland grew by 7.0% and sales elsewhere by 12.0%. Sales in the speciality goods' leisure trade decreased by 6.8%, while sales in the machinery trade decreased by 34.2%. Reported sales in the building and technical trade increased by 8.5%. Sales in the car trade totalled €72.5 million in March, representing a decrease of 15.6% in comparable terms. Reported sales decreased by 17.4%. Kesko Group's sales in euros, excluding VAT, in March 2019: March 2019 Comparable € million Change, % change, %Grocery trade, total 463.2 -4.7 -3.7Building and technical trade, Finland 170.8 +4.6 +4.8Building and technical trade, other countries 183.0 +12.3 +8.7Building and technical trade, total 353.8 +8.5 +6.8Car trade, total 72.5 -17.4 -15.6Common functions and eliminations -0.3Grand total 889.3 -1.2 -1.1 Finland, total 706.3 -4.2 -3.3Other countries, total 183.0 +12.3 +8.7Grand total 889.3 -1.2 -1.1 Kesko Group's sales in euros, excluding VAT, in January - March 2019: 1.1.-31.3.2019 Comparable € million Change, % change, %Grocery trade, total 1,275.9 -1.0 +0.4Building and technical trade, Finland 474.6 +3.3 +3.5Building and technical trade, other countries 489.2 +10.3 +6.2Building and technical trade, total 963.7 +6.7 +4.8Car trade, total 205.6 -22.3 -21.7Common functions and eliminations -1.2Grand total 2,444.0 -0.5 -0.5 Finland, total 1,954.9 -2.9 -2.0Other countries, total 489.2 +10.3 +6.2Grand total 2,444.0 -0.5 -0.5 Change, % indicates the change when compared to the corresponding period of the previous year. The comparable change % has been calculated for the grocery trade by excluding the impact of acquisitions and divestments completed in 2018, and by including in the sales those stores formerly belonging to Suomen Lähikauppa which have been operating under the retailer business model in both years. The comparable change % for the building and technical trade has been calculated in local currencies and excluding the impact of acquisitions and divestments completed in 2018 and 2019. The reported sales for Kesko Group’s continuing operations include the acquisitions completed in 2018 and 2019, which are Reinin Liha and Kalatukku E. Eriksson in the grocery trade, Skattum Handel AS, Gipling AS, 1A Group and Sørbø Trelast AS in the building and technical trade, and the Volkswagen, Audi and SEAT businesses of Huittisten Laatuauto and LänsiAuto in the car trade. In March 2019, the number of Kesko's wholesale selling days in Finland was 21, which equals the number of wholesale selling days the year before. Likewise, the number of selling days in January-March 2019 equalled the number in 2018.  Kesko publishes advance information on K Group's retail sales quarterly in connection with interim reports. Further information is available from Vice President, Group Controller Eva Kaukinen, tel. +358 10 5322 338. Kesko Corporation DISTRIBUTIONMain news mediawww.kesko.fi

Scandic climbs in the Sustainable Brand Index – ranked higher in all countries

- We’re extremely proud to see an improvement in all countries and our success is thanks to our 18,000 team members who drive our sustainability work forward every day. We launched many positive initiatives last year that are now widespread, and our ranking this year indicates that consumers have both gotten the message and think it’s positive. This will definitely give us extra energy to advance even more next year, says Vanessa Butani, who is responsible for sustainability at Scandic. During 2018, Scandic launched a number of sustainability initiatives starting with a Sustainability Hackathon involving all team members to brainstorm ideas on how to make Scandic even more sustainable. Scandic also made the decision to stop using all plastic straws, cocktail sticks and coffee lids and to stop serving cage eggs. Not only that, the company introduced a plant-based burger and became a member of the International Tourism Partnership. - Alongside these initiatives, Scandic has been focusing on the UN’s Sustainable Development Goals since 2015. One example of this is our work to reduce food waste by optimizing the entire meal chain from purchasing to preparation and serving. This has led to partnerships with Too Good To Go and Karma that have resulted in 150,000 portions of leftover food being sold onwards on digital platforms instead of being thrown out. Sustainability has always been important to us and will always be so, concludes Vanessa. Ranking in Scandic’s countries of operation:Sweden: 18 (22) of 355 brandsDenmark: 45 (57) of 219 brandsFinland: 45 (59) of 174 brandsNorway: 14 (15) of 233 brands How the study was carried outThe Sustainable Brand Index is Europe’s largest independent brand study with a focus on sustainability and it has been carried out annually since 2011. The study aims to highlight sustainability and to increase knowledge about it. In 2019, about 50,000 people were interviewed of which 18,600 in Sweden, 7,700 in Norway, 7,400 in Denmark and 10,300 in Finland as well as 6,000 in the Netherlands. The target group for the study is individuals from the public in each country between age 16 and 70. The selection is representative of each country’s population demographic. The interviews were conducted between November 2018 and January 2019 and February and March 2019 (divided into quantitative and qualitative studies). Read more at www.sb-insight.com  For more information, please contact:Anna-Klara Lindholm, PR-Manager, Scandic Hotels GroupEmail: anna-klara.lindholm@scandichotels.com (peter.bodor@scandichotels.com)Phone: +46 70 973 52 31

Fiskars to publish its Interim Report for January-March 2019 on April 26, 2019

Fiskars CorporationPress ReleaseApril 12, 2019 at 9:00 (EEST)  Fiskars to publish its Interim Report for January-March 2019 on April 26, 2019Fiskars Corporation will publish its Interim Report for January-March 2019 on April 26, 2019 at approximately 8:30 a.m. (EEST). The Interim Report will be available on the company's website www.fiskarsgroup.com after publication.Analyst and media conferenceA combined live webcast and presentation for analysts and media on the first quarter results will be held on April 26, 2019 at 11:00 a.m. at the company’s headquarters, Fiskars Campus, Hämeentie 135 A, Helsinki. Presentation materials will be available at www.fiskarsgroup.com.The conference call will be held in English and can be followed as a live webcast at: https://fiskars.videosync.fi/2019-q1-resultsAn on-demand version of the webcast will be available on the company website. Personal details gathered during the event will not be used for any other purpose.FISKARS CORPORATIONMedia and investor contacts:Corporate Communications, tel. +358 204 39 5031, communications@fiskars.com  Making the everyday extraordinaryFiskars Group’s purpose is to make the everyday extraordinary. With our family of lifestyle brands including Fiskars, Gerber, Iittala, Royal Copenhagen, Waterford, and Wedgwood, we want to create a positive, lasting impact on our quality of life. Our products are available in more than 100 countries and we employ around 7,900 people in over 30 countries. Please visit us at www.fiskarsgroup.com for more information. 

Collaboration between Gasum and Tampere Regional Solid Waste Management: biogas produced by new plant to be distributed for use as road fuel

Scheduled to be operational in 2020, Tampere Regional Solid Waste Management's new biogas plant will process the biowaste of 17 municipalities and the wastewater sludge of the City of Nokia. The plant will produce renewable biogas and organic fertilizers.  The annual production capacity of the plant will be around 25 GWh of biogas, with the bulk of this to be injected into the Gasum transmission network. The amount is equivalent to the consumption of around 2,000 gas-fueled cars and covers the current biogas sales of Gasum's filling stations in the Tampere region as well as the growing demand of the years ahead. Increasing the use of biogas as a road vehicle fuel is one solution in action towards emission-free transport. - Buying biogas from Tampere Regional Solid Waste Management enables us to support the targets set for transport emission reductions and improve access to biogas. Our collaboration is an excellent example of the regional opportunities available in circular economy where the value of waste as a raw material is understood, says Matti Oksanen, Director, Business Development, Biogas, from Gasum. Biogas use in waste transport to increase For Tampere Regional Solid Waste Management, the transport use of biogas enables emission reductions and a frontrunner role in the entire waste management supply chain. The aim for the next few years is to achieve strong growth in the use of biogas to fuel waste transport. - By collaborating with Gasum we can secure the full energy recovery of biogas right from the opening of the plant. We’ll organize centralized competitive tendering for waste transport and will therefore be able to generate significant growth in demand for biogas as a road fuel, says Managing Director Harri Kallio from Tampere Regional Solid Waste Management.  Gas will also be available for fill-ups at a distribution point to be constructed in the immediate vicinity of the plant. The energy company Gasum is the leading biogas producer in the Nordic countries and owns the transmission network used for distribution of gas as well a gas filling station network in Finland. Gasum is investing strongly in increasing the transport use of gas by constructing new gas filling stations in Finland and creating a filling station network for heavy-duty vehicles in the Nordics.  Tampere Regional Solid Waste Management is a company owned by 17 municipalities and tasked with the municipalities' statutory waste management service provision. The two-line biogas plant connected to the wastewater treatment plant will be unique in Finland and result in a major improvement in the company’s treatment services. Biowaste and sludge will be processed at the plant in their own lines, which will enable the further processing of biowaste into organic fertilizers and the high-quality nutrient cycling of nitrogen and phosphorus. The total value of the biogas plant investment exceeds €23 million. The Finnish Ministry of Economic Affairs and Employment has granted the project €4.55 million in key energy project support.  

A first-of-its-kind dynamic electric road system will be built in Sweden

Today, the Swedish Transport Administration (Trafikverket) announced the pre-commercial procurement results for the electric road system tender.The consortium Smart Road Gotland (Gotland GPe Circuit AB as its applicant) won the final round of the tender with the highest evaluation points, despite the much bigger industrial competitors.Electreon AB (a wholly owned subsidiary of Electreon Wireless) will lead the project’s next phase to provide vital knowledge of the future potential of dynamic wireless mobile power transfer through this demonstration road system.This public-private initiative, based on Electreon’s leading technology, will be the first in the world to charge inductively both an electric truck and a bus while in full motion.To enable the mission-critical knowledge transfer to the Swedish Transport Administration, the Smart Road Gotland consortium will deploy a fully functional public shuttle service and test bed through a 1.6 km long electric road as part of the total route of 4.1 km between the airport and city center of Visby on the idyllic island of Gotland, an eco-municipality in the middle of the Baltic Sea. The electric truck will be test-driven by a professional in varied seasonal conditions to ensure that the system is ready for large-scale projects on highways. As an integral strategic step towards implementing the Swedish government’s national roadmap for electric road systems, the Smart Road Gotland project will create a vital learning curve for the authority.Long haul heavy trucks benefit significantly from the Electreon solution since no heavy and costly batteries, nor stops for charging, are needed. This optimal solution enables installation of electric road systems without the environmental impact (benefits are both physical and visual) of a conductive system.After acquiring relevant ERS demonstration results, the Swedish Transport Administration can evaluate the potential for larger scale electric road investments.Initially, Gotland GPe Circuit AB (GotlandRing, world’s first sustainable race and test circuit) - with the support of World Ecological Forum (a global crossover sustainability network, a facilitator and enabler of green business and entrepreneurship) started the project in co-operation with Electreon- ‘For the whole consortium, it’s wonderful news that we have been selected as the top candidate. It is of utmost importance to significantly reduce CO2-emissions within the transport sector. To commence with the heavier transports is logical since the biggest emission improvements can be gained where the usage and tonnage is the highest. The future positive impact could be global.’, comments Alec Arho-Havrén, CEO/Founder Gotland GPe Circuit/GotlandRing and World Ecological Forum.- ‘We, the Swedish Transport Administration, believe that electric roads are an important contribution to reducing CO2-emissions from heavy transportation. Demonstrating and evaluating new technical solutions for electric routes is one of our most important steps in our long-term plan for a potential rollout of electrified routes on the heavy road network in Sweden.’, says Jan Pettersson, program manager, Trafikverket (The Swedish Transport Administration)- ‘We are excited that we have been selected to take part in the Swedish government's ambitious program to examine and implement electric road technology as a solution to electrify heavy trucks on highways. Electreon's wireless electric road technology makes it possible to electrify truck fleets economically without the need to carry huge batteries and stop for charging and without creating a visual hazard. The selection of Electreon by the Swedish government after careful filtration testifies to the recognition of the potential of the technology to bring the global electrification revolution to the next critical stage of full implementation.’, Oren Ezer, CEO of Electreon, comments.- ‘It is exciting and positive that Trafikverket wants to see this unique technology and test bed realised on Gotland. It strengthens the image of Gotland as one of the most innovative and climate smart regions in the world.’, says the chairwoman of the regional government, Eva Nypelius (C). The Smart Road Gotland consortium members include: · Electreon AB - a fully owned Swedish subsidiary of Electreon wireless (publicly traded on the Tel Aviv Stock Exchange, a leader in dynamic wireless power transfer technology · EiTech - a Swedish subsidiary of Vinci, one of the world's biggest infrastructure and construction companies · RISE RESEARCH INSTITUTES OF SWEDEN - Sweden’s research institute and innovation partner and a leading research institute in the field of electric roads · Gotland GPe Circuit AB, Gotland Ring - world’s first sustainable race and test circuit, traffic electrification partner for the vehicle industry · World Ecological Forum - a global crossover sustainability network, a facilitator and enabler of green business and entrepreneurship (project initiator) · Matters Group - a sustainability consultancy · Flygbussarna - a local Swedish public transportation operator owned by TransDev, formerly Veolia TransDev, a French international public transport operator, with operations in 20 countries · Swedavia - the Swedish airport authority · Dan transport - Israel’s leading bus operator and a strategic investor in Electreon will provide a HIGER E-Bus based on Supercapacitor · Hutchinson - a leading French manufacturer will manufacture the underground coils · Eco-municipality of Gotland - the most popular tourist destination summer time, an eco region · GEAB - utility company, electricity supplier (owned 75% by Vattenfall, 25% by the municipality) Smart Road Gotland synopsis · Technology: Dynamic mobile wireless power transfer, https://www.electreon.com/technology · Invisible installation to road users (coils deployed 8 cm under the surface) and activated only when corresponding vehicle drives on top of it · Located in Visby, Gotland, the Swedish island in the Baltic Sea, an eco-municipality · 1.6 km of the 4.1 km airport route will be electrified · Compatible with all types of EVs, including buses, trucks, passenger cars, including self-driving vehicles (a typical passenger car can be equipped with just one 12 kg receptor, heavier vehicles can have more units to optimise charging levels) · The main project mission is acquiring knowledge for the Swedish Transport Administration, including demonstrating the environmental and commercial benefits · World Ecological Forum and Gotland GPe Circuit AB/GotlandRing initially contacted Electreon (Tel Aviv listed public company) to initiate a demonstration test bed on Gotland, which is now realised thanks to Trafikverket · Budget for the public-private project: SEK 116 M About ElectreonElectreon Wireless is an Israeli publicly traded company developing DWPT (Dynamic wireless power transfer) technology. The technology enables a shared infrastructure that significantly reduced the need to charge vehicles’ batteries during day/overnight and decreases the size of the battery. It can support any type of EV - buses, trucks, and passenger vehicles. It is fully compatible for autonomous and self-driving EVs. Electreon is a global leader in its field because of its deep technological capabilities and focus on making the technology cost effective, durable and efficient. Smart Energy Road and Traffic System (SERTS) synopsis · Smart Energy Road and Traffic System (SERTS), an energy harvesting smart infrastructure, finalist i InfraAwards 2017, testbeds planned on GotlandRing in the future · The vision is to enable access to limitless sustainable energy through smart infrastructure development and simultaneously urge the paradigm for e-mobility. Our mission is to develop and commercialise an energy harvesting electric road system, a modular, self healing micro smart grid with wireless, mobile dynamic charging for electric vehicles. · Unique combination of solar, thermal, wind, kinetic, and hydraulic energy harvesting technology that provides decentralised and secure energy · Innovative infrastructure with options - in road, covered tiling, contoured (roadside) solar panels, can also be combined with existing road · Synergetic systems for energy harvesting, capture, storage of 100% renewable energy · Enables smart e-mobility on a large scale and solves range anxiety · Electreon’s dynamic wireless power transfer is an important planned feature for the SERTS GotlandRing/Gotland GPe Circuit AB synopsis · World’s first sustainable race and test circuit, traffic electrification and new model launch partner for the vehicle industry · Located in a former limestone quarry · Green business campus and eco resort development area · About to enter an expansion phase making it the longest modern standard race circuit in the world For more information about Gotland GPe Circuit/GotlandRing, World Ecological Forum and Smart Energy Road and Traffic System (SERTS), please contact: Lina HavrénTel +46 730 668 688Email: tzvetelina@gotlandring.com Alec Arho-Havrén,Founder & CEO, Gotland GPe Circuit ABFounder and Chairman, World Ecological ForumTel +46 731 822 822Tel +358 50 55 55 696Email: alec@worldecologicalforum.comEmail: alec@gotlandring.com

Finnish startup Living Spaces Ltd launch Worlds only freely constructible soft furniture elements

Helsinki 4.4.2019. Living Spaces Ltd is taking pre-orders of a new set of modular soft elements that makes configuring a living room upholstered furniture as easy as working with a construction toy set. Furniture made of BiT elements can be completely resized, reformed and even change color to meet various environments, number of guests or intended event.  "Imagine a living room furniture capable of transforming into a larger number of seats for extra guests, then be reshaped for a gaming session amongst teenagers, as a castle for the younger children's play center and as multiple beds for overnight guests. That's a multi-functionality one can expect from a BiT elements.", says the polytechnic designer Sanna Myllylä. She chose the magnetic connection method for the BiT elements. Her husband, an innovator Mika Myllylä designed the connector. Research and testing took five years. BiT represents a minimalistic Scandinavian design but the functionality gives nearly infinite ways to construct furniture. "Our daughter, Taika, was born half a year after research was started.  Above all, we wanted to make BiT as safe as possible for the kids. She once bumped her head to our previous sofa's arm. We didn't want that to happen again. Bouncing on a sofa is just what kids do.", Mika recalls. Not only castles and huts for kids, But BiT can also be equipped with latest game controllers using BiT adapters for a serious gaming event. Constructing a car, aeroplane or a tractor is limited only by imagination. "PC gaming was pretty hard on a couch before because they lack places for keyboard and mouse. BiT supports both PC and console game controllers. Flight sticks, throttle, wheels, pedals, keyboards and mouses are just a start of the long list of equipments attachable to BiT elements. Adapters have AMPS hole pattern which makes it easy to install phones, phablets, tablets, monitors, microphones and cameras to gaming cockpits. "If you can attach it on a car, motorcycle or boat, it can be attached to BiT elements.", Mika describes. Furniture constructed of BiT element is like a stripped version of traditional furniture since elements don't contain any glue, paints, solvents, lacquers or even wood. Changing sofa color or cleaning is easy since upholstery is removable. All pieces are frameless for added child safety. Strong magnets keep pieces together. Fully automated and fast connectors are cast inside the soft foam. The core functionality of a sofa has been unchanged for 400 years. Modularity made possible to align the sofa with the wall. BiT is the next step in evolution. Families are choosing smaller apartments which increase the demand for multi-functional furniture according to market research companies. "Smaller space can make limitations to hobbies or projects. With BiT furniture elements that restriction is gone. One of the features we wanted BiT to have is the possibility to pile the pieces against the wall when needed.", Mika says. "I'm confident we managed to make furniture which is fun for both children and adults.", Sanna sums up. Pieces are manufactured in Poland which is known for it's large furniture manufacturing industry. Magnets are delivered from China. BiT game controller adapters are made in Finland. BiT soft furniture elements can be pre-ordered from Indiegogo crowdfunding platform. Orders are delivered worldwide on October 2019 by Amazon. Link to Indiegogo campaign: https://igg.me/at/bitblockCompany web page: www.livingspaces.fiInstagram: www.instagram.com/bitmagnetblockFacebook: www.facebook.com/bittuote ### Photo and video gallery in Onedrive directory: https://1drv.ms/f/s!AuwLcOsV0WsnkbcparpQ3GnX5PRwHAAll photos, 3D renders and video by Mika Myllylä  ### Mika Myllylä+358 40 7329 116mika.myllyla@livingspaces.fiSkype: mikamyllyla@outlook.comwww.livingspaces.fi

Increased interest in the DrugLog® technology apparent after intensive exhibition weeks

EAHP, or European Association of Hospital Pharmacist, was held this year in Barcelona 26/3 - 28/3 and is the largest European pharmacy conference with over 3,500 delegates. Clear focus at the conference was increased interest in systems for safe drug handling. Above all, delegates from Germany showed an increased interest in Pharmacolog and DrugLog® as they in Germany have had incidents with chemotherapy preparations that proved to lack active substance. Torbjörn Norberg, Product Manager commented: “The increased focus on quality control combined with Pharmacolog and DrugLog® becoming more established meant a great interest from both potential distributors and potential strategic partners. Above all, our integrated solution where DrugLog® directly communicates with prescription software generated great interest” The Child Week (Barnveckan) is a Swedish meeting for doctors, nurses and pharmacists in pediatric care. The meeting was held this year in Örebro on April 1-4 with over 1000 delegates and about 40 exhibitors. The theme for this year was "the severely sick child" where a substantial part of the program was allocated to questions about medication. Kent Öbrink, Sales and Marketing Manager commented: “Control of medication is particularly important in child care, since children are much more sensitive to incorrect dose than adults. There was a great deal of interest in our ReVal ™ prototype and the project Pharmacolog runs with Astrid Lindgren's children's hospital. With the introduction of a database for preparations of drugs for children, ePed, on a broad front in Sweden, interest in how to control the preparations also increases.” NADDI, the National Association of Drug Diversion Investigators, is an organization that carries out healthcare training in preventing Drug Diversion. Each year NADDI organize a larger meeting where the focus is on sharing experiences and discussing technology and methods. In connection with this, an exhibition is held for companies in the industry. The meeting was held this year in St. Petersburg Florida and a total of 200 delegates, all of whom work in hospitals responsible for the Drug Diversion Prevention program. Mats Högberg, CEO comments: “It is very rewarding to participate in smaller, a little more intimate, meetings where all delegates have one and the same purpose with their participation. It was very clear that several people got their eyes on DrugLog® and the rumor has spread, more people came to our stand and said that they heard about DrugLog® and wanted a demonstration. Then it was extra pleasing to also be able to tell about our order for the NewYork Presbyterian, which further increased interest.”

German publisher Computec Media to grow digital revenues with Cxense

Oslo, Norway – 12 April 2019 – Cxense ASA (OSE: CXENSE), the AI-powered data management and intelligent personalization company that drives revenues for publishers and brands, today announced that COMPUTEC MEDIA GmbH (Computec Media), a German media company with a focus on gaming and technology, has extended their agreement to use Cxense DMP and personalization solutions including Conversion Engine. During the past years, Computec Media has successfully applied Cxense DMP to grow advertising revenues with rich user profiles and high-value interest segments. By implementing Conversion Engine, the publisher now plans to personalize customer journeys in order to boost engagement on their digital properties and build closer relationships with their readers. Computec Media is part of Marquard Media Group, a leading European media house that publishes lifestyle, special interest, gaming and electronic entertainment titles in Germany, Poland and Hungary. “Creating content that has the highest relevance for our audiences has always been our core focus. With the help of Cxense we want to leverage this ability even more and explore new ways of matching content to interests in order to drive engagement.” says Christian Müller, COO at Computec Media. “We are pleased with our strengthened relationship with Computec Media and look forward to helping them monetize their first-party data by creating personalized experiences that are great for readers and advertising customers alike,” says Christian Printzell Halvorsen, Cxense CEO. About Computec Media:Computec Media GmbH is a subsidiary of Marquard Media Group AG, Baar/Switzerland and Germany's leading, trusted, brand-centric and transaction-focused Media Platform Provider dedicated to Communities enthusiastic about Gaming and IT Entertainment. For more than 30 years, Computec Media has been a pioneer in media solutions for German-speaking audiences and the corresponding industries. The company reaches over 8 million Unique Users each month via its 13 print & digital magazines (PC Games, play4, N-Zone, SFT, Widescreen, Raspberry Pi Geek, etc.), 14 websites (gamesworld.de, pcgames.de, pcgameshardware.de, buffed.de, 4players.de, areamobile.de, etc.), apps, events (German Game Developer Award), B2B activities (golem.de, Making Games, Linux Magazin) or the 4Netplayers game server provider platform. Computec Media currently employs around 180 people at its headquarters in Fürth and in its subsidiaries and offices in Berlin, Hamburg, Cologne and Munich. About Cxense:Cxense is an AI-powered Data Management and Intelligent Personalization platform that helps 200 leading publishers and marketers around the globe build personal, profitable relationships with their customers. Our technology organizes first party data into powerful custom segments and 1:1 user profiles before applying machine learning to understand and predict customer behavior and intent. As a result, our clients are able to deliver unique and relevant content and offers to customers in real time, driving more subscriptions, sales, and higher customer lifetime value. Our solutions process interactions from about 7,000 websites on 2 billion devices each quarter. Cxense is listed on the Oslo Stock Exchange and has offices in Norway, the US, Japan, Russia, Germany, and Argentina. Visit www.cxense.com for more information.Investor Relations contact:Jørgen Evjen, Chief Financial OfficerEmail: jorgen.evjen@cxense.comMobile: +47 928 04 014Media contact:Tobias Arns, Head of Marketing and CommunicationsEmail: tobias.arns@cxense.comMobile: +47 920 24 305

SenzaGen appoints Axel Sjöblad as new CEO – mission to lead the company into an expansive sales phase

Axel Sjöblad has extensive experience in managing and developing global growth companies in medical technology and Life Science. He was most recently the CEO of BioGaia AB, a company with sales in 100 countries. During his time as CEO of BioGaia from 2016 to 2018, the company strengthened its market-leading position, with an increased market cap from around SEK 4 billion to approximately SEK 7 billion. Prior to working for BioGaia, Sjöblad was President Sales and Service North Europe and CEO of Getinge Sverige AB and Regional Vice President Northern European Markets at Gambro with responsibility for subsidiaries running operations in several European countries. He holds an MBA and Executive MBA from the Stockholm School of Economics. He is a board member of VibroSense Dynamics and former elite player in handball.“We are pleased to welcome Axel Sjöblad as CEO during this important phase of our growth journey. Axel has solid commercial background in the Life Science sector and will add valuable expertise through his broad experience of driving sales expansion into international markets. The Board is convinced that Axel has the necessary skills, vision and determination to build on the foundations that CEO Anki Malmborg Hager, has successfully laid in recent years,” says Carl Borrebaeck, Chairman of SenzaGen.Axel's focus is to expand global sales based on SenzaGen's unique product portfolio for animal-free allergy tests.“SenzaGen is a very well-run company that has developed with a long-term and serious focus and I look forward to further leading the company towards full-scale commercialization. The company's test methods have the potential to fulfill a unique customer need and to promote a paradigm shift for industrial tests. For the first time substances that cause allergies can be identified both with greater accuracy and most importantly without any animal testing. I very much look forward to being a part of this,” says Sjöblad. SenzaGen has evolved rapidly from an exciting innovative start-up to a company in the commercialization phase, since Anki Malmborg Hager joined in 2014. In a short time, the company has developed a unique test methodology with strong potential in several application areas and industries, as well as signing important license and distribution partners. Within the testing industry, a conversion process is already underway in which SenzaGen is playing a key role.“Anki has done a fantastic job by taking an academic innovation into a finished product. With her drive and vision, she has broadened the market potential for the GARD® platform thereby building the company's market value with an increased number of license and distribution agreements. In order to secure continued access to her broad expertise and experience, the company's main shareholders will propose Anki as a board member of SenzaGen at the Annual General Meeting on May 15,” says Carl Borrebaeck, Chairman of SenzaGen. For more information, please contact: Carl Borrebaeck, Chairman of the board, SenzaGen ABEmail: carl.borrebaeck@immun.lth.se | Telephone:  +46 708 218330Tina Dackemark Lawesson, Director Investor Relations & Corporate CommunicationsEmail: tina.lawesson@senzagen.com | Telephone: +46 708 202944 This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above on April 12, 2019 at 08.30 CET. About GARD® GARD® consists of a group of tests for analyzing chemicals' ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD® generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today's standard method – tests on mice – which only achieves 70-75 percent precision. SenzaGen's test can also quantify the allergenic potential of a chemical substance. About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the USA.SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.senzagen.com. 

Notice to the Annual General Meeting 2019 in Crown Energy AB (publ)

The shareholders of Crown Energy AB (publ), reg. no. 556804-8598, (the “Company”) are hereby invited to the Annual General Meeting to be held on Tuesday 14 May 2019 at 10.00 a.m. at Baker & McKenzie’s premises on Vasagatan 7 in Stockholm, Sweden. REGISTRATION AND NOTIFICATION  Shareholders who wish to attend the general meeting must:     i.            on the record day, which is Wednesday 8 May 2019, be registered in the share register maintained by Euroclear Sweden AB (“Euroclear”). Shareholders whose shares are registered in the name of a nominee must no later than on Wednesday 8 May 2019 temporarily register the shares in their own name in order to be entitled to participate at the general meeting; and    ii.             notify the Company of their, and any advisors (maximum two) participation at the general meeting no later than on Wednesday 8 May 2019. Notice of participation at the general meeting shall be sent by e-mail to info@crownenergy.se, by telephone on +46 8 400 207 20, or by regular mail to Crown Energy AB (publ), Norrlandsgatan 18, SE-111 43 Stockholm, Sweden. Upon notification, the shareholders should state their full name, personal identification number or corporate registration number, address and telephone number, and, where applicable, details of representative, proxy holder and advisor. A shareholder who wishes to be represented by proxy shall issue a written and dated proxy to the proxy holder. If the proxy is issued by a legal entity, a certified copy of the certificate of registration or corresponding document (”Registration Certificate”) shall be enclosed. The proxy must not be more than one year old, however, the proxy may be older if it is stated that it is valid for a longer term, maximum five years. In order to facilitate a effective entrance to the meeting the proxy in original and the Registration Certificate, if any, should well before the meeting be sent to the Company by post (at the address above). A proxy form will be available on the Company’s website www.crownenergy.se. THE PROPOSED AGENDA  1. Opening of the general meeting and election of chairman of the general meeting.  2. Appointment of keeper of the minutes. 3. Preparation and approval of the voting list. 4. Approval of the agenda. 5. Election of one or two persons to certify the minutes. 6. Determination of whether the general meeting has been duly convened. 7. Presentation of the annual report and the audit report and the consolidated financial statements and the audit report for the group. 8. Resolutions regarding:  a)   adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet;   b)   allocation of the Company’s profit or loss according to the adopted balance sheet; and   c)   discharge from liability for the board members and the managing director Determination of the number of ordinary directors and deputy directors of the board and auditors 9. Determination of the number of ordinary directors and deputy directors of the board and auditors10. Determination of remuneration to the board of directors and the auditor. 11. Election of ordinary directors, deputy directors, if any, chairman of the board of directors and auditors. 12. Resolution regarding guidelines for remuneration to senior executives. 13. Closing of the general meeting. PROPOSAL FOR RESOLUTIONS  Item 1: Opening of the general meeting and election of chairman of the Annual General Meeting The shareholders YBE Ventures and Cement Fund representing app. 85,2 percent of all the votes in the Company propose that Joakim Falkner, attorney at law, at Baker & McKenzie Advokatbyrå is appointed as chairman of the Annual General Meeting. Item 8(b): Resolution regarding allocation of the Company’s profit or loss according to the adopted balance sheet The board of directors proposes that all funds available to the Company shall be carried forward. Items 9-11: Determination of the number of ordinary directors, deputy directors and auditors, determination of remuneration to the board of directors as well as election of ordinary directors and deputy directors, if any, chairman of the board of directors and auditors The shareholders YBE Ventures and Cement Fund representing app. 85,2 percent of all the votes in the Company propose the following with regard to determination of the number of ordinary directors, deputy directors and auditors, determination of remuneration to the board of directors as well as election of ordinary directors and deputy directors, if any, chairman of the board of directors and auditors. It is proposed that the board of directors shall comprise of four directors without deputies. The number of auditors shall be one registered audit firm. It is proposed that the remuneration to each director elected by the meeting and who is not employed by the company shall be SEK 75,000 (SEK 75,000) and the chairman of the board of directors is to receive SEK 150,000 (SEK 150,000), in total SEK 300,000 (SEK 300,000). Remuneration to the auditor is to be paid according to approved invoice. It is proposed to re-elect the directors Jean Benaim, Alan Simonian, Yoav Ben-Eli and Pierre-Emmanuel Weil. Furthermore, Pierre-Emmanuel Weil is proposed to be re-elected as chairman of the board of directors. It is further proposed to re-elect the registered audit firm Öhrlings Pricewaterhouse-Coopers AB for the period until the end of the Annual General Meeting 2020. Öhrlings PricewaterhouseCoopers AB has announced its appointment of Bo Lagerström as main responsible auditor. Information regarding the for re-election proposed directors is available at the Company website and in the annual accounts for 2018. Item 12: Resolution regarding guidelines for remuneration to senior executives The board of directors proposes that the Annual General Meeting resolves to adopt the following guidelines for remuneration to senior executives. The guidelines are mainly the same as last year. The board of directors shall be entitled to deviate from the guidelines in an individual case if there are special reasons for it. In such event information regarding this and the reason for the deviation shall be presented at the next Annual General Meeting. Salary and other benefits: Remuneration to the managing director and other senior executives shall consist of a base salary in line with current market practice. Benefits, if any, shall only be a limited part of the remuneration. Pension: Pensions to the managing director and other senior executives shall consist of a defined contribution which means that accrual is made through the parent Company’s yearly premium payments. The managing director’s pension contributions shall amount to 30 percent of the salary each year. Pension to other senior executives shall follow the ITP plan.  Severance payment: Upon termination by the Company, severance pay shall be paid to senior executives with an amount corresponding to a maximum of 24 months’ salary, including base salary during the notice period. Incentive programs: Resolutions on share and share-price related incentive programs for senior executives should be resolved by the general meeting. Share and share-price related incentive programs should be designed with the aim of achieving greater community of interest between the participating senior executive and the Company’s shareholders. Programs that involve the acquisition of shares shall be designed so that one's own shareholding in the Company is promoted. The vesting period, or the time from the conclusion of the contract until the shares may be acquired, shall not be less than three years. Directors, who are not employed by the Company, shall not participate in programs aimed at management or other employees. Stock options shall not be included in programs directed to the board of directors. Work carried out by a director in addition to the board work: The members of the board of directors may in special cases be remunerated for services carried out within their specific area of expertise, which do not constitute board work. For such services, market compensation shall be paid, which is subject to approval by the board and to information at the Annual General Meeting. The total amount of remuneration granted or to be granted directly or indirectly by the Company to the senior executives is fully described in the consolidated financial accounts of the Company, as disclosed in its annual accounts for 2018 which is available at the Company’s website, www.crownenergy.se. NUMBER OF SHARES AND VOTES The total numbers of shares and votes in the Company on the date of this notice amount to 477 315 350 The Company does not hold any own shares. PROCESSING OF PERSONAL DATA For information on how personal data is processed, see the privacy notice available on Euroclear’s webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf MISCELLANEOUS  The complete proposals of the resolutions are included in the notice. Copies of the accounting documentation, the auditor’s report and auditor statement regarding guidelines for remuneration to senior executives and will be available at the Company and at the Company’s website, www.crownenergy.se, at least three weeks in advance of the Annual General Meeting. The documents will also be sent to shareholders upon request provided that the shareholders state their postal address. The shareholders are reminded of their right to request information at the Annual General Meeting from the board of directors and the managing director in accordance with Ch. 7 Section 32 of the Swedish Companies Act. Stockholm in April 2019 Crown Energy AB (publ) The board of directors MORE INFORMATION  Please contact Andreas Forssell, CEO, Crown Energy AB +46 8 400 207 20 +46 760 15 15 95 ABOUT CROWN ENERGY Crown Energy is an international group providing customised solutions for housing, offices and associated services, as well as oil and gas exploration in Africa and the Middle East. For more information please visit www.crownenergy.se 

NOTE and DeLaval enters into an extensive cooperation in electronics production

“For a long time, we have invested heavily in the collaboration with DeLaval and it is extremely gratifying that such a prominent company such as DeLaval now chooses NOTE as a strategic manufacturing partner for electronics. Through our global customer team, we will provide industrialisation services from Norrtälje in Sweden as well as both industrialisation services and volume production from Pärnu in Estonia and Tangxia in China," says Fredrik Schultz, Chief Sales Officer.   “DeLaval will hereby become one of NOTE's most important customers and the production is currently ramping up and will reach approximately SEK 60 million on an annual basis. The fact that we get this confidence shows that we have a complete and competitive customer offering," says Johannes Lind-Widestam, NOTE's President and CEO. “We are incredibly pleased with the choice of NOTE as a strategic partner for volume production and industrialisation of new products. NOTE is a great fit to our requirements, both in terms of competence and geography. We see a very good match between the companies and look forward to a long and successful cooperation,” says John-Erik Hermansson, EVP Supply Chain DeLaval. For more information, please contact:Johannes Lind-Widestam, CEO and President, tel. +46 (0)70 541 7222 Henrik Nygren, CFO, tel. +46 (0)70 977 0686Fredrik Schultz, Chief Sales Officer, tel:  +46 (0)70 244 0546 About NOTENOTE is one of northern Europe’s leading EMS partners, producing PCBAs, subassemblies and box build products. NOTE’s offering covers the complete product lifecycle, from design to after-sales. NOTE has a presence in Sweden, Finland, the UK, Estonia and China. Net sales in the last 12 months were SEK 1,379 million; the group has approximately 1,080 employees. NOTE is listed on Nasdaq Stockholm. For more information, please go to www.note.eu. The information was submitted for publication at 8:30 a.m. CET on 12 April 2019. 

Collaboration agreement with FMCG company in Functional Food discontinued

As earlier communicated, in late 2017 Probi signed a collaboration agreement with a global FMCG company (fast-moving consumer goods) concerning launch of a Functional Food product in the North American market. Probi has been informed by the partner, that they after a strategic review of the product, has decided to discontinue the collaboration agreement. The product launch was scheduled for the second half of 2019. "We are obviously disappointed that the collaboration is discontinued. There is a good working relationship and we will continue the dialogue with the partner regarding other potential business opportunities. The termination of the agreement results in a revision of our short-term growth outlook for Probi’s business area Functional Food. In parallel, Probi is working on projects with other partners in Functional Food that we plan to materialize in the future.”, says Probi’s CEO Tom Rönnlund. Business area Functional Food had sales of SEK 37 million in 2018, accounting for approximately 6% of Probi's total sales revenues of SEK 604 million. This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 12 April 2019 at 8.30 CET. FOR FURTHER INFORMATION, CONTACT:Tom Rönnlund, CEO: tel +46 46 286 89 40, e-mail: trd@probi.comHenrik Lundkvist, CFO: tel +46 46 286 89 41, e-mail: henrik.lundkvist@probi.com ABOUT PROBIProbi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four sites, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2018, Probi had net sales of MSEK 604. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has approximately 4,000 shareholders. Read more at www.probi.com.

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

Right to attend the Annual General Meeting Shareholders who wish to attend the Annual General Meeting must -          be registered in the share register maintained by Euroclear Sweden AB on Thursday 9 May 2019, and must also -          notify the company of their intention to attend the meeting, no later than Thursday 9 May 2019. The notification must be made in writing by e-mail to nina.carlen@vicorepharma.com, or by post to Vicore Pharma Holding AB (publ), attn. Nina Carlén, c/o Bioventurehub, Pepparedsleden 1, 431 83 Mölndal, Sweden. The notification must state the shareholder’s name, personal identity number/registration number, shareholding, address, day time telephone number and information about the attendance of any assistants (maximum two) and, if applicable, information about any proxies. Information submitted in connection with the notification will be computerised and used exclusively for the general meeting. See below for additional information on the processing of personal data.   Proxy Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney is executed by a legal person a certified copy of the certificate of registration or equivalent should be attached. The power of attorney and the certificate of registration may not be older than one year, however, the power of attorney may be older provided that the power of attorney according to its wording is valid for a longer period, although, not more than five years. The original power of attorney and the certificate of registration should be sent to the company at the address mentioned above well in advance of the general meeting. A proxy form is available at www.vicorepharma.com and will also be sent to shareholders who so request and state their postal address. Nominee-registered shares Shareholders whose shares are registered in the name of a nominee through a bank or a securities institution must re-register their shares in their own names in order to be entitled to attend the general meeting. Such registration, which may be temporary, must be duly effected in the share register maintained by Euroclear Sweden AB on Thursday 9 May 2019, and the shareholders must therefore contact their nominees well in advance of this date. Number of shares and votes As per the date of this notice there are a total of 42,374,714 shares outstanding in the company that entitle to one vote per share at the general meeting. As per the date of this notice the company holds no treasury shares. Proposed agenda 1)       Opening of the meeting 2)       Election of chairman of the meeting 3)       Preparation and approval of the voting register 4)       Approval of the agenda 5)       Election of one or two persons to verify the minutes 6)       Determination of whether the meeting was duly convened 7)       Presentation of the annual report and auditor’s report and the consolidated financial statements and auditor’s report for the group 8)       Resolutions regarding 1. adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet 2. allocation of the company’s profit or loss according to the adopted balance sheet, and 3. discharge from liability for board members and the managing director 9)       Determination of the number of board members and auditors 10)    Determination of fees for the board of directors and the auditors 11)    Election of members of the board of directors and auditors 12)    Resolution on principles for appointing the nomination committee 13)    Resolution on guidelines on remuneration to members of group management 14)    Resolution to authorize the board of directors to issue new shares 15)    Closing of the meeting Item 2, 9-11 – The nomination committee’s proposal to the annual general meeting 2019 The nomination committee of Vicore Pharma, which consists of Leif Darner (chairman of the board of directors), Staffan Lindstrand (appointed by HealthCap VII L.P.), Göran Wessman (appointed by Protem Wessman AB) and Evert Carlsson (appointed by Swedbank Robur), proposes the following: -          that Leif Darner shall be appointed chairman of the annual general meeting; -          that the number of members of the board of directors shall be six without deputies; -          that a registered audit company shall be appointed as auditor; -          that the directors’ fees shall be paid with SEK 300,000 to the chairman of the board of directors and SEK 100,000 to each one of the other members, with SEK 75,000 to the chairman of the audit committee and SEK 50,000 to the other members of the audit committee, with SEK 50,000 to the chairman of the remuneration committee and SEK 25,000 to the other members of the remuneration committee and, SEK 50,000 to the chairman of the scientific committee and SEK 25,000 to the other members of the scientific committee; -          that the fee to the auditor shall be paid in accordance with approved statement of costs; -          that the board members Leif Darner, Jacob Gunterberg, Maarten Kraan, Sara Malcus, Hans Schikan and Peter Ström are re-elected for the period up until the end of the next annual general meeting. Kjell Stenberg has declined re-election; -          that Leif Darner is re-elected chairman of the board of directors; and -          that the audit company EY AB is re-elected as auditor for the period up until the end of the next annual general meeting, with the request that Andreas Mast acts as auditor in charge, which is in accordance with the audit committee’s recommendation. Information regarding the proposed members of the board of directors is available on the company’s webpage www.vicorepharma.com, as well as in the company’s annual report.  Item 8b – Allocation of the company’s profit or loss according to the adopted balance sheet The board of directors proposes that no dividends shall be paid for the financial year 2018. Item 12 – Resolution on principles for appointing the nomination committee The nomination committee proposes that the annual general meeting resolves on principles for appointing the nomination committee in accordance with the following. The nomination committee shall consist of members appointed by each of the three largest shareholders, in terms of votes, based on the shareholders’ register maintained by Euroclear Sweden as of 31 August 2019, and the chairman of the board of directors. Should any of the three largest shareholders renounce its right to appoint one representative to the nomination committee, such right shall be transferred to the shareholder who then in turn, after these three shareholders, is the largest shareholder in the company. The chairman of the board of directors shall convene the nomination committee. The member representing the largest shareholder shall be appointed chairman of the nomination committee, unless the nomination committee unanimously appoints someone else. Should a shareholder having appointed a member to the nomination committee no longer be among the three largest shareholders, the member appointed by such shareholder shall resign and the shareholder who is then among the three largest shareholders shall have the right to appoint one member to the nomination committee. Unless there are specific reasons at hand, the already established composition of the nomination committee shall, however, remain unchanged in case such change in the ownership is only marginal or occurs within three months of the annual general meeting. Where a shareholder has become one of the three largest shareholders due to a material change in the ownership at a point in time falling later than three months before the annual general meeting, such shareholder shall in any event have the right to appoint a member of the nomination committee to take part of the work of the committee and participate at its meetings. Should a member resign from the nomination committee before its work is completed, the shareholder who has appointed such member shall appoint a new member. If such shareholder no longer is one of the three largest shareholders, any substitute member shall be appointed in the above order. A shareholder who has appointed a member of the nomination committee shall have the right to discharge such member and appoint a new member. Changes to the composition of the nomination committee shall be announced immediately. The term of office for the nomination committee ends when the next nomination committee has been appointed. The nomination committee shall carry out its duties as set out in the Swedish Code of Corporate Governance. Item 13 – Resolution on guidelines on remuneration to members of group management The board of directors proposes that the annual general meeting resolves to approve guidelines on remuneration to members of group management in accordance with the following. Vicore Pharma shall offer remuneration in accordance with market practice which enables the recruitment and retention of internationally qualified senior executives. Remunerations within Vicore Pharma shall be based on principles of performance, competitiveness and fairness. Senior executives refer to the CEO and the other members of the executive management. The guidelines shall apply to employment agreements concluded after the annual general meeting’s resolution to adopt these guidelines, as well as when changes are made to existing agreements thereafter. The remuneration to senior executives consist of fixed remuneration, variable remuneration, share and share-price related incentive programs, pension and other benefits. The fixed remuneration shall reflect the individual’s responsibility and experience level. The fixed remuneration shall be reviewed annually. Variable remuneration paid in cash may not exceed 40 per cent of the annual fixed remuneration for the CEO and may not exceed 30 per cent of the annual fixed remuneration for other senior executives. Variable remunerations shall be connected to predetermined and measurable criteria, designed with the aim of promoting the company’s long-term value creation. Share and share-price related incentive programs shall, if resolved on, be decided by the shareholders’ meeting. Pension shall, where possible, be premium-based. For the CEO and other senior executives, the premium may, in situations where premium-based pension is applicable amount to a maximum of 30 per cent of the fixed salary. Notwithstanding the above, the board of directors is entitled to offer other solutions which, in terms of cost, are equivalent to the above. Between the company and the CEO, the notice period shall be up to six months upon notice by the company. If notice is given by the company, the board of directors can decide that the CEO shall be entitled to a severance pay equal to an amount up to twelve months’ salary. Upon notice by the CEO, the notice period shall be up to six months. For other senior executives, notice periods of three to six months shall apply. During the notice period, normal salaries shall be paid. Senior executives may be awarded other customary benefits such as company health care etc. Such other benefits shall not constitute a substantial part of the total remuneration. The board of directors is entitled to deviate from the guidelines if the board of directors, in a certain case, deems that there is cause for deviation. Item 14 – Resolution to authorize the board of directors to issue new shares The board of directors proposes that the annual general meeting resolves to authorize the board of directors, at one or several occasions and for the period until the next annual general meeting, to increase the company’s share capital by issuing new shares. Such share issue may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The number of shares that may be issued under the authorization may not entail a dilution effect of more than 20 per cent, based on the number of outstanding shares and votes at the time of the annual general meeting 2019. The purpose of the authorization is to increase the financial flexibility of the company and the general flexibility of the board of directors. Should the board of directors resolve on a share issue with deviation from the shareholders' preferential rights, the reason for this shall be to finance acquisitions of businesses or to procure capital to finance the development of projects. Upon such deviation from the shareholders’ preferential rights, the new issue shall be made at market terms and conditions. The CEO shall be authorized to make such minor adjustments to this resolution that may be necessary in connection with the registration. Majority requirements A resolution in accordance with item 14 above requires approval of at least two thirds (2/3) of the shares represented and votes cast at the general meeting. Other information The shareholders are reminded of their right to request information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. The annual report and the auditor’s report for the financial year 2018 will be held available at the company’s office on c/o BioVentureHub, Pepparedsleden 1, in Mölndal and on the company’s website, www.vicorepharma.com, at least three weeks before the general meeting. Further, the nomination committee’s motivated statement will be available on the address and website stated above at least four weeks before the general meeting. Copies of the documents will be sent to the shareholders who so requests and informs the company of their postal address. For information on how your personal data is processed, see the integrity policy that is available at Euroclear’s webpage, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. _____________________  This is an in-house translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish version shall prevail. _____________________  Mölndal, April 2019 Vicore Pharma Holding AB (publ) The Board of Directors This information was submitted for publication on 12 April 2019 at 8:30 a.m. CEST.

TagMaster receives an extension order for the larger Paris train system area

Press Release, Stockholm, Sweden 12 April 2019 TagMaster, a leading supplier of advanced sensor systems for Smart Cities within Traffic and Rail, has through its subsidiary Balogh SA, received an extension order for SNCF Transilien that is the train system supporting the larger Paris area. Balogh is one of the pioneers in the RFID technology and was founded in 1958. Balogh has since 2009 provided SNCF Transilien with detection systems. The Balogh equipment is used to detect elevated station platforms for wheel chair access, developed as part of the European RMU program “Reduced Mobility User”. This system automatically bridges the gap between the train and the elevated platform using Balogh RFID equipment for precise train positioning, thus providing safe wheelchair access. The extension order, dedicated to the SNCF fifth and sixth train batches T05 and T06 comprises the well proved product range of MOL 81 1315 that have been in the market for many years. The products will be delivered from 2020 through early 2022 and the total order value is approximately € 700 000. Baloghs customer is one of the major global actors within train systems. ”TagMaster has earlier expressed its enthusiasm for the Balogh acquisition and this order confirms that our ambition that, together with Balogh, become a stronger supplier within Rail Solutions is materializing. We together have a wider product offering and we will together become one of the leading actors in train signaling”, says Jonas Svensson, CEO, TagMaster. For further information, please contact Jonas Svensson, CEO, +46 8-6321950, jonas.svensson@tagmaster.com  This information is information that TagMaster AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on April 12, 2019.   About TagMaster TagMaster is an application driven technology company that designs and markets advanced sensor systems and solutions based on radio and vision technology (RFID, Radar and ANPR) for demanding environments. Business areas include Traffic Solutions and Rail Solutions sold under the brands TagMaster, CitySync, Balogh, CA Traffic, Magsys and Hikob with innovative mobility solutions in order to increase efficiency, security, convenience and to decrease environmental impact within Smart Cities. TagMaster has dedicated agencies in the US and in China and exports mainly to Europe, The Middle East, Asia and North America via a global network of partners and systems integrators. TagMaster was founded in 1994 and has its headquarters in Stockholm. TagMaster is a public company and its shares are traded on First North stock exchange in Stockholm, Sweden. TagMasters certified advisor is Erik Penser Bank phone +4684638300, E-mail: certifiedadviser@penser.se  www.tagmaster.com

Enersize Oyj receives additional order from Stora Enso through Momentum

Momentum is a distributor of Enersize's cloud service LEAQS in the Swedish market and a nationwide player for industrial supplies for the Swedish manufacturing industry. Momentum also offers maintenance and repair services to the industry. In spring 2019, Momentum received training from Enersize in order to be able to independently conduct sales of LEAQS, which in a short time led to two signed agreements. Through the acquisition of LEAQS, Enersize has also established itself in Europe and gained access to a vast customer and distribution network. With LEAQS for leakage minimization and Enersizes Q+ for monitoring and optimization of compressed air systems, Enersize now has a broad customer offering that can be sold by independent distributors and parties within industrial maintenance. Momentum is a clear example of this type of independent actors who already have a well-established relationship with large industrial customers and thus quickly can scale up sales of Enersize's products. The leakage search at Stora Enso's plant in Skutskär is expected to start in May 2019.  ”It feels extremely exciting that we in such a short time through Momentum have received an additional order from Stora Enso. Momentum has a strong drive, an extensive pipeline and has shown that they can sell our products independently. This shows both that LEAQS is a popular product that creates ongoing business for Enersize and that our new business structure with major companies in industrial supplies and industrial maintenance that sells our products independently works really well. Our goal now is to continue to scale up by linking many similar partners to us for the resale of both LEAQS and Enersize Q+”, comments Anders Sjögren, CEO of Enersize.

Notice of Annual General Meeting of SenzaGen AB (publ)

Right to attend the general meeting and notificationShareholders who wish to attend the Annual General Meeting must be included in the share register maintained by Euroclear Sweden AB as of Thursday of the 9 May 2019. Shareholders shall also notify the Company of their participation and any assistants (no more than two) in the Annual General Meeting no later than Thursday of the 9 May 2019 The notification shall be in writing to SenzaGen AB, Medicon Village, 401, 223 81 Lund or by e-mail to anmalan@senzagen.com. The notification should state the name, personal/corporate identity number, shareholding, address and telephone number and, when applicable, information about representatives, counsels and assistants. When applicable, complete authorization documents, such as registration certificates and powers of attorney for representatives and assistants, should be appended the notification. Nominee-registered shares Shareholders, whose shares are registered in the name of a bank or other nominee, must temporarily register their shares in their own name with Euroclear Sweden AB in order to be entitled to participate in the Annual General Meeting. Such registration, which normally is processed in a few days, must be completed no later than Thursday of the 9 May 2019 and must therefore be requested from the nominee well before this date. The complete notice is available via the link below. For more information, please contact:Anki Malmborg Hager, CEO, SenzaGen ABEmail: anki.malmborg.hager@senzagen.com | Telephone: +46 768 284822Tina Dackemark Lawesson, Director Investor Relations & Corporate CommunicationsEmail: tina.lawesson@senzagen.com | Telephone: +46 708 202944About GARD® GARD® consists of a group of tests for analyzing chemicals' ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD® generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today's standard method – tests on mice – which only achieves 70-75 percent precision. SenzaGen's test can also quantify the allergenic potential of a chemical substance.About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the USA.  SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.senzagen.com. 

Notice to Annual General Meeting

To the shareholders of Nustay A/S The board of directors hereby convenes the annual general meeting of Nustay A/S, CVR no. 36 09 03 16, (the ”Company”), to be held on: Tuesday 30 April 2019 at 10.00 (CET) at Gorrissen Federspiel Advokatpartnerselskab, Axeltorv 2, DK-1609 Copenhagen V, Denmark Agenda 1.              Election of chairman of the meeting  2.              The board of directors’ report on the Company’s activities in the past financial year 3.              Presentation of the Company’ annual report for 2018 for adoption 4.              Resolution concerning the appropriation of profits or losses as recorded in the adopted annual report 5.              Election of members to the board of directors 6.              Election of auditor 7.              Any proposals from the board of directors or shareholders   7.a            Proposal from the board of directors to hold the general meeting in English and to prepare documents in connection with or following the general meeting in English 8.              Any other business  --- Items on the agenda, including complete proposals Item 1: Election of chairman of the meeting The board of directors will elect the chairman of the general meeting.   Item 2: The Board of Directors’ report on the Company’s activities in the past financial year The board of directors proposes that the report on the Company’s activities in 2018 be noted by the general meeting. Item 3: Presentation of the Company’s annual report for 2018 for adoption The board of directors proposes that the Company’s annual report for 2018 be adopted. Item 4: Resolution concerning the appropriation of profits or losses as recorded in the adopted annual report The board of directors proposes that no dividend be distributed for financial year 2018. Item 5: Election of members to the board of directors The board of directors proposes to re-elect Lone Fønss Schrøder, Piyush Jain, Carl Erik Skovgaard, Simon Skouboe and Michael Telling Jørgensen to the board of directors.  A description of the competencies and other executive functions in Danish and foreign companies held by the candidates proposed to the board of directors is attached as Appendix 1 to the notice to convene. Item 6: Election of auditor The board of directors proposes that the Company’s current auditor, Deloitte Statsautoriseret Revisionspartnerselskab, be re-elected. Item 7: Any proposals from the board of directors or shareholders  The board of directors has submitted proposal 7.a below, and no proposals have been submitted by shareholders. Item 7.a: Proposal from the board of directors to hold the general meeting in English and to prepare documents in connection with or following the general meeting in English The board of directors proposes that the general meeting approves that general meetings of the Company going forward shall be held in English, and that documents prepared for use of the general meeting in connection with or following the general meeting shall be prepared in English. --- Majority requirementsAll proposals on the agenda may be adopted by a simple majority of votes. Share capital   At the time of the notice of the general meeting, the Company’s nominal share capital is DKK 728,826.60, divided into shares of nominally DKK 0.04 each. Each share of DKK 0.04 carries one vote.  Registration date and shareholders’ voting rights  The registration date is Tuesday 23 April 2019. The right of a shareholder to attend a general meeting and to vote is determined on the basis of the number of shares held by the shareholder at the registration date.  The shares held by each shareholder are determined at the registration date based on the number of shares held by that shareholder as registered in the Company’s register of shareholders and on any notification of ownership received by the Company at the registration date for the purpose of registration in the Company’s register of shareholders, which have not yet been registered. Participation is conditional upon the shareholder having obtained an admission card in due time as described below. Admission cards  Shareholders who are entitled to attend the general meeting and who wish to attend the general meeting must request an admission card no later than on Friday 26 April 2019 at 23.59 (CET).  Admission cards for the general meeting may be obtained by one of the following ways:  -       Electronically through the “InvestorPortal” under the menu “Investor” on the Company’s website, https://investor.nustay.com. -       In writing by using the registration form, which is available on the Company’s website, https://investor.nustay.com/investor/#agm. The completed and signed form must be scanned and emailed to VP Investor Services A/S either by email to vpinvestor@vp.dk or by ordinary mail to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark. Admission cards ordered will be distributed to the email address which has been stated on the registration form.  Admission cards and the related ballot papers must be printed and brought to general meeting. If it is not possible for you to print your admission card and ballot paper, please contact VP Investor Services A/S by email to vpinvestor@vp.dk.  Proxy Subject to having requested an admission card, shareholders may attend the general meeting in person or by proxy. Proxies may be submitted by one of the following ways: -       Electronically through the “InvestorPortal” under the menu “Investor” on the Company’s website, https://investor.nustay.com. -       In writing by using the proxy form, which is available on the Company’s website, https://investor.nustay.com/investor/#agm. The completed and signed form must be scanned and emailed to VP Investor Services A/S either by email to vpinvestor@vp.dk or by ordinary mail to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark. Proxy forms must be received by VP Investor Services A/S no later than on Friday 26 April 2019 at 23:59 (CET).  It is possible to submit either proxy or vote by correspondence, cf. below, but not both. The right to attend and vote by proxy is subject to presentation of appropriate identification. If appropriate identification is not presented, attendance and/or voting right may be rejected.  Voting by correspondence Shareholders who are not able to attend the general meeting may vote by correspondence. Votes by correspondence may be submitted by one of the following ways: -       Electronically through the “InvestorPortal” under the menu “Investor” on the Company’s website, https://investor.nustay.com. -       In writing by using the voting by correspondence form, which is available on the Company’s website, https://investor.nustay.com/investor/#agm. The completed and signed form must be scanned and emailed to VP Investor Services A/S either by email to vpinvestor@vp.dk or by ordinary mail to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark. Votes by correspondence must be received by VP Investor Services A/S no later than on Monday 29 April 2019 at 16:00 (CET).  It is possible to submit either proxy or vote by correspondence, cf. above, but not both. Additional information Until and including the day of the general meeting, additional information regarding the general meeting will be available on the Company’s website, https://investor.nustay.com, including:  -       The notice to convene the general meeting, including the agenda and the complete proposals and Appendix 1;  -       The proxy/voting by correspondence form for use in connection with voting by proxy or by correspondence; -       The aggregated number of shares and voting rights as of the date of the notice to convene the general meeting; and -       The Company’s annual report for 2018.  The general meeting will be held in Danish.   In connection with the general meeting, tea and coffee will be served.  Questions from the shareholders Shareholders may ask questions regarding the agenda and documents concerning the general meeting may be submitted in writing prior to general meeting by ordinary mail to the Company to the address Nyhavn 43B, DK-1051 Copenhagen, or by email to investor@nustay.com. Questions must be received no later than on Friday 26 April 2019.  Personal dataWith regards to collection and processing of personal data, reference is made to the Company’s information sheet on data protection in connection with the annual general meeting, which is available on the Company’s website,https://investor.nustay.com/investor/#agm.  Copenhagen, 12 April 2019 Nustay A/S The board of directorsAppendix 1: Description of the candidates for the board of directors   Lone Fønss Schrøder Board candidate (current chairman of the board of directors) Born 1960 Female Danish nationality Independent Other managerial dutiesLone Fønss Schrøder is the founder and CEO in Schrøder Consult ApS and is a member of the board of directors and CEO in Geely Financials Denmark A/S.  In addition to this, Lone Fønss Schrøder is a member of the board of directors in Volvo Car AB, INGKA Holding B.V. (IKEA Group), Kværner ASA, Akastor ASA, Bilfinger SE and CSL Group, Inc. Former managerial dutiesLone Fønss Schrøder has previously been a member of the board of directors in Saxo Bank A/S, NKT A/S and Coderstrust Global ApS. EducationLone Fønss Schrøder holds an MSc from Copenhagen Business School and a LL.M. from the University of Copenhagen. Michael Telling Jørgensen Board candidate  (current member of the board of directors) Born 1967 Male Danish nationality  Independent Other managerial dutiesMichael Telling Jørgensen is co-founder, the CEO and a member of the board of directors in Telling & Nesager ApS as well as the CEO in TN Asset & Property Management ApS, TN Financial Services ApS, TN Human Capital ApS, TN Manpower & Training ApS and TN Communications & PR ApS. In addition to this, Michael Telling Jørgensen is the founder and CEO of Hotelling Holding ApS and also a member of the board of directors in Rødvig Kro & Badehotel A/S, Residens Møen ApS and Flying Elephant AS. Former managerial dutiesMichael Telling Jørgensen has previously been CEO in Slotshotellet ApS and CEO in First Hotels AS. Education Michael Telling Jørgensen holds a BSc in International Hospitality & Tourism Management from the University of Surrey. Carl Erik Skovgaard Board candidate  (current member of the board of directors) Born 1958 Male Danish nationality Independent Other managerial dutiesCarl Erik Skovgaard is a partner in DLA Piper Advokatpartnerselskab and chairman of the board of directors in Cashbackpoint Nordic ApS, Cofur ApS, Kulturretur A/S, SPECTRAS A/S, NRT – Nordisk Røntgen Teknik A/S, Servicepoint A/S, Bykvalitet ApS, Bedre By ApS, Fyns Kran Udstyr A/S, Epico-IT ApS, Multi Køl & Energi A/S, DS Triple A/S, TFD, Total Finans Danmark A/S, TFD II, Total Finans Danmark A/S, EHJ Holding ApS, EHJ Energi A/S, Ejendomsselskabet MCR ApS, ProCon Technic A/S, AA Transport-Service A/S, Alex Andersen. Ølund A/S, Danforel Olie & Protein A/S, Danforel A/S, Danforel Holding ApS, Danforel Udstyr A/S, Proby Ingredients A/S, Danaqua ApS, Jytas A/S, Jytas Udlejning ApS, Carta Autofinans A/S, Carta Leasing A/S, Carta Flexleasing A/S, Carta Deleleasing A/S, Firmainvest A/S, Firmainvest Holding A/S, Spiger ApS, Passon Solutions ApS, Green Cotton Group Denmark A/S, Unisense A/S, Unisense Holding 2 A/S, Unisense Enviroment A/S, LACE A/S, LACE Holding A/S, Søbohus Holding ApS, Veksø-Taulov Holding ApS, ALEKSANDER PANTEBREVE A/S, Via Biler A/S, Via Biler Gruppen A/S, Via Biler Ejendomme ApS, Innovator A/S, Innovator REC Herning ApS, Innovater Rec N1 A/S, Innovator Rec 1 A/S, Innovater Aabyen Rec A/S, Innovator Rec 3 A/S, Innovator Rec 4 A/S, Innovator Rec 5 A/S, Ejendomsselskabet Amalievej ApS, Bjert Private Equity A/S, Bjert Invest A/S, Bjert Ejendomsudvikling A/S, Bjert Ejendomme A/S, Design City Vest A/S, Bjert Erhvervsejendomme A/S, Bjert Boligejendomme A/S, Stutteri Evo ApS, Bjert Finans A/S, Bjert Trading ApS, Bjert Holding ApS, SELSKABET AF 17.01.2014 A/S, SELSKABET AF 21. MAJ 2014 A/S, X-Mile ApS, X-Mile Holding A/S, R&D Group A/S, R&D Test Systems A/S, R&D Tools and Structures A/S, R&D Engineering A/S, Mileage Book Group A/S, Mileage Book ApS and Aarhus Projekt 1 ApS.  In addition to this, Carl Erik Skovgaard is a member of the board of directors in AMC Lastbiler A/S, ProCon Group ApS, ProCon Wind Energy A/S, Alex Andersen Ølund Holding A/S, Au2mate A/S, Jørgen P. Potteplanteri A/S, ID Hair Company A/S, Kohsel A/S, Maass & Co. A/S, Scrouples A/S, WOCA Denmark A/S, SuperCore IVS, MBLS Holding A/S, Den Jyske Opera, Rhinix ApS, Patrade A/S, Skanderborgvej ApS, Cars A/S, Via Biler Udlejning A/S, Dkventure ApS, Conceptmaking ApS, Airteam A/S, Airteam Holding ApS, Airteam TopCo ApS, Ingemann Components A/S, Ingemann A/S af 1989, Ingemann Supply A/S and Ingemann Packaging A/S, and also a director in athome apartments ApS, Halmskov ApS, Advokatanpartsselskabet SkovSø, RTB Invest ApS, Ejendomsselskabet Kirstinehøj 62, Kastrup ApS, Merian Holding ApS, CES SH ApS, Jytas Projekt I ApS, Jytas Projekt II APS and Jytas Projekt III ApS.Education   Carl Erik Skovgaard has a Master of Law degree from Aarhus University, and was admitted to the Danish Bar in 1985. In addition to this, Carl Erik Skovgaard holds a Diploma in Economics and Accountancy. Simon Skouboe Board candidate  (current member of the board of directors) Born 1982 Male Danish nationality Independent Other managerial dutiesSimon Skouboe is the chairman of the board of directors in S3E ApS, Vigmas A/S, KPR Towers Holding ApS and KPR Towers A/S. In addition to this, Simon Skouboe is a member of the board of directors in Møllehegnet Holding A/S, Selskabet af 6.April 2010 ApS, Mølledammen 4 ApS, Tiger Infrastructure Pte. Ltd., Skytem Surveys ApS, Telcon A/S, Anpartsselskabet af 19/12 2008, Anpartsselskabet af 5. Januar 2010, Airborne Instruments ApS, Anpartsselskabet af 30/3 2011, FS Holding Kolding ApS, K/S Joinflight V, and also the CEO in Anpartsselskabet af 30. august 2017 and JF V ApS. Simon Skouboe is also the founder and CEO in SS Holding Kolding ApS and partner in Henne Kirkeby Kro I/S and Kong Hans Kælder I/S. Former managerial dutiesSimon Skouboe has previously the chairman of the board of directors in Restaurant Kong Hans Kælder A/S, and also CEO in SS Holding Kolding 2012 ApS and Carbon Nano Europe A/S. In addition to this, Simon Skouboe has been a member of the board of directors in Mølledammen 2 ApS, Mølledammen 3 ApS, Møllehegnet Mallorca ApS, Ortovision Composites ApS and Schou & Skouboe A/S. Education  Simon Skouboe has an MSc in Economics and Business Administration from Copenhagen Business School. Piyush Jain Board candidate  (current member of the board of directors) Born 1985 Male Indian nationality  Independent Other managerial dutiesPiyush Jain does not have any other managerial duties.Education   Piyush Jain has a B.Sc. in Economics from University of Pennsylvania and a Master in Public Policy from Harvard University.

Cereno Scientific conducts a Rights Issue of approximately SEK 55.6 million and announces a bridge financing

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. The resolution requires approval at an Extraordinary General Meeting, which will be held on May 15, 2019. The notice of the Extraordinary General Meeting will be published in a separate press release. Summary · Existing shareholders are entitled to subscribe for one (1) subscription right for each share held on the record date of 21 May 2019, regardless of share class. One (1) subscription right entitles the holder to subscribe for one (1) newly issued share of class B. · The Rights Issue consist of a maximum of 19,181,302 new shares of class B and are offered at a subscription price of SEK 2.90 per share, which means that the Company will receive SEK 55.6 million before issuing costs, if the Rights Issue is fully subscribed. · The Rights Issue is guaranteed up to 80 percent by subscriptions and underwriting commitments. · The subscription period for subscription of shares will be from May 23, 2019 until June 7, 2019. · To enable allocation to subscribers who may not receive allocation in the Rights Issue and to potentially broaden and strengthen the Company's ownership base, the Board proposes authorization for the Board of Directors to decide on an over-allotment issue amounting to SEK 5.0 million, if fully exercised. · To finance repayment and termination of the previous outstanding convertible loan and to secure the short-term working capital requirement, the Company has entered into agreement regarding a short-term bridge loan of SEK 12 million. The bridge loan is intended to be repaid with proceeds received from the Rights Issue. · The Company carries out the Rights Issue to finance preparations for the Phase 2 study, to initiate pre-clinical studies with the newly acquired drug substance and to repay short-term loans. The Bridge Loan In connection with the Rights Issue, the Company entered into an agreement with Formue Nord Markedsneutral A/S regarding a bridge loan of SEK 12 million. The Bridge Loan enabled full repayment and termination of the previous outstanding convertible loan issued by the European High Growth Securities Opportunities Fund ("EHGOSF"). The Bridge Loan also ensures the short-term working capital requirement. The cost of the Bridge Loan corresponds to a monthly interest rate of 2.5 percent per initiated 30-day period. The Bridge Loan is intended to be repaid with cash received from the Rights Issue. Background and rational in summary Cereno Scientific develops drugs that restore the body's own defense system against thrombosis to be used in the prevention of thrombosis-related complications to cardiovascular disease in the global market. In June 2018 the Company received positive results from the Phase 1 study with its drug candidate CS1 and is ready to continue the clinical development with a phase 2 study, planned to begin in H1 2020. The overall purpose of the upcoming Phase 2 study is to validate its therapeutic effect and tolerance of CS1. In addition to CS1, Cereno Scientific has signed an agreement with Emeriti Bio AB regarding an acquisition of the substance EB014 in order to broaden Cereno Scientific's portfolio in cardiovascular diseases. During March 2018, Cereno Scientific entered into an agreement regarding a financing solution with the European High Growth Opportunities Securitization Fund, EHGOSF, for the purpose of obtaining working capital and to finance the clinical development of CS1. On March 1, 2019, Cereno Scientific terminated the agreement. The Company’s proposed financing is the present Rights Issue, including the Bridge Loan, which is considered to be the alternative creating the right conditions for the Company´s operations and long-term shareholder value. Cereno Scientific intends to use the total proceeds raised for the following purposes, specified in order of priority: · Repayment of the Bridge Loan used to finance the Company’s operations after the previously mentioned financing solution was terminated. · Complete the planning work and to submit the application for the Phase 2 study during Q3 2019 to the authorities in order to obtain approval for the study during Q1 2020. · Scale the production of the clinical trial drug CS1 to be used in the Phase 2 study. · After approval, initiate the Phase 2 study during H1 2020. · Initiate preclinical studies on new drug substance in collaboration with Emeriti Bio. · Continuing the development of the Company’s patent portfolio. · Finance operating costs. The Company intends to use the proceeds that might be raised from the over-allotment issue to the following: · Accelerate Phase 2 study initiation. The Rights Issue The Board of Cereno Scientific has resolved to issue shares with preferential rights for the Company's existing shareholders in accordance with the terms listed below. The decision is conditional on the following extraordinary general meeting´s subsequent approval, and that the extraordinary general meeting resolves to amend the Company's Articles of Association regarding the number of shares and share capital. · All existing shareholders receive one (1) subscription right for each share, regardless of share class, held on the record date, May 21, 2019. One (1) subscription right entitles the holder to subscribe for one (1) newly issued share for a subscription price of SEK 2.90. · The Rights Issue entails the issue of a maximum of 19,181,302 shares of series B. At full subscription of the Rights Issue, the Company receives proceeds amounting to approximately SEK 55,6 million, before issuing costs. As a result, the share capital may increase from SEK 1,918,130.20 to SEK 3,836,260.40, representing an increase of SEK 1,918,130.20. · The subscription period will be from May 23, 2019 up and until June 7, 2019. · Existing shareholders who choose not to participate in the Rights Issue will experience a dilution amounting to 50 percent, if the Rights Issue is fully subscribed. Subscription commitments and guarantees The Rights Issue is partially secured through subscription commitments of approximately 6.6 percent and through underwriting commitments of approximately 73.4 percent. In total, 80 percent of the Rights Issue is secured by subscription and underwriting commitments. Subscription commitments have been provided by Björn Dahlöf privately and via company (Board Member and CMO), Jonas Faijerson Säljö via company (Board member and Head of Intellectual Property Rights), Sverker Jern (Board member), Anders Svensson (Board member), Niklas Bergh via company (Board deputy and CSO), Sten R. Sörensen via company (CEO), Jan-Peter Idström (Senior Director Development) and GU Ventures AB. The underwriting commitments have been provided by external parties. For the underwriters, an underwriting compensation of ten (10) percent of the underwritten amount is paid in cash. The underwriters may also choose to receive compensation in shares instead of cash, in which case the compensation is twelve (12) percent. No compensation is paid to the shareholders who entered into subscription commitments. Proposal for amendment of the Articles of Association At the Extraordinary General Meeting, the Board also proposes to decide on the Articles of Association to be amended regarding the share capital limits and the number of outstanding shares limits by adjusting the share capital to a minimum of SEK 1,900,000 and a maximum of SEK 7,600,000 and the number of shares to a minimum of SEK 19,000,000 and a maximum of 76,000,000. Amendment of the Articles of Association is a prerequisite for the Rights Issue. Proposal for authorization for the Board to decide on over-allotment issue To enable allocation to subscribers who may not receive allocation in the Rights Issue and to potentially broaden and strengthen the Company's ownership base, the Board proposes the Board of Directors to be authorized to issue an additional maximum of 1,724,137 shares of class B to be issued by an over-allotment issue at the same subscription price as the shares issued in the Rights Issue. Upon full utilization of the over-allotment issue, the Company will receive an additional SEK 5.0 million. The over-allotment issue is conditional on a fully subscribed Rights Issue and will, if fully utilized, increases the share capital by an additional SEK 172,413.70 to SEK 4,008,674.10. The over-allotment issue would entail an additional dilution of 4.3 percent, resulting in dilution totaling 52.2 percent for a shareholder who does not subscribe in the Rights Issue upon capitalization of the entire over-allotment. Timetable +--------+-------------------------------------------------------------------+|May 17, |Last day of trading including the right to receive subscription ||2019 |rights. |+--------+-------------------------------------------------------------------+|May 20, |First day of trading excluding the right to receive subscription ||2019 |rights. |+--------+-------------------------------------------------------------------+|May 20, |The prospectus is expected to be published.  ||2019 | |+--------+-------------------------------------------------------------------+|May 21, |The record date. Shareholders who are registered in the Euroclear ||2019 |Sweden AB share register as of this day will receive subscription || |rights which entitle the holder to participate in the Rights Issue.|+--------+-------------------------------------------------------------------+|May 23 –|Trading with subscription rights on Spotlight Stock Market ||June 4, | ||2019 | |+--------+-------------------------------------------------------------------+|May 23 –|The Subscription Period for the Rights Issue. ||June 7, | ||2019 | |+--------+-------------------------------------------------------------------+|June 12,|The announcement of the outcome of the offering is expected to be ||2019  |published. |+--------+-------------------------------------------------------------------+ Advisors  Mangold Fondkommission AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman MAQS is acting as the legal adviser to the Company. For further information, please contact:Sten R. Sörensen – CEOTel: +46 733 74 03 74E-mail: sten.sorensen@cerenoscientific.comwww.cerenoscientific.se About Cereno Scientific AB Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub  and is supported by GU Ventures . Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558. This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on April 12, 2019. Important information This press release is not an offer to subscribe for shares in Cereno Scientific and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Cereno Scientific will only be made through the prospectus that Cereno Scientific is expected to publish on May 20, 2019. This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Neither subscription rights, shares subscribed for ("BTA") or newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law. There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States. This press release may contain certain forward-looking information that reflects Cereno Scientific's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Cereno Scientific makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.

Anna Storåkers appointed as new Member of the Board of Directors of Nordax Bank

The Board of Directors of Nordax Bank AB (publ) now consists of: Chairman: Hans-Ole Jochumsen Non-executive Board Members: Christopher Ekdahl, Christian Frick, Heiki Kapanen, Henrik Källen, Anna Storåkers och Ville Talasmäki For further information, please contact: Andreas Frid, Head of Marketing & Communication, tel: +46 705 29 08 00 or andreas.frid@nordax.se  About Nordax Bank Nordax Bank is a leading specialistbank in Northern Europe owned by Nordic Capital Fund VIII and Sampo. The client base today consists of 185.000 private clients in Sweden, Norway, Finland and Germany. We are a specialistbank who through responsible lending help people make informed decisions for a life they can afford. We are a flexible complement to the major banks. Instead of quantity we have specialised in a few selected products like private loans, mortgages, equity release products and savings accounts. Since 2019 Svensk Hypotekspension, which are specialists in equity release products, is a fully-owned susbsidiary to Nordax Bank. Nordax has about 200 employees where almost all employees works from one central office in Stockholm. The credit assessment process is one of Nordax core competencies. It is thorough, sound and datadriven. Nordax customers are financially stable individuals. As of 31 December 2018 the lending to the public amounted to 15.1 bn SEK and deposits from the public amounted to 11.3 bn SEK. Read more about Nordax on www.nordaxgroup.com.

Ortoma signs exclusivity agreement

At the beginning of the year, the companies evaluated the opportunities for collaboration to take the Ortoma Treatment Solution (OTS) to the market, not only in Asia but also in other parts of the world. The initial evaluation has been positive and the companies are now initiating in-depth evaluation of technology and commercial discussions. Linus Byström, CEO, comments: “The initial discussions not only gave the potential partner the opportunity to evaluate OTS, but also gave us an understanding of the their vision for the future. We are impressed by their insights in the orthopedic market and their vision for continued development. The company has a strong focus on innovation and a unique solution for customized implants. To accurately position these implants with OTS would further strengthen them and us in the market. Our visions for the future correspond very well. They are constantly looking for innovations that are at the forefront and see opportunities to take OTS to a unique position for hip joint surgery and then develop it further into other areas. " Under MoU, Ortoma is free to continue discussions with companies that have headquarters outside Asia. The Chinese market for orthopedic implants is young, and only about 20 hip implant surgeries per 100,000 inhabitants are carried out per year. The corresponding figure for Japan is about 60, and for Sweden about 350. In China, however, around 700 000 surgeries with hip and knee implants are already performed per year, and market growth is about 20%. Ortoma Treatment Solution™ - careful planning and precise surgery.

Invitation to presentation of Pandox AB’s interim report January-March 2019

Agenda (CEST) 07:00 – Interim report published via Cision and www.pandox.se  08:00 (approx.) – Presentation material published at www.pandox.se  09:00 – Telephone conference with CEO Anders Nissen and CFO Liia NõuTo follow the telephone conference on-line go to https://edge.media-server.com/m6/p/4j7ohbg2. To participate in the telephone conference and ask questions, please call in using any number indicated below approximately 10 minutes before the start of the conference. Standard International: +44 (0) 2071 928000SE LocalCall: +46 (0) 850 692 180SE Tollfree: 0200125581UK LocalCall: +44 (0) 8445 718892UK Tollfree: 08003767922US LocalCall: + 1 631-510-7495Conference ID: 1086516  A recorded version of the telephone conference will be available at www.pandox.se. FOR MORE INFORMATION, PLEASE CONTACT:Anders Berg, Head of Communications and IR, +46 (0) 760 95 19 40 The information was submitted for publication at 09:15 CEST on 12 April 2019. About PandoxPandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio currently comprises 144 hotels with approximately 32,300 hotel rooms in 15 countries. Pandox’s business is organised into Property Management, which comprises hotel properties leased on a long-term basis to market leading hotel operators, and Operator Activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are listed on Nasdaq Stockholm. www.pandox.se

Invitation – Presentation of Sobi’s Q1 2019 results

On 25 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ)  (Sobi™) will publish its report for the first quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 10:00 am CET. The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English. The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference. To participate in the telephone conference, please call: SE: +46 8 505 583 69 UK: +44 33 330 090 35 US: +1 646 722 49 57Click here to go to the live webcast.  After the live event the webcast will be available on-demand via the same URL. --- About Sobi™ At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com. For more information please contact Media relations/Investor Investor relationsrelationsLinda Holmström, Senior Jörgen Winroth, Senior IR AdvisorCommunications/IR Manager +46 708 734 095  +1 347 224 0819, +1 212 579 0506linda.holmstrom@sobi.com   jorgen.winroth@sobi.com Paula Treutiger, Head ofCommunications & InvestorRelations+46 733 666 599paula.treutiger@sobi.com

Invitation to Press and Analyst Meeting for Presentation of Saab’s Interim Report January-March 2019

Date:          Friday, 26 April at 10:00 (CET). Address:    Saab, Olof Palmes Gata 17, 5th floor, Stockholm, Sweden The report is published at 07.30 a.m. (CET) the same day.  You are welcome to participate on site at Saab, watch the live webcast or dial in to the conference call. It is possible to post questions also over the web and conference call.  Live webcast: http://saab-interimreport.creo.se/190426 Conference call: Please, dial in using one of the numbers below. Sweden:                  +46 8 566 427 07 United Kingdom:      +44 333 300 9031 United States:         +1 833 526 8382 The interim report, the presentation material and the webcast will be available on http://www.saabgroup.com/investor-relations. R.S.V.P.  E-mail: marie.bergstrom@saabgroup.com Tel: +46 8 463 02 45 For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com  Saab Investor Relations Ann-Sofi Jönsson, +46 (0) 734 187 214 www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab   Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Nel ASA: Receives purchase order from Shell for two additional heavy duty fueling stations

(Oslo, 12 April 2019) Nel Hydrogen Inc., a subsidiary of Nel ASA (Nel, OSE:NEL), has received a purchase order for the delivery of two additional H2Station® units for fueling of heavy duty fuel cell electric trucks in California from EQUILON Enterprises LLC (d/b/a/ Shell Oil Products US). The purchase order is issued under the previously announced framework agreement between Nel and Shell Global Solutions International B.V. “We are happy to support Shell with two additional H2Station® fueling stations for heavy-duty trucks in California. We look forward to assist with expansion of the hydrogen fueling coverage in the Greater Los Angeles area which can help a transition to renewable and zero emission trucking.” says Jon André Løkke. The purchase order has a total value exceeding $7 million. The stations will be located in the Greater Los Angeles area and expand the fueling coverage for hydrogen powered heavy duty fuel cell electric trucks. ENDS For additional information, please contact: Jon André Løkke, CEO, +47 907 44 949 Bjørn Simonsen, VP Market Development & Public Relations, +47 971 79 821 About Nel Hydrogen | www.nelhydrogen.com       Nel Hydrogen is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy.  We  serve  industries,  energy  and  gas  companies  with  leading  hydrogen  technology.  Since its origins in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today. 

ZF coPILOT Enables Enhanced Safety and Driving Comfort

Friedrichshafen/Shanghai. ZF today announced the debut of ZF coPILOT, an intelligent advanced driver assistance system (ADAS) leading to enhanced safety and driving comfort opportunities. Leveraging the power of AI and equipped with a comprehensive sensor set, vehicles can perform various automated driving functions, especially on freeways. In addition, ZF coPILOT can be operated with voice commands and is designed to recognize traffic conditions, sense vehicle handling and monitor the driver, helping to pre-empt hazardous situations through active control intervention. ZF coPILOT is powered by the ZF ProAI central computer and the NVIDIA DRIVE platform. It is designed for volume production and will be available from 2021. Just three months after ZF and NVIDIA announced that ZF ProAI is the first system to run NVIDIA’s DRIVE software, ZF coPILOT debuts at the Shanghai International Automobile Industry Exhibition. Together, the high-tech companies present an attractive "Level 2+" system leading to enhanced safety and driving comfort opportunities in passenger cars. “The ZF coPILOT is equipped with artificial intelligence, a 360° sensor set, the powerful ZF ProAI central computer and NVIDIAs DRIVE platform, thus offering driving and safety functions that surpass the performance of a regular Level 2 system for semi-automated driving. This enables us to achieve an improved quality in semi-automated driving,” said Torsten Gollewski, Head of Autonomous Mobility Solutions at ZF. The ZF coPILOT demonstration vehicle, which will be presented for the first time at Auto Shanghai, clearly demonstrates the functional scope and relative comfort and safety benefits for drivers: The vehicle can perform specific driving maneuvers autonomously, for example entering and leaving highways under the appropriate conditions. For more relaxed highway driving, the ZF coPILOT combines an advanced cruise control with active steering assistance and lane keeping assist. In addition, the ZF coPILOT can proactively change lanes, pass, and merge. Furthermore, the system can continuously analyze vehicle surroundings, recognizing pedestrians, oncoming traffic, and intersections. The ZF coPILOT is also equipped with sensors and functions that monitor the driver and can trigger warnings in the event of potentially dangerous situations. For example, were the driver to become distracted, their focus too far removed from traffic on the road or show signs of drowsiness. In addition to intelligent route guidance including "MyRoute" – a map function that recognizes repeat routes – the ZF coPILOT is also equipped with voice recognition so that the driver can conveniently enable, operate and disable driver assistance functions via voice commands, if they wish to drive manually. The ZF sensor set in the demonstration vehicle consists of a front radar, four corner radars, and a total of eight cameras. Two cameras are directed forwards and one backwards, two are integrated into each side mirror and one monitors the driver. In order to evaluate the massive amount of data collected in real-time by the comprehensive sensor set, high performance processing power is required. That is the job of the ZF ProAI Gen2 central computer that powers ZF coPILOT: With the high-performance, energy efficient computation of the NVIDIA DRIVE Xavier processor at its core, ZF ProAI can integrate and completely control the pre-trained algorithms for all driver assistance functions. The system is flexible, scalable, and seamlessly updateable. If desired, automotive manufacturers can add additional features and functions of their own or those developed by ZF. With a product family comprising four models from Level 0 to Level 5, ZF ProAI covers the entire automotive operating range. The top model, ZF ProAI RoboThink, features up to 600 trillion operations per second (600 teraOPS), making it the most powerful AI-enabled supercomputer currently available in the mobility industry. Advanced Driver Assistance – Whenever and However You Need ItSince highly automated driving at SAE Level 3 is not permitted in many countries, the ZF coPILOT is based on semi-automated driving at SAE Level 2, which requires the driver to continuously monitor traffic conditions. But the enhanced Level 2+ technologies from ZF and NVIDIA provide reliable and convenient assistance, performing like a “co-pilot” to support the driver. “We are convinced that an extended Level 2+ system like the ZF coPILOT is very attractive for manufacturers: Due to its wide range of functions, it offers consumers significant added value in terms of safety and driving comfort – and at a competitive price," said Torsten Gollewski. Captions - photos: Introducing ZF coPILOT, the integrated Level 2+ system for next-generation advanced driver assistance. Powered by ZF ProAI and NVIDIA DRIVE. Image: ZF Captions - sensor set: The sensor set of the ZF coPILOT consists of a front radar, four corner radars, and a total of eight cameras. The heart of the system is the ZF ProAI Gen2. Image: ZF Press Contact: Florian Stemmler, Technology and Product Communications,Phone: +49 7541 77-2367, e-mail: florian.stemmler@zf.com   Robert Buchmeier, Head of Technology andProduct Communications, Heritage Communications,Phone: +49 7541 77-2488, e-mail: robert.buchmeier@zf.com

Cxense ASA has divested L’Agora Premium Audience Network S.L., finalizing Cxense’s divestment of its non-core advertising business

Oslo, 12 April 2019. Reference is made to Cxense ASA’s (“Cxense” or the “Company”) strategic decision to divest its non-core business. Cxense has entered into and completed the sale of all shares in the majority owned subsidiary Premium Audience Network S.L. (“L’Agora”) to AdUX SA (“AdUX”), a French digital marketing services company listed on Euronext Paris. The transaction was for all practical purposes completed on 5 April 2019. The sale of L’Agora is the last divestment of non-core assets, marking the finalization of Cxense’s strategic divestment processes. The transaction is based on an initial purchase price of EUR 190 thousand and a contingent price (earn-out) potentially payable in May 2020 capped at EUR 400 thousand. Prior to the transaction, the shareholder loans previously given to L’Agora were converted into shares, bringing Cxense’s ownership of L’Agora from 53.8% to 81.9%. L’Agora is a digital advertising company based in Spain. The company operates within the native advertising field, delivering contextually targeted ads through a network of premium sites, primarily editorial groups. L’Agora financials are fully consolidated into Cxense financials, but booked separately under discontinued operations in the P&L and under assets and liabilities held for sale in the balance sheet. For accounting purposes, the estimated effect is a P&L gain of USD 0.7 million from the sale of the shares due to the consolidated negative equity in L’Agora. Aabø-Evensen & Co Advokatfirma AS has acted as legal advisor to Cxense ASA in connection with the transaction. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Investor Relations Contact:Jørgen Evjen, Chief Financial OfficerEmail: ir@cxense.comMobile: +47 928 04 014

Cimco Marine AB (publ) publishes convening notice for annual general meeting and proposes issue authorisation for the board

The shareholders in the Company are hereby convened to the annual general meeting on Tuesday 14 May 2019, at 2 pm, at Best Western Plus Hus 57, Östergatan 57 in Ängelholm. Notice etc. Shareholders who wish to participate at the annual general meeting must: -                   on Wednesday 8 May 2019, be registered in the share register kept by Euroclear                    Sweden AB ("Euroclear"); and -                   at the latest on Wednesday 8 May 2019 notify the intention to attend the general                    meeting by e-mail to alexandra.niemela.ingvarsson@lindahl.se or by post to                    Advokatfirman Lindahl KB, att. Alexandra Niemelä Ingvarsson, Box 11911, 404                    39 Göteborg. Such notification shall include the shareholder’s name and should include personal identification number or corporate registration number (or similar), address and daytime telephone number, number of shares, details on advisors (no more than two), if any, and where applicable, details of representatives or proxies. Nominee-registered shares To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share register maintained by Euroclear. Such registration must be duly effected (registered with Euroclear) in the share register on Wednesday 8 May 2019, and the shareholders must therefore advise their nominees well in advance of such date. Proxy Shareholders represented by proxy must submit a dated proxy. If the proxy is executed by a legal person, a copy of the registration certificate or equivalent must be attached. The proxy may not be valid for a period longer than five years from its issuance. The original proxy and certificate of registration should be submitted to Advokatfirman Lindahl KB by mail at the address mentioned above in due time prior to the general meeting. The Company provides a form of proxy at request and it is also available at the Company’s website, www.oxe-diesel.com. Proposed agenda 1. Opening of the general meeting and election of chairman of the general meeting 2. Preparation and approval of the voting list 3. Election of one or several persons to verify the minutes of the meeting 4. Determination of whether the meeting has been duly convened 5. Approval of the agenda 6. Submission of the annual report and the auditor’s report 7. Resolutions on            a) the adoption of the income statement and the balance sheet;            b) allocation of the Company’s result according to the adopted balance sheet; and            c) discharge from liability for each of the members of the board of directors and the managing director 1. Determination of remuneration to the board of directors and the auditor 2. Election of board of directors 3. Election of auditor 4. Resolution on principles for appointment of nomination committee 5. Resolution to amend the articles of association 6. Resolution on authorisation for the board of directors to issue new shares, warrants and/or convertibles 7. Resolution on introduction of incentive plan for employees 8. Close of the general meeting Proposals to resolutions Item 1 – Election of chairman of the general meeting The nomination committee, consisting of Anders Berg in his capacity as chairman of the board and shareholders Per Lindberg, Tedde Jeansson and Jonas Wikström, proposes that Mikael Mellberg, Advokatfirman Lindahl KB, is elected as chairman of the general meeting. Item 7b) – Allocation of the Company’s result according to the adopted balance sheet The board does not propose any dividends for the financial year 2018. Item 8–11 – Determination of remuneration to the board of directors and the auditor, election of board of directors and auditor and resolution on principles for appointment of nomination committee The nomination committee will well in advance of the general meeting present its proposals for remuneration to the board of directors and the auditor, election of members of the board of directors and auditor, and principles for appointment of nomination committee for the annual general meeting 2020. The proposals will be held available at the Company’s office with address Metallgatan 17 B in Ängelholm and on the Company’s website. Item 12 – Resolution to amend the articles of association In order to enable new issues of shares in accordance with the authorisations proposed under items 13 and 14, the board of directors proposes that the articles of association are amended as follows. Adjustment of limits for share capital The limits for the Company’s share capital in Section 4 of the articles of association are proposed to be amended as follows. The share capital shall not be less than SEK 2,000,000 and not exceed SEK 8,000,000. Adjustment of limits for number of shares The limits for the Company’s number of shares in Section 5 of the articles of association are proposed to be amended as follows. The number of shares shall not be less than 75,000,000 and not more than 300,000,000. Item 13 – Resolution on authorisation for the board of directors to issue new shares, warrants and/or convertibles The board of directors proposes that the general meeting resolves to authorise the board to, at one or several occasions during the time up until the next annual general meeting, resolve on new issues of shares, warrants and/or convertibles. The board shall have the right to resolve on new issues of shares, warrants and/or convertibles with deviation from the shareholders’ pre-emption rights and/or with provisions on payment in kind, by set-off of claims or otherwise on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1–3 and 5, of the Swedish Companies Act. The total increase of shares that may be issued based on or as a result of this authorisation cannot in aggregate exceed 20 per cent of the number of outstanding shares in the Company at the time of the resolution on the issue. Issues based on the authorisation shall be made at market price, including market rate discount, if applicable. The board shall have the right to set the terms and conditions for issues under this authorisation as well as to decide who shall have the right to subscribe for the new shares, warrants or convertibles. The reasons for the board to resolve on issues with deviation from the shareholders’ pre-emption rights and/or with provisions on payment in kind, by set-off of claims or otherwise on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1–3 and 5, of the Swedish Companies Act are to be able to carry out directed share issues to raise capital to the Company and/or to strengthen the Company's financial position. Item 14 – Resolution on introduction of incentive plan for employees Some of the Company’s largest shareholders propose that the general meeting resolves to introduce a share-related incentive plan for the Company’s employees. The terms and conditions for the incentive plan is currently under preparation. The complete proposal will be held available at Company’s office with address Metallgatan 17 B in Ängelholm and on the Company’s website not later than three weeks before the general meeting, i.e. not later than 23 April 2019. Majority requirements Resolution under items 12 and 13 above requires, for its validity, that a minimum of two thirds of the votes cast and the shares represented support the resolution. Documentation The annual report, the auditor’s report, the board of directors’ and some of the largest shareholders of the Company’s complete proposals, as well as other documents according to the Swedish Companies Act will be held available at the Company’s office with address Metallgatan 17 B in Ängelholm and on the Company’s website not later than three weeks before the general meeting, i.e. not later than 23 April 2019. The nomination committee’s complete proposals under items 8–11 will be held available at the Company’s office and the Company’s website well in advance of the general meeting. The documents will also be sent, without charge, to shareholders who so request and inform the Company of their postal address. The documents will also be available and presented at the general meeting. Processing of personal data For information on the Company’s processing of personal data in connection with the annual general meeting, please refer to https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Ängelholm in April 2019 Cimco Marine AB (publ) The board of directors Certified Adviser Västra Hamnen Corporate Finance AB is Certified Adviser for Cimco. Contact details to Västra Hamnen Corporate Finance AB: tel. +46 40 20 02 50, e-mail ca@vhcorp.se. For further information, please contact:   Anders Berg, Chairman, anders.berg@oxe-diesel.com, +46 70 358 91 55 Andreas Blomdahl, CEO, andreas.blomdahl@oxe-diesel.com, +46 431 44 98 99 Myron Mahendra, CFO and EvP in charge of Administration and HR, myron.mahendra@oxe-diesel.com, +46 76 347 59 82 Cimco Marine AB (publ) is obligated to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 12 April 2019 at 10:35 am. Cimco Marine AB (publ) has, after several years of development, constructed the OXE Diesel, the world's first diesel outboard engine in the high-power segment. Cimco's unique patented engine-to-propulsion power transmission solutions have led to high demand for the Company's engines worldwide. 

Bonava named most active housing developer in Germany

- We are very proud to, for the seventh consecutive year, be named the most active project developer for residential real estate and thus creates the most living space in the German metropolises. This is now Bonava’s largest market – in 2018 net sales in Germany increased by 14 per cent compared to 2017 – and the bulwiengesa result is evidence that our strategy to offer affordable housing is working very well, says Joachim Hallengren, President and CEO of Bonava. Every year, the independent consulting company bulwiengesa identifies Germany’s most active property developer. The analysis includes the number of square metres developed in Germany’s largest property markets (Berlin, Cologne, Dusseldorf, Frankfurt am Main, Hamburg, Munich and Stuttgart) in the housing, office, retail and hotel sectors. For more information, please contact: Ann-Sofi Danielsson, CFO and Head of Investor Relationsann-sofi.danielsson@bonava.comTel: +46 706 740 720 Bonava’s media lineir@bonava.comTel: +46 704 30 10 05 Bonava is a leading residential development company in Northern Europe. Bonava has been creating homes and neighbourhoods since the 1930s. Bonava has 2,100 employees and operates in Germany, Sweden, Finland, Denmark, Norway, St. Petersburg, Estonia and Latvia, with sales of SEK 14.0 billion in 2018. Bonava’s shares are listed on Nasdaq Stockholm. For more information about us, visit: www.bonava.com

Mr Green launches personalized Jackpots

Mr Green has taken another step towards offering a fully personalized user experience by introducing individual jackpots to their players. Jackpots are a classic casino feature that up until now have only been offered as a pooled prize with a low probability of winning. With ‘Personal Jackpot’, each player is a guaranteed winner and the jackpot widget allows players to follow their very own pot building up. “Our new product ‘Personal Jackpot’ is a fully bespoke jackpot which adds an additional layer of excitement and anticipation during gameplay,”said Jacqui Gatt, Head of Gaming, Mr Green Ltd, and continues; “In this first version, each player can see their current pot amount in the ‘My Account’ section as well as in-game. We look forward to continue development of this exciting new product together with the team at BlueRibbon by expanding our offering across all player segments and introducing more innovative functionalities over the coming months.”  ‘Personal Jackpot’ has been developed with jackpot marketing platform provider BlueRibbon. Amir Askarov, co-founder and CEO of BlueRibbon, said: “We are excited to have partnered with Mr Green, an innovative and market-leading online casino brand.  “They, like us, believe that bespoke segmented and achievable jackpots can deliver tremendous added value to players and Personal Jackpot certainly delivers in this regard. In a sector where competition is so fierce, and player demand so high, jackpots can ensure Mr Green will stand out.”

Adelis Equity Partners has acquired majority in RopoHold Oyj and RopoHold has redeemed its up to EUR 75,000,000 senior secured floating rate bonds

As announced on 19 March 2019, the Company redeems early its up to EUR 75,000,000 senior secured floating rate bonds with ISIN FI4000292461 (the “Bonds”) as a result of the transaction becoming effective. The Company has today redeemed all the outstanding Bonds in full. The notice of the voluntary redemption of the Bonds given to bondholders was subject to and conditioned upon the completion of the acquisition.The Company will apply for delisting of the Bonds from the official list of Nasdaq Helsinki Ltd.For more information, please contactROPOHOLD OYJToni Rönkkö, CFOphone: +358 44 5698 168email: toni.ronkko@ropocapital.fiDISTRIBUTION:Nasdaq Helsinki LtdMain mediawww.ropocapital.fi/enAbout Ropo CapitalRopo Capital is an invoice lifecycle services provider driven by strong technological platform. Currently it is the only company in the Nordics with the ability to cover the full value chain of invoicing lifecycle management services, from invoicing and sales ledger management to receivables financing and debt collection, by leveraging completely in-house developed technology. The Company’s ability to automate the invoicing lifecycle process enables a superior customer value proposition through more efficient receivables management and reduced process complexity. Ropo Capital was established in 2008 and today approximately 8,000 companies in Finland use its services. The Company employs approximately 180 professionals in Kuopio, Porvoo and the capital region.

Wihlborgs completes new billion-krona acquisition – purchases 51,000 square metres in Helsingborg

The acquisition comprises the Hermes 10 and Hermes 16 properties immediately south of Helsingborg C. The main building was designed by the architect Mogens Mogensen for Helsingborgs Gummifabrik AB, which later became Tretorn. The property has a lettable area of 51,000 m², mainly comprising office and educational premises, a popular restaurant and around 1,000 parking spaces. The seller is Alecta Pensionsförsäkring, Ömsesidigt, and the transaction was completed today, 12 April 2019. The properties were acquired through a property transaction for a consideration of SEK 1,255 million. The rental value is around SEK 95 million and the properties are currently just over 97 percent let. When fully let, the yield is estimated at around 5.5 percent. The main financing for the investment is through existing credit facilities. Major tenants include Lund University, the City of Helsingborg, IKEA IT and CapGemini. Another tenant is Mindpark, a coworking operation with around 75 companies and entrepreneurs, conference and meeting rooms of different sizes, event spaces, a café, and business incubators and accelerators. “The acquisition is an important part of our continued growth in Helsingborg. We see a healthy demand and our existing office properties in Helsingborg are essentially fully let. With this addition, we can help both current and new customers develop their operations,” says Ulrika Hallengren, CEO of Wihlborgs Fastigheter. “Helsingborg is an active and attractive city that’s at the forefront of areas including business climate, digitisation and the environment. The city is heading toward an exciting future and we’re pleased to be able to contribute to development both through expanding the properties we’ve now acquired and through creating new, attractive office space in Prisma in Oceanhamnen. We’re also confident that the renovations at Helsingborg C will contribute to positive development in the city.” Wihlborgs Fastigheter AB (publ) This information is of such a kind that Wihlborgs Fastigheter AB (publ) is legally required to disclose pursuant to the EU’s Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the agency of the above contact people on 12 April 2019, at 11:15 a.m. CEST.

Resolutions of the Annual General Meeting of Kamux Corporation and the Decisions of the Constitutive Meeting of the Board of Directors

Kamux Corporation   Stock Exchange Release   April 12, 2019 at 12:15 Resolutions of the Annual General Meeting of Kamux Corporation and the Decisions of the Constitutive Meeting of the Board of Directors RESOLUTIONS OF THE ANNUAL GENERAL MEETING Kamux Corporation's Annual General Meeting was held on Friday 12 April 2019. The Meeting approved the Financial Statements and discharged the members of the Board of Directors and CEO from liability for the year of 2018. The Board of Directors proposal for a dividend of EUR 0.16 per share was approved. The record date for dividend payments is April 16, 2019 and the dividend will be paid on April 25, 2019. The Annual General Meeting confirmed that the Board of Directors will consist of six members and Mr. Matti Virtanen, Ms. Reija Laaksonen, Mr. David Nuutinen, Mr. Jokke Paananen, Mr. Vesa Uotila and Mr. Harri Sivula were re-elected as members of the Board of Directors. The Annual General Meeting elected Mr. Matti Virtanen as the Chairman of the Board and Mr. Harri Sivula as the Vice Chairman of the Board. The Annual General Meeting resolved a monthly compensation of EUR 3,000 be paid for the Chairman of the Board and EUR 1,700 for the Board Members, and an additional compensation of EUR 1,500 per year to the Board members belonging to a committee. Travel expenses will be reimbursed in accordance with the Company’s travel policy. Authorized Public Accountant PricewaterhouseCoopers Oy was re-elected as the company's auditor. The remuneration of the auditor will be paid according to the invoice as accepted by Company. PricewaterhouseCoopers Oy has informed that Authorized Public Accountant Mr. Janne Rajalahti will act as the principal auditor. The Annual General Meeting resolved to authorize the Board of Directors in accordance with the proposal of the Board to resolve on the issuance of a maximum of 4,000,000 shares in one or more tranches corresponding to approximately 10 % of all the shares in the company. The Board of Directors decides on the terms and conditions of the issuance of shares. The authorization concerns both the issuance of new shares as well as the transfer of treasury shares. The issuance of shares may be carried out in deviation from the shareholders’ pre-emptive right (directed issue). The authorization cancels previous unused authorizations regarding share issues despite the part of the previously given authorization that has been given for the Company’s share-based incentive schemes. The authorization is valid until the closing of the next Annual General Meeting, however, no longer than until 30 June 2020.  The Annual General Meeting resolved to authorize the Board of Directors in accordance with the proposal of the Board to resolve on the repurchase of a maximum of 2,000,000 company’s own shares using the unrestricted equity of the company representing about 5 % of all the shares in the company. The authorization includes the right to accept company’s own shares as a pledge. The shares shall be acquired through public trading, for which reason the shares are acquired otherwise than in proportion to the share ownership of the shareholders and the consideration paid for the shares shall be the market price of the Company’s share in public trading at Nasdaq Helsinki Ltd at the time of the acquisition. Shares may also be acquired outside public trading for a price which at most corresponds to the market price in public trading at the time of the acquisition. The authorization includes the Board’s right to resolve on a directed repurchase or the acceptance of shares as a pledge, if there is a compelling financial reason for the company to do so as provided for in Chapter 15, section 6 of the Finnish Limited Liability Companies Act. The shares shall be acquired to be used for execution of the Company’s share-based incentive schemes or for other purposes determined by the Board of Directors. The decision to repurchase or redeem company’s own shares or to accept them as pledge shall not be made so that the shares of the company in the possession of or held as pledges by the company and its subsidiaries would exceed 10% of all shares. The authorization is valid until the closing of the next Annual General Meeting, however, no longer than until 30 June 2020. The Board of Directors shall decide on any other matters related to the repurchase of the company’s own shares and/or accepting them as a pledge. DECISIONS OF THE CONSTITUTIVE MEETING OF THE BOARD OF DIRECTORS In its constitutive meeting convening after the Annual General Meeting, the Board of Directors decided to establish an Audit Committee. The Board reappointed Mr. Harri Sivula (Chairman), Ms. Reija Laaksonen and Mr. Vesa Uotila as the members of the Audit Committee. The Board assessed the independence of the directors in accordance with the Finnish Corporate Governance Code. It was concluded that Ms. Reija Laaksonen, Mr. David Nuutinen and Mr. Harri Sivula are independent of the company and its significant shareholders, Mr. Jokke Paananen and Mr. Vesa Uotila are independent of the company, and Mr. Matti Virtanen is independent of the significant shareholders of the company. In Helsinki, April 12, 2019 Kamux Corporation For more information, please contact: Juha Kalliokoski, CEO Tel. +358 50 544 5538 Kamux Corporation is a retail chain specializing in the sale of used cars and related integrated services that has grown rapidly. The first Kamux car showroom started its operations in 2003 in Hämeenlinna, Finland and the company currently has 47 car showrooms in Finland, fifteen in Sweden and four in Germany. Since its founding, the company has sold more than 200,000 used cars, of which 46,596 were sold in 2018. Kamux’s revenue reached EUR 527.8 million in 2018. In 2018, Kamux’s average number of employees was 472 in terms of full-time equivalent employees. The shares of Kamux are listed on Nasdaq Helsinki. www.kamux.com

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today the proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors. The nomination committee of Q-linea AB submits the following proposals to be presented at the annual general meeting of shareholders to be held on 22 May 2019, with regard to the number and election of members of the board of directors. The nomination committee proposes seven members of the board of directors and no deputy members of the board of directors. The nomination committee proposes the following persons for re-election as members of the board of directors: Erika Kjellberg Eriksson, Marianne Hansson, Hans Johansson, Ulf Landegren, Mats Nilsson, Marcus Storch and Per-Olof Wallström. Jon Heimer has informed the nomination committee that he declines re-election due to personal reasons. The nomination committee proposes Erika Kjellberg Eriksson to be re-elected as chairperson of the board of directors. The members of the nomination committee are Öystein Engebretsen (Investment AB Öresund, chairperson of the nomination committee), Erika Kjellberg Eriksson (Nexttobe AB, chairperson of the board) and Jannis Kitsakis (Fjärde AP-fonden). Information about all persons proposed as members of the board of directors of Q-linea AB, the nomination committee’s statement regarding the proposal for the board of directors and the nomination committee’s complete proposal can be found on Q-linea AB’s website, www.q-linea.com, and will, free of charge, be sent to the shareholders who request the company to do so. April 2019The nomination committee of Q-linea AB (publ) For more information, please contact: Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com+46 (0)70-323 77 60 Anders Lundin, CFO, Q-linea ABanders.lundin@qlinea.com+46 (0)70-600 15 20 About Q-linea Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Green Landscaping approved for listing on Nasdaq Stockholm

The first day of trading on Nasdaq Stockholm is projected for Tuesday, 16 April 2019, with the last day of trading on Nasdaq First North on Monday, 15 April 2019. The shares will be traded under the same ticker (GREEN) and ISIN code (SE0010985028) as before. No new shares will be issued in connection to the change in listing, and shareholders in Green Landscaping do not have to take any action in connection to the change. “The listing on First North in March 2018 was part of Green Landscaping’s long-term growth strategy, and the change in listing to Nasdaq Stockholm signifies an even stronger seal of quality that provides comfort to our customers and supports our continued growth. It is fully in line with our focus on customer value, quality and sustainability”, says Johan Nordström, CEO of Green Landscaping. “During its first year as a listed company, Green Landscaping has doubled in size and strengthened the position as Sweden’s leading company in outdoor maintenance and landscaping services. It is the ambition of the management and board that the company will continue to play a central part in the consolidation of the outdoor environment industry. Our assessment is that Green Landscaping’s position as an attractive buyer will be further reinforced with the change in listing to Nasdaq Stockholm”, says Per Sjöstrand, Chairman of Green Landscaping. ProspectusThe prospectus that has been prepared in connection to the change in listing will be published on Green Landscaping’s website, www.greenlandscapinggroup.se, no later than on the day before the first day of trading on Nasdaq Stockholm. AdvisorsPareto Securities AB has acted as financial advisor and Cirio Advokatbyrå AB has acted as legal advisor in relation to the listing process. For further information:Johan Nordström, VD, 070-838 58 12, johan.nordstrom@greenlandscaping.seCarl-Fredrik Meijer, CFO, 070-108 70 19, carl-fredrik.meijer@greenlandscaping.se This is information that Green Landscaping Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:40 CET on 12 April 2019. Green Landscaping Group is the #1 landscaping service provider in Sweden. Our business idea is to refine our customers’ outdoor environments by offering services focused on high customer value, long-term sustainability and quality. The group has approximately 1,230 employees and sales amount to approx. SEK 2 billion. The company’s shares are listed on Nasdaq First North with ticker GREEN. The company’s certified adviser is Pareto Securities AB (+46 8 402 50 00, certifiedadviser.se@paretosec.com). For more information, please visit www.greenlandscapinggroup.se.

Enersize Oyj extends its cooperation with JoinTeam in China with license sales

JoinTeam has been a Chinese partner of Enersize for several years and the company works mainly in the Beijing region of China. JoinTeam has been a business partner of Enersize in the profit sharing projects that have been successful, such as Enersize's first profit sharing agreement in China with Beijing Optoelectronics, which generated nearly 9 MSEK in profit sharing during the agreement's three-year period. BOE3 and Foton Cummins, which are both in the profit-sharing phase and generate revenue, have also been signed and implemented in collaboration with JoinTeam. JoinTeam and Enersize have continuously discussed how the business model in China can be improved and streamlined to provide better scalability and shorter sales cycles. JoinTeam's insights and knowledge of the Chinese market have been important factors in the development of Enersize's updated business model. Through the acquisition of LEAQS and the further development of Enersize Q+ smart monitoring and optimization systems, Enersize today has the opportunity to offer partners cooperation through distribution and resale of licenses to Enersize's products and cloud services, which facilitates sales to local customers where these partners already have an established customer relationship. Enersize's offering also gives local players the opportunity to offer advanced projects and services themselves based on Enersize's software, such as leak detection and repair projects or advanced monitoring and optimization. In essence, the letter of intent between Enersize and JoinTeam includes the following: ·  That JoinTeam will become a full-scale partner to Enersize within the framework of Enersize's developed business model and that JoinTeam thereby will be able to offer services based on Enersize products directly to factories in China; ·  That JoinTeam will establish resale in China to their existing and future customers of Enersize's products; ·  Enersize must provide JoinTeam with training so that JoinTeam can sell, install, use and train on its own regarding Enersize's products without assistance from Enersize; ·  That JoinTeam will pay Enersize license fees for the use of the company's products. ·  That JoinTeam, together with Enersize, can still offer profit-sharing projects in cases where it is considered appropriate. For more information about JoinTeam, please see http://www.jointeam6.com/ “Enersize's new business model and product portfolio is exactly what JoinTeam has requested and JoinTeam has expressed great interest in independently processing the Chinese market with Enersize's new products in order to be able to expand faster. With JoinTeam as a full-scale partner to Enersize in China, there is a good opportunity to generate good revenue from both projects and license sales. JoinTeam has already proven itself by being one of the few partners who have succeeded in delivering functioning profit sharing projects. Both JoinTeam and Enersize have learned a lot on the way through the joint profit sharing projects, and we are both convinced that this new approach will yield significantly better outcomes with lower risk and capital requirements”, comments Anders Sjögren, CEO of Enersize. “In our cooperation with Enersize, we have previously focused solely on large profit-sharing projects. We have succeeded well with some while others have been delayed due to various factors. With the new set-up that is more product-based and gives a lower entry threshold, we can process the customers step by step and expand the business as customers see the benefit of what we can offer. This is both applicable to the major industries we previously prospected but also opens up for large-scale sales even to the countless small and medium-sized factories that we have access to here in China. What we know from before is that the demand for this type of product is great and that the market has great potential,” comments Ivy Yuan, Chairman of the Board of JoinTeam.

Notice to Annual General Meeting in SSM Holding AB (publ)

NOTICE OF ATTENDANCE, ETC.Shareholders who wish to attend at the Meeting must be registered in the share register maintained by Euroclear Sweden AB on Thursday May 9, 2019, and give notice of attendance to the Company by telephone to +46 (0)771-24 64 00 or by mail to Computershare AB, Attn: SSM Holding ABs årsstämma (AGM), Box 610, SE-182 16 Danderyd, Sweden.Notice of attendance must be received by the Company no later than on Thursday May 9, 2019. Notification shall include the shareholder’s name, personal identification number/corporate registration number, address, daytime telephone number, and, if applicable, the number of accompanying advisors (no more than two) who are attending the Meeting.Shareholders who are represented by a proxy must submit a dated and signed power of attorney. The original version of the power of attorney and, for legal entities, a certified copy of a certificate of registration, should be sent to the Company at the postal address above in due time prior to the Meeting. The power of attorney may not be valid for a longer period than one year from its issuance. However, the power of attorney may be valid for up to five years from its issuance if so explicitly stated. A form of power of attorney is available on the Company’s website, www.ssmlivinggroup.com .Shareholders whose shares are registered in the name of a nominee (e.g. shares held at a custody account with a bank) must temporarily re-register their shares in their own name to be entitled to participate at the Meeting. Such registration must be completed at Euroclear Sweden AB before Thursday May 9, 2019. The nominee should therefore be contacted well in advance of this date.PROPOSED AGENDA 1. Opening of the Meeting 2. Appointment of a chairman of the Meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of one or two persons to approve the minutes 6. Determination of whether the Meeting has been duly convened 7. Presentation of the annual accounts and the auditors’ report and the consolidated accounts and the auditors’ report on the consolidated accounts 8. Presentation by the CEO, and shareholders’ questions to the board of directors and the senior management of the Company 9. Resolution on(a) adoption of the income statement and the balance sheet and the consolidated income statement and balance sheet,(b) allocation of the result of the Company in accordance with the adopted balance sheet and the consolidated balance sheet, and(c) discharge of liability for the members of the board of directors and the CEO10. Determination of the number of members of the board of directors and auditor11. Determination of remuneration for the members of the board of directors and auditor12. Election of members of the board of directors and audit company13. The nomination committee’s proposal on principles for appointment of the nomination committee and instruction for the nomination committee14. The board of directors’ proposal on guidelines for remuneration to the senior management15. Closing of the Meeting PROPOSALS FOR RESOLUTIONSProposal on appointment of chairman of the Meeting (item 2)The nomination committee proposes that SSM’s chairman of the board Anders Janson is appointed as the chairman of the Meeting.Proposal on allocation of the Company’s results (item 9 (b)) The board of directors proposes that no dividend shall be paid for the financial year 2018 and that the disposable funds of SEK 603 877 865 available to the Meeting shall be carried forward on new account.Proposal on the number of members of the board of directors and auditors, remuneration for the members of the board of directors and the auditor as well as election of members of the board of directors and the audit company (items 10–12)The nomination committee proposes the following: ·  The board of directors shall be comprised by seven (7) members, with no deputy members. The Company shall have one auditor, with no deputy auditor. ·  For the period until the end of the next annual general meeting, the remuneration for the board of directors shall amount to SEK 350,000 for the chairman and SEK 175,000 for each of the other board members elected by the Meeting. ·  For the period until the end of the next annual general meeting, the remuneration for members of the audit committee shall amount to SEK 75,000 for the chairman of the committee and SEK 50,000 for each of the other members. ·  For the period until the end of the next annual general meeting, the remuneration for members of the remuneration committee shall amount to SEK 30,000 for the chairmanof the committee and SEK 10,000 for each of the other members. ·  No remuneration shall be paid for work in the investment committee. ·  The auditor’s fee shall be paid in accordance with invoice approved bythe board of directors. ·  Anders Janson, Bo Andersson, Per Berggren, Sheila Florell, Ulf Morelius, Ulf Sjöstrand and Jonas Wikström shall be re-elected as members of the board of directors for the period until the end of the next annual general meeting. Anders Janson shall be re-electedas the chairman of the board of directors. ·  Öhrlings PricewaterhouseCoopers AB shall be re-elected as the Company’s auditorfor the period until the end of the next annual general meeting. Proposal on principles for appointment of the nomination committee and instructionfor the nomination committee (item 13)Appointment of the nomination committee etc.The nomination committee proposes that the Meeting resolves on the following principles for appointment of the nomination committee and instruction for the nomination committee for the next annual general meeting.The nomination committee shall consist of four members – one representative for each of the three largest shareholders with respect to votes at the last day of trading of shares in September, who wish to appoint a member of the nomination committee, as well as the chairman of the board of directors.The chairman of the board of directors shall, as soon as possible after the information on the largest shareholders with respect to votes at the last day of trading of shares in September has become known, contact the three largest shareholders with respect to votes to inquire whether they wish to appoint members of the nomination committee. Should any of the three largest shareholders with respect to votes abstain from their right to appoint a member of the nomination committee, the chairman of the board of directors shall offer other large shareholders to appoint members of the nomination committee. In this event, the offer shall be made in the order to the largest shareholders with respect to votes (that is, first to the fourth largest shareholder with respect to votes, thereafter to the fifth largest shareholder with respect to votes etc.). The procedure shall continue until the nomination committee has four members.The determination of which shareholders are entitled to appoint members of the nomination committee shall be based on the information about shareholding and groups of shareholders in the register of Euroclear at the last day of trading of shares in September. The name of the members and the shareholders they represent shall be made public on the Company’s website at the latest six months prior to the annual general meeting. The chairman of the board of directors shall be convenor of the nomination committee’s first convening. At this convening, the nomination committee shall appoint a chairman amongst its members. The chairman of the board of directors shall not be chairman of the nomination committee. The mandate period of the nomination committee shall extend until the next nomination committee is appointed.In the event that a change of ownership occurs amongst the three largest shareholders with respect to votes, and a shareholder who has not previously had the right to appoint a member of the nomination committee thereby becomes a larger shareholder then one or several of the other shareholders who have appointed a member of the nomination committee (“new major shareholder”), the nomination committee shall, if the new major shareholder requests to appoint a member of the nomination committee, decide that the member of the nomination committee who represents the smallest shareholder with respect to votes shall be dismissed and replaced by a member appointed by the new major shareholder. In the event that a new major shareholder wishes to appoint a member of the nomination committee, the new major shareholder shall give notice of this to the chairman of the nomination committee. The notification shall contain the name of the person that the new major shareholder wishes to appoint as member of the nomination committee.A shareholder who has appointed a member of the nomination committee has the right to dismiss the member and appoint a new member. If such an exchange takes place, the shareholder shall without delay give notice of this to the chairman of the nomination committee (or, if it is the chairman of the nomination committee who shall be exchanged, to the chairman of the board of directors). The notification shall contain the name of the dismissed member and the person who shall replace him as member of the nomination committee.In the event that a member of the nomination committee who represents a shareholder resigns prematurely, the nomination committee shall without delay call upon the shareholder who has appointed the member to appoint a new member. If a new member is not appointed by the shareholder, the nomination committee shall offer other larger shareholders with respect to shares, to appoint members of the nomination committee. Such offer shall be made in the order to the largest shareholders with respect to shares (that is, first to the largest shareholder with respect to shares who has not already appointed a member of the nomination committee or previously abstained from the right to do so, thereafter to the second largest shareholder with respect to shares who has not already appointed a member of the nomination committee or previously abstained from the right to do so etc.). The procedure shall continue until the nomination committee is complete. A member who prematurely resigns from his task shall give notice of this to the chairman of the nomination committee (or, if it is the chairman of the nomination committee who shall resign, to the chairman of the board of directors). The nomination committee shall meet the requirements of composition set out in the Swedish Corporate Governance Code (“the Code”).If the larger shareholders who have the right to appoint members of the nomination committee wish to appoint persons with the consequence that the requirements of composition provided in the Code are not fulfilled, the first choice of the larger shareholder shall have precedence over a smaller shareholder. At the appointment of a new member, the shareholder who shall appoint the new member shall consider the composition of the current nomination committee. Changes in the composition of the nomination committee shall made public on the website of the board of directors as soon as they have occurred.Assignments etc.The nomination committee shall propose:(a) chairman of the annual general meeting;(b) number of elected board members;(c) election of the chairman and other elected board members;(d) remuneration and other payment to each of the elected board members and to the members of the board’s committees;(e) election of audit company;(f) remuneration to auditors; and(g) election of the nomination committee, or resolution on principles for appointment of the nomination committee, and resolution on instruction for the nomination committee.When preparing its proposal on board of directors, the nomination committee shall consider those requirements on the number of board members and its composition that follows from the Swedish Companies Act, the Code and Nasdaq Stockholm’s rule book for issuers.When preparing its proposal on audit company, the nomination committee shall consider those requirements on auditors that follows from the Swedish Companies Act and Regulation (EU) No 537/2014 of the European Parliament and of the Council on specific requirements regarding statutory audit of public-interest entities. The nomination committee’s proposal to the general meeting on election of audit company shall contain the auditor committee’s recommendation.If the proposal deviates from the alternative that the auditor committee recommend, the reasons not to follow the committee’s recommendation shall be specified in the proposal. The auditor(s) that the nomination committee proposes must have been included in the auditor committee’s selection procedure (if the company was obliged to arrange such selection procedure).The nomination committee shall consider those requirements that follows from the Code when preparing its proposal on resolution on election of the nomination committee, or proposal on resolution on principles for appointment of the nomination committee, and resolution on instruction for the nomination committee. Furthermore, the requirements on the composition of the nomination committee shall be considered.If the nomination committee’s proposal results in a deviation from the Code, the nomination committee shall provide the company with an explanation to the deviation in connection with its proposal.In connection with the nomination committee’s notification to the company of its proposals, it shall provide the company with a motivated statement in relation to its proposal on board of directors in which it shall take into account what is stated in the Code regarding the board’s composition.The nomination committee shall provide the company with information of its assignments in order for the company to fulfil its information obligation pursuant to the Code.At least one member of the nomination committee shall attend the annual general meeting. At board meeting where election of board members or auditor shall occur, the nomination committee shall provide a statement in relation to how its work has been carried out as well as present and motivate its proposals.MeetingsThe nomination committee shall meet as often as required for the nomination committee to fulfil its assignments. The chairman of the board shall convene the nomination committee to its first meeting. Notice to the other meetings are issued by the chairman of the nomination committee. If a member requests that the nomination committee shall convene, such request shall be obeyed.The nomination committee forms a quorum when more than half of the members are present. However, resolution in matter may not be made unless all members have been offered to participate in the matter.At election of chairman of the nomination committee, the person who obtains most votes shall considered to be elected. If the number of votes is equal, the election is decided by lot.The opinion that more than half of the present members vote for or, if the number of votes is equal, the opinion of the chairman of the nomination committee shall apply as the nomination committee’s resolution.At the nomination committee’s meetings, minutes shall be kept that are signed and verified by the chairman of the nomination committee and the member which the nomination committee appoints. The minutes shall be kept in numerical order and in a safe manner.ConfidentialityMember of the nomination committee shall be subject to confidentiality in relation to the company’s matters and at the company’s request, each member shall confirm this obligation by signing certain confidentiality agreements between the member and the company.MiscellaneousThe members of the nomination committee shall be entitled to compensation from the company for verified reasonable expenses in order to perform the assignment, for example expenses for recruiting services.The nomination committee shall in connection with the presentation of its work at the annual general meeting account for paid compensation.Proposal on guidelines for remuneration to the senior management (item 14)The board of directors proposes that the Meeting resolves on the following guidelines for remuneration to the Company’s senior executives for the period until the end of the next annual general meeting. The guidelines will apply to the agreements entered into after the Meeting.The Company shall offer remuneration and other terms of employment which enables the Company to recruit, motivate and retain senior executives with the skills that the Company needs in order to execute its strategy and reach the targets of the operations. The general principles for the remuneration to the senior executives is that they shall be competitive and in line with market conditions.Senior executives refer to the CEO and to members of the group management of the group who report directly to the CEO. Company’s senior executives are at present the CEO, the Business development Director, the Chief Project & Sales, the Chief Production & Sourcing, the Chief Legal Officer, the Financial director, the CFO, the Chief Communications/Sustainability & IR Officer (i.e. in total eight persons).The remuneration to the senior executives comprises of: ·  fixed remuneration, ·  variable remuneration, ·  pension, and ·  other customary benefits The fixed remuneration shall be based on market conditions and be determined with consideration of the qualitative performance of the employee. The fixed remuneration is normally reviewed once per year.The distribution between fixed remuneration and variable remuneration shall stand in proportion to the employee’s position and duties. The total remuneration shall be in line with market conditions, competitive and reflect the employee’s area of responsibility and the complexity of the position.The variable remuneration shall include payments for annual leave and be pensionable. For the CEO, the variable remuneration shall not exceed twelve monthly salaries (calculated with the fixed monthly salary). For other senior executives, the variable remuneration shall not exceed four monthly salaries (calculated with the fixed monthly salary).The variable remuneration may comprise a variable cash part and a long-term variable remuneration in the form of shares and/or share related instruments in the Company.Variable remuneration in form of cash shall require achievement of defined and objectively measurable goals which are based on the group’s reported results before taxes.Long-term remuneration in form of shares and/or share related instruments in the Company shall be distributed through the participation in a long-term incentive programme resolved upon by the general meeting. Such programmes shall be based on performance, require a continuing employment in the group and demand an investment by the participants themselves. The vesting period (alternatively, from the time at which the agreement was entered into until the time of the acquisition of a share) shall not be less than three years. The goal with the incentive programme shall be to achieve an aligned interest between the participating senior executive and the Company’s shareholders, as well as to create long-term value for the shareholders.The board of directors shall annually evaluate whether a long-term share related incentive programme shall be proposed to the general meeting or not.The Company applies the ITP-plan for all employees. The CEO’s pension shall be premium based and based on the fixed salary according to customary principles.Other benefits shall constitute a limited value in relation to the total remuneration, and correspond to what normally occurs at comparable companies.Upon the termination of employment agreements, the notice period shall, upon termination by the Company not exceed twelve months, and upon termination by the senior executive not exceed six months, except in relation to the CEO where a termination period of twelve months shall apply. No severance pay shall be paid.The guidelines shall apply for employment agreements entered into after the Meeting, and for potential amendments to existing terms. The board of directors may deviate from the guidelines for specific reasons in a particular case.The CEO receives pension provisions corresponding to 30 per cent of his fixed salary and the other senior executives receive pension provisions in accordance with the applicable collective bargaining agreement between The Swedish Construction Federation (Sw. Sveriges Byggindustrier) and Ledarna (Sweden’s organisation for managers), The Swedish Association of Graduate Engineers (Sw. Sveriges ingenjörer) and Unionen (a Swedish white-collar trade union).The CEO is entitled to an annual bonus corresponding to two per cent of an amount which is based on the Company’s operating profit including financial income from its jointly owned associated companies. The bonus cannot exceed twelve fixed monthly salaries for the last bonus qualifying financial year.The other senior executives of the group participate in an incentive programme, within which they have the possibility to receive an annual bonus of not more than four monthly salaries. The outcome of the bonuses depends on whether certain limits have been reached in relation to the group’s operating profit.AVAILABLE DOCUMENTSThe annual report, the auditor’s report, complete proposals together with statements and opinions and form of power of attorney will be made available at the Company (address and telephone as above) and on the Company’s website www.ssmlivinggroup.com. The documents will be sent free of charge to shareholders who request it and who inform the Company of their postal address. All documents above will be presented at the Meeting.SHAREHOLDERS’ RIGHT TO REQUEST INFORMATIONAt the Meeting, shareholders have the right to information – should the board of directors consider that this can occur without significant damage to the Company – on circumstances that could impact on the evaluation of an item on the agenda and relationships that could impact on the evaluation of the Company’s or subsidiary’s financial situation.OTHER INFORMATIONAt the date of this notice, the Company has 39,252,542 shares and votes in SSM. The company holds no treasury shares.PROCESING OF PERSONAL DATAFor information on how personal data is processed in connection with the AGM, see the privacy policy available on Euroclear Sweden AB’s website at euroclear.com. _____________________Stockholm in April 2019SSM Holding AB (publ)The board of directorsN.B. The English version is an unofficial translation of the Swedish original. In case of any discrepancies, the Swedish original shall prevail.                                                                                                                                         

Getinge announces its commitment to training at Charing Cross Symposium 2019

April 12, 2019London, UK Getinge, a leading global provider of innovative medical technology, announces today that it will host a series of (endo) vascular workshops, supported by Vascular International at Charing Cross Symposium taking place from 16-18 April 2019, Olympia Grand, London UK. Getinge understands the importance of providing the appropriate training and guidance to surgeons early on in their medical careers. Attendees will have the possibility to learn, in closely supervised modules, the latest techniques from experts in the field: repairing an open abdominal aortic aneurysm, practice renal stenting and experience the endovascular treatment of complex iliac cases. “In addition to the workshops, Getinge will be sponsoring the edited live case on April 16 which will present the best approaches in aortic infection treatments. With over 15 years of experience with a reliable, proven, trusted balloon-expandable covered stent, Advanta V12, we are also pleased to announce that we will be sponsoring a lunch symposium on April 17 where delegates can hear more about the reliable performance and proven long term results of a balloon-expandable stent” shared Markus Stirner-Schilling, Senior Director, Acute Care Therapies, Global Commercial Operations. Learn more here  About Charing Cross Symposium: The Charing Cross Symposium raises vascular and endovascular controversies so that a world-class faculty challenges the available evidence in order to reach a consensus after discussion with an expert audience. In addition to the discussions, participants have the opportunity to enhance skills and network with peers and medtech exhibitors. About Getinge at Charing Cross: Registered visitors are invited to visit Getinge on booth 170 from 16-18 April 2019, Olympia Grand, London UK. For further information, please contact Tracey DaweDirector Communications - Global SalesPhone: + 44 77 177 84965   Email: tracey.dawe@getinge.com About Getinge Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the every-day life for people, today and tomorrow.

IK to support fire protection company BST

BST provides a wide range of sprinkler system services, including consultancy & design, installation and repair & maintenance. Through its strong local presence across Sweden with a full-service offering and blue-chip client base, the Company has established a solid market position. The Swedish sprinkler market has experienced strong growth historically and is expected to continue to grow at a high pace driven by favourable trends such as tightening regulation, increased safety awareness and urbanisation. “Despite its relatively young age, BST has established itself as a Swedish market leader within the fire protection market. We are truly impressed with the management team and all of BST’s employees, and we look forward to supporting the company as it continues on its growth trajectory,” said Kristian Carlsson Kemppinen, Partner at IK Investment Partners and advisor to the IK Small Cap II Fund. “IK is a strong partner to support BST’s future development. BST has been a successful holding for Infrea and has increased its sales by over 50% during the ownership period," added Tony Andersson, CEO of Infrea. “BST was founded by entrepreneurs in 2012 and has grown rapidly since. I would like to thank Infrea for their support over the past few years. We are very excited to team up with IK given their vast experience in the fire protection industry,” concluded Peter Bühler, CEO and Co-Founder of BST. BST will be the third investment in the fire protection segment made by IK Funds. In 2009, IK facilitated the merger between Minimax and Viking, resulting in one of the world’s largest companies in fire protection, and in 2015, the IK Small Cap I Fund backed svt Group, a leading German provider of passive fire protection.

Nordax Annual Report and Sustainability Report has been published

The reports are available at https://www.nordaxgroup.com/en/investors/financial-reports/ For further information, please contact: Andreas Frid, Head of Marketing & Communication, tel: +46 705 29 08 00 or andreas.frid@nordax.se  About Nordax Bank Nordax Bank is a leading specialistbank in Northern Europe owned by Nordic Capital Fund VIII and Sampo. The client base today consists of 185.000 private clients in Sweden, Norway, Finland and Germany. We are a specialistbank who through responsible lending help people make informed decisions for a life they can afford. We are a flexible complement to the major banks. Instead of quantity we have specialised in a few selected products like private loans, mortgages, equity release products and savings accounts. Since 2019 Svensk Hypotekspension, which are specialists in equity release products, is a fully-owned susbsidiary to Nordax Bank. Nordax has about 200 employees where almost all employees works from one central office in Stockholm. The credit assessment process is one of Nordax core competencies. It is thorough, sound and datadriven. Nordax customers are financially stable individuals. As of 31 December 2018 the lending to the public amounted to 15.1 bn SEK and deposits from the public amounted to 11.3 bn SEK. Read more about Nordax on www.nordaxgroup.com This information is information that [company] is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 CET on April 11 2019.

Fluvius upgrades cable network with Teleste’s optical nodes in Belgium

TURKU, FINLAND – 12 April 2019 – Teleste has been selected as a vendor of optical nodes for Fluvius’ network upgrade project in Belgium. With the deliveries taking place by the end of 2021, the frame agreement consists of more than 750 of Teleste’s AC8810 intelligent 1.2 GHz nodes and its value is estimated to be approximately EUR 1.1 million. Owned by 14 intermunicipal companies, Fluvius is the largest multi-utility operator that offers its services to homes or workplaces through a network of pipes and cables throughout the Flanders region in Belgium. The company took care of a cable network with approximately 500,000 homes passed in 2018 and it is now updating the cable infrastructure to ensure the future capabilities in providing high speed data transmission for the subscribers within its network. “We appreciate that Fluvius trusted us and our technology in upgrading their network for future-proof capacity performance and fibre-level broadband speed. Being present on the Belgian cable market for more than 30 years, Teleste is committed to bringing additional value for the subscribers within the Fluvius network through improved service reliability, and a proven track record in meeting the local infrastructure requirements”, stated Rami Kimari, vice president of HFC Networks for Teleste. Teleste’s AC8810 optical nodes provide Fluvius with fibre-level data transmission capacity, cost-effective operation and high redundancy. Fluvius’ public bidding process was based on the product price and evaluation of the technical criteria, including features such as remote ingress switching, power supply and housing as well as user-friendly configuration. Supporting DOCSIS 3.1 frequencies, the AC8810 is an intelligent optical node platform with advanced technical features delivering real customer benefits in terms of capacity performance and redundancy. Besides cutting edge capacity performance, the node is also easy and economical to operate. For example, its power save technology helps operators to reduce power consumption in response to channel load changes in order to achieve lower network operating costs and a smaller CO₂ footprint. Please visit our website for more information about the AC8810 node . Inquiries for more information:Mirkka LamppuDirector of Communications, Teleste CorporationTel. +358 2 2605 611Email: mirkka.lamppu@teleste.com About Teleste Teleste offers an integrated product and service portfolio that makes it possible to build and run a better networked society. Our solutions bring television and broadband services to your home, secure your safety in public places and guide your use of public transport. With solid industry experience and drive for innovations, we are a leading international company in broadband, security and information technologies and related services. We connect with our customers through a global network of offices and partners. In 2018, Teleste’s net sales reached EUR 250 million and on average it had approximately 1400 employees. Teleste is listed on Nasdaq Helsinki. For more information see www.teleste.com and follow @telestecorp  on Twitter.

TARGOVAX ASA - APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. Oslo, 12 April 2019: Reference is made to the stock exchange announcements by Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") on 9 April 2019, regarding (i) the publication of the annual report for the financial year 2018 and (ii) the proposed re-scheduling of the subscription period in the subsequent offering of up to 2,104,394 new shares in the Company, each with a par value of NOK 0.10 (the "Subsequent Offering"), as further described in the prospectus prepared by the Company, dated 27 March 2019 (the "Prospectus"). The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today approved the supplemental prospectus dated 12 April 2019 (the "Supplemental Prospectus") to the Prospectus, that has been prepared by the Company in connection with the publication of the Company's annual report for the financial year 2018 and the proposed re-scheduling of the subscription period in the Subsequent Offering. The information contained in the Supplemental Prospectus shall be considered an integral part of, and is to be read together with, the Prospectus. The Prospectus and the Supplemental Prospectus are available on the following websites: www.targovax.com and www.dnb.no/emisjoner. Hard copies of the Prospectus and the Supplemental Prospectus may also be obtained at the offices of Targovax ASA, Lilleakerveien 2 C, 0283 Oslo, Norway or by contacting DNB Markets at +47 23 26 81 01. DNB Markets will be acting as manager in the Subsequent Offering. For further information, please contact: Øystein Soug, CEO Phone: +47 906 56 525 Email: oystein.soug@targovax.com About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102's targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phaseII trial. Another trial, in checkpoint inhibitor refractory advanced melanoma, is expected to produce important proof-of-concept immune activation data in heavily pre-treated patients. Targovax is also developing a neo-antigen cancer vaccine targeting tumors with oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program has shown strong RAS-specific immune activation and a signal of clinical efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested in a phase I trial in colorectal cancer, both as monotherapy and in combination with Keytruda (an anti -PD1 check point inhibitor). IMPORTANT INFORMATION These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "Prospectus Directive" means Directive 2003/71/EC as amended (together with any applicable implementing measures in any Member State. In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intends", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. This announcement is made by and, and is the responsibility of, the Company. The Managers are acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein. Neither the Managers nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement. Each of the Company, the Managers and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Camanio Care continues to expand on the Canadian market

Canada is a potentially growing market for Camanio Care’s reminiscence tool BikeAround jDome. More and more care home facilities are showing interest in the tool and that interest is now starting to translate into business deals. – The BikeAround experience bike is an amazing tool for individuals with ailments affecting the memory. It has shown great results for quality of life and calming especially those living with dementia or Alzheimer’s disease. It is making memories come to life and has been successfully used in social contexts as well, creating experiences for entire communities at the care homes. We are happy that the interest for it is increasing, as this will bring joy to even more people, says Jasmine Dahlberg, head of operations at Camanio Care Inc.   The Canterbury Foundation is a non-profit organization that has provided quality senior care, housing and supportive services for over 44 years. With three living options; independent, supportive, and memory care, The Canterbury Foundation continually aims to provide the ’Promise of Home’ to seniors in Edmonton. This is clearly demonstrated through their initiative to take in such an innovative tool as the BikeAround jDome, to not only boost their senior care overall but especially provide a boost for their memory care program. The Canterbury Foundation is the first establishment to take in the BikeAround in West Canada.  Ocean View Continuing Care Centre is a charitable organization that has been operating since the early 1960’s. Between in-care living and community supports, Ocean View serves over 500 individuals each year through 320+ staff and 100+ volunteers. Their vision is to be the “community of choice” for Nova Scotians needing support in a place they call home. Innovation is one of the core values of Ocean View, something that clearly shows through their purchase of the BikeAround jDome. Ocean View is hoping to add a more innovative and exciting tool to their memory care program. – The collaboration with these excellent care homes means that we can bring joy to more people and we get the chance to prove to even more care professionals what the BikeAround can do for the people in their care. We believe that the BikeAround is a tool that deserves to be brought to more people and we are confident that the Canadians are now ready to take the tool to their hearts, says Jasmine Dahlberg, head of operations at Camanio Care Inc.  Facts about Alzheimer’s disease and dementia Today there are over half a million Canadians living with dementia, with about 25,000 new cases diagnosed every year. Roughly 56,000 Canadians with dementia are cared for in hospitals. The rest are cared for in care centers or through home care. For more information, please contact: Catharina Borgenstierna, CEOTelephone: +46 733-93 00 07E-mail: catharina.borgenstierna@camanio.com About Camanio Care Camanio Care is a care technology company developing smart solutions for digital home care with the individual in focus. The company offers digital service platforms, products and services, such as Vital Smart Care, ICE, BikeAround, Bestic and Giraff. Through optimizing the mix of physical and digital care, Camanio Care works to support the basic needs of individuals and increasing the freedom, efficiency and quality of care. Camanio Care has its headquarters in Stockholm, the subsidiary Camanio Care Inc. in the U.S., and distributors in Asia, Middle East, Hongkong, Australia and tens of European countries. Visit our website and subscribe to our newsletter, www.camanio.com. 

IFRS 16 effect on Recipharm's income statement and balance sheet 2019

The new accounting standard, IFRS 16 will have an estimated positive impact on EBITDA of SEK 90 million in 2019. The new accounting standard led to an increase of the opening balance of the financial net debt of SEK 312 million per first of January 2019. More details will be provided in the 2018 Annual Report and in the Q1 2019 interim report. Contact informationThomas Eldered, CEO, telephone: +46 8 602 52 10Tobias Hägglöv, CFO, ir@recipharm.com, +46 8 602 52 00 This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 12 April 2019, at 14:00 CET. About RecipharmRecipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.For more information on Recipharm and our services, please visit www.recipharm.com 

The Nomination Committee proposes Professor Anna Martling and Thomas von Koch as new Board members

Anna Martling is Professor of Surgery and Dean of Campus North at Karolinska Institutet and at the same time Senior Consultant Surgeon in cancer at the Karolinska University Hospital in Stockholm. Anna Martling has a PhD from Karolinska Institutet and broad experience of both clinical work and research, especially in cancer diseases. Anna Martling's research has received multiple awards, among others from the Royal Academy of Sciences and the Swedish Surgical Society. Since 2019, Anna Martling is a member of the Faculty Board at Karolinska Institutet. Anna Martling has a holding of 823 B shares in Bactiguard. Thomas von Koch is one of two founders and principal owners of Bactiguard and was chairman of the Board in the period 2005 to 2014. In connection with his appointment as CEO of EQT Partners AB (EQT), Thomas von Koch resigned his assignment on the board of Bactiguard in March 2014. At the end of 2018, he stepped down from the CEO role in EQT and thus freed more room for other assignments. Thomas von Koch has a Master of Science in Business Administration from the Stockholm School of Economics and has solid experience of board work, investments, structural transactions and strategic alliances in several different industries. Thomas von Koch has a holding of 2,000,000 A shares and 4,125,878 B-shares in Bactiguard (directly and via companies), corresponding to 18.4 percent of the capital and 34.8 percent of the votes in the company. The Nomination Committee proposes re-election of the Board members Mia Arnhult, Christian Kinch and Jan Ståhlberg, also to be re-elected as Chairman of the Board. Marie Wickman-Chantereau and Svante Östblom have both declined re-election. The Nomination Committee's complete proposal will be presented in the notice to the Annual General Meeting 2019 and at the company's website at the same time.  This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2019-04-12, at 14.00

Loudspring Releases Impact Results for 2018

Loudspring today announces the impact results of 6 of its portfolio companies for 2018. Loudspring portfolio companies considered for this report include: ResQ Club, Nuuka Solutions, Eagle Filters, Enersize, Sofi Filtration and Swap.com. The total impact in terms of avoided CO2 emissions was 146 948 ton. The total water savings calculated for 2018 were 15 731 156 cubic metres. Full PDF version of the report can be downloaded here: https://loudspring.earth/files/Loudspring_Impact_18.pdf Like previous impact reports from Loudspring, the impact assessment for 2018 estimates how much water and greenhouse gas (GHG) emissions were saved or ‘avoided’ through the operations of a select number of Loudspring portfolio companies. The full report goes into much more detail about this method for measuring impact, as well as the recently released Loudspring Impact Review and Methodology document that was released earlier this year. You can read the Loudspring Impact Review and Methodology here: https://loudspring.earth/files/Loudspring_Literature_Review_18.pdf This year’s Impact Results from Loudspring also adds for the first time reference of the Loudspring portfolio to biodiversity impacts and also the Sustainable Development Goals. It was found that the Loudspring portfolio impacts 8 of the 17 UN Sustainable Development Goals. CEO of Loudspring, Lassi Noponen comments: “This is the third impact report from us as a company group and it is by far the most comprehensive yet, with references to the Sustainable Development Goals and biodiversity. Reporting impact is still in its infancy for most companies, but I believe that it will only become expected that businesses measure and report their impacts as climate concerns increase and more stress is put on natural resources.” “I am happy that Loudspring can take a leadership position in this space, but I am also very happy that we are able to share our methods openly through events like our Impact Evening with Spark Sustainability tonight in Helsinki.” Download the full impact report here: https://loudspring.earth/files/Loudspring_Impact_18.pdf

Programming marathon with 70,000 in prize pool

[Organizers Malin Winsa Boden Business Park and Nils Lindh Boden Business ParkBoden Business Agency] Solve a given blockchain programming task in 48 hours and compete for the first prize of SEK 50,000. These are the basic conditions for Arctic Chain Hackathon. You can either compete in teams or alone and both students and experienced programmers are welcome to register. The second best solution wins SEK 20,000. - This is a chance for talents to show their skills, but also for us to develop new business ideas, says Malin Winsa, Boden Business Park. The organizers hope that this will, above all, be a fun event where you get to hang out with like-minded people, let your imagination flow and together create a focused and creative environment. Here you should both be able to learn from each other and find new inspiration. - Our long-term goal is to create a development hub for blockchain solutions here and then a hackathon feels right. It is part of the development of an ecosystem around our data center initiative, says Nils Lindh, Boden Business Park. During the days, dinners and lunches are organized where there is the opportunity to meet useful contacts in the industry. - We want to show that there are opportunities in Boden, that you do not have to move south to get a fun programming job. It happens a lot here, Malin says. The theme of the coding competition is Democracy 4.0 and for the assignment iGrant.io stands. They have developed a solution that makes it possible for different organizations to exchange personal data between them - in a way that the individual himself has power over his own tasks. The case to which the participants must relate is how to simplify the management of consent and exchange of personal data between the individual and the public sector. - For us, it feels like a natural step to look at how blockchain can interact with GDPR. Therefore, Arctic Chain Hackathon is an excellent way for us to test new solutions based on our platform, says Lotta Lundin, founder and CEO of iGrant.io. Here's how it goes:  On Tuesday morning (May 7), the iGrant.io presents the assignment and the contestants get 48 hours to solve it in the best way. Most of the work is done on its own, but there are experts on site to give advice and guidance. On Thursday morning (May 9), the teams pitch their solutions to a jury who then appoints the first and second prize winners. These will be presented at the inauguration of the Blockchain North conference at 11 am on 9 May in Studio Nord. Parallel to the programming competition, there is a competition for best business concept in blockchain. Here, the contestants pitch their business idea for a jury consisting of experts and venture capitalists who can take the idea further. The winner will be presented during dinner on Wednesday, May 8th. Read more: arcticchainhackathon.com/en  Caption, first image: Organizers Malin Winsa, Boden Business Park, and Nils Lindh, Boden Business Park/Boden Business Agency.  Photographer: KOMM / Boden municipality Caption, second image: A hackathon is a programming marathon where programmers help each other and learn from one another. At Arctic Chain Hackathon, the teams compete over first prize, 50,000 SEK, and the theme is blockchain. Photographer: Annie Spratt/Unsplash